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Abstract 
AMP-activated protein kinase (AMPK) is a well characterised central regulator of energy 
homeostasis with many downstream substrates and potential therapeutic targets. Recently 
several kinases related to AMPK have been identified which are activated by the same 
upstream kinase, LKB1, and share significant sequence homology with the catalytic α subunit 
of AMPK. Previous studies have implicated NUAK1, one of these related kinases, in cell cycle 
regulation and other studies have identified various partner proteins but as yet there is no 
consensus model of its regulation or physiological role. This aim of this study was to 
investigate the regulation and interactions of NUAK1 using an in vitro system and also use an 
in vivo tissue specific mouse knockout system to investigate its function in two different 
tissues.  
The results of these studies reveal new insights into the regulation of NUAK1 in vitro and 
suggest that the kinase is capable of activation by autophosphorylation, in the absence of 
LKB1. NUAK1 is shown to interact with 14-3-3 proteins and evidence that this interaction may 
be important for the function of the kinase is presented. Cell based studies in mouse 
embryonic fibroblasts (MEFs) lacking NUAK1 show that it is involved in proliferation and there 
are suggestions of pathways involved in regulating this effect. 
NUAK1 liver-specific knockout mice were generated and extensive metabolic phenotyping 
analyses were carried out. In young animals deletion of NUAK1 in liver did not lead to any 
obvious changes in whole body metabolism. However, preliminary studies revealed a possible 
role for NUAK1 in metabolic regulation in older mice and in response to liver damage. Mice 
with heart-specific deletion of NUAK1 were generated and these mice were found to have a 
cardiac hypertrophy phenotype in response to angiotensin II treatment. Potential signalling 
pathways downstream of NUAK1 in the heart were then investigated in this model.   
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1  Introduction 
AMP-activated protein kinase (AMPK) is an important enzyme involved in metabolism and 
energy regulation (Carling, 2004; Hardie, 2008). The structural composition, signalling 
pathways and effects of AMPK have been well studied. It is involved in many clinical and 
pathological conditions leading to great interest in the therapeutic potential of AMPK (Zhang 
et al., 2009; Zhou et al., 2009). Recently twelve kinases related to AMPK that are regulated by 
the same upstream kinase, LKB1, have been identified (Lizcano et al., 2004). LKB1 is a 
heterotrimeric kinase, requiring partner proteins STRAD and MO25 for optimal activity (Alessi 
et al., 2006; Lizcano et al., 2004; Manning et al., 2002). Eleven of these related kinases contain 
a conserved regulatory threonine residue which is phosphorylated by LKB1 and they appear 
to have many diverse functions including regulation of cell polarity, cell growth, 
differentiation and control of cellular energy (Alessi et al., 2006). It is thought that LKB1 is 
constitutively active but there is little information to suggest how this affects the regulation 
of the AMPK-related kinases (Bright et al., 2009). The AMPK signalling network has been well 
studied and the upstream kinases and downstream targets have been well characterised 
(Boudeau et al., 2004; Inoki et al., 2003; Woods et al., 2005). However currently there is 
relatively little known about the function and regulation of the AMPK-related kinases.  
 
This thesis represents a study of the role and regulation of NUAK1. In this chapter, the 
background of the regulation and function of AMPK is given as an introduction to the field of 
AMPK-related kinases. The existing understanding of the role of NUAK1 and some of the other 
AMPK-related kinases is reviewed. The role of LKB1 and other kinases linked to NUAK1 are 
also discussed and the current understanding of pathological processes investigated within 
the project are outlined.  
 
1.1 AMPK 
AMPK is a highly conserved serine-threonine kinase with a varied range of intracellular and 
whole body functions. As its name would suggest, it is activated by AMP which is formed 
mainly by the action of adenylate kinase converting 2ADP > ATP + AMP. Recent data has also 
shown that AMPK is activated by ADP (Xiao et al., 2011). The activation by AMP and ADP is a 
  Chapter 1 - Introduction 
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useful way of measuring the energy consumption by the cell and because it is capable of 
sensing the ADP:ATP and AMP:ATP ratios, AMPK has a crucial role in controlling cellular 
energy homeostasis. If the cell is subjected to any form of stress that interferes with ATP 
synthesis (e.g. hypoxia or lack of nutrients), the ADP:ATP and AMP:ATP ratios will increase. 
There are also pharmacological AMPK activators, such as metformin that reduces ATP 
synthesis by inhibiting complex I of the respiratory chain (Owen et al., 2000). This reduction 
in ATP levels will also increase the ADP:ATP and AMP:ATP ratios, thereby activating AMPK. 
Similarly any cellular stresses that increase ATP consumption, such as muscle contraction, will 
likewise activate AMPK by changing the ADP:ATP and AMP:ATP ratios. Because ATP levels are 
so important to maintaining cell integrity, AMPK has a fundamental role in switching off 
anabolic (ATP consuming) pathways and switching on catabolic (ATP producing) pathways 
during periods of energy limitation. 
 
As would be expected from such a key cell signalling protein, the essential role of AMPK is 
preserved in orthologues from almost every eukaryotic organism for which the genome has 
been sequenced (Hardie et al., 2012). The yeast orthologue of AMPK from Saccharomyces 
cerevisiae, SNF1, has been widely studied and has provided many insights into downstream 
pathways and the broader function of AMPK (Hardie, 2007). Other studies have identified 
ways in which AMPK is regulated by cytokines and hormones that are known to regulate 
whole-body metabolism (Kahn et al., 2005). Various pharmacological compounds, including 
anti-diabetic drugs metformin and phenformin, are known to activate AMPK probably by 
interfering with ATP synthesis (Hardie, 2008). These data, and other indications, show that 
AMPK may play a crucial role in diseases such as obesity, diabetes and the metabolic 
syndrome. 
 
Although a huge amount is known about AMPK and its upstream and downstream pathways, 
there are still many questions concerning nuances of the way its activity is regulated and the 
effect of attenuating its actions. Major outstanding issues include the identity of protein 
phosphatases responsible for dephosphorylating AMPK and ways of investigating non-
canonical mechanisms of activation. The eventual aim of this field of research is to identify 
novel therapeutic drugs and, with such wide-ranging effects, it will be crucial to elucidate the 
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exact changes involved in activating or inhibiting AMPK activity in different cell types and 
organs. 
 
1.1.1 AMPK structure and regulation 
AMPK is a heterotrimeric kinase and over the past 10 years a great deal of work has been 
undertaken to clarify the individual roles of each of the different subunits. AMPK is formed of 
a catalytic α subunit and regulatory β and γ subunits (Figure 1.1). The α-subunit contains the 
kinase activity and the binding of AMP or ADP to the γ subunit has been reported to promote 
phosphorylation of a conserved threonine residue within the kinase domain (referred to as 
Thr172 as it was originally identified in rat AMPK (Davies et al., 1995; Oakhill et al., 2011). The 
phosphorylation of this residue has been shown to be essential for activity (Hawley et al., 
1996). Early data also showed that AMP binding protects against the dephosphorylation of 
the α subunit, providing another mechanism to further increase the activity of the kinase 
(Davies et al., 1995). The binding of AMP, but not ADP, to the γ subunit also allosterically 
activates the enzyme and collectively these two effects cause over a 1000-fold increase in 
AMPK activity (Sanders et al., 2007; Suter et al., 2006). 
 
Interestingly, recent data has suggested that the protection against dephosphorylation may 
be the more physiologically relevant mechanism of AMPK regulation (Sanders et al., 2007). In 
addition, new data has emerged that shows ADP can also produce the same protection 
against dephosphorylation and provides new insight into how the balance of the adenine 
nucleotides could affect the activation of AMPK in a cellular environment (Xiao et al., 2011). 
This report indicates that AMP or ADP can change the equilibrium between structures of 
AMPK that are sensitive or insensitive to dephosphorylation, thereby attenuating the 
reduction in activity caused by protein phosphatases. However, a consensus on the 
mechanism of AMPK activation is still proving elusive, as another group have recently shown 
that these conclusions based on bacterially expressed recombinant AMPK may not be 
physiologically relevant (Gowans et al., 2013). Using purified rat liver AMPK, their 
observations suggested that AMP, rather than ADP, would be the most important 
physiological regulator. These inconsistencies may prove to be an artefact of experimental 
conditions or a genuine difference in the mechanism of activation under different conditions. 
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Figure 1.1 Domain structure of AMPK subunits (from Hardie, 2007) 
The catalytic α subunits have a C‑terminal domain (α-CTD) that is required for binding the β 
and γ subunits and an autoinhibitory domain (AID) that inhibits the activity of the catalytic 
domain. The β subunit contains a carbohydrate binding module (CBM) but the exact function 
of this in the active kinase is unclear. The regulatory γ subunits (of which there are three in 
mammalian systems) contain four cystathionine β‑synthase (CBS) domains which form the 
interface for binding adenine nucleotides. The kinase domain also contains the T-loop with 
the critical threonine residue that must be phosphorylated for activity. 
 
 
1.1.2 Upstream kinases of AMPK 
AMPK requires phosphorylation of T172 in the activation loop of the catalytic α subunit by an 
upstream kinase in order to be active (Davies et al., 1995; Hawley et al., 1996). To date, three 
kinases upstream of AMPK that are capable of activating the critical threonine residue have 
been identified. The first of these kinases to be described was the tumour suppressor liver 
kinase B1 (LKB1) (Hawley et al., 2003; Woods et al., 2003). In order to be active, LKB1 requires 
the binding of two subunits, STE20-related adaptor (STRAD) and mouse protein 25 (MO25). 
Numerous studies have looked at the role of LKB1 as it has been identified as a tumour 
suppressor involved in the hereditary cancer predisposition syndrome, Peutz-Jeghers. LKB1 
appears to be ubiquitously expressed and constitutively active (Boudeau et al., 2003). Recent 
data has indicated that the binding of AMP or ADP to AMPK plays a crucial role in its activation 
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despite LKB1 being constitutively active (Oakhill et al., 2011). The binding of AMP or ADP can 
protect AMPK against the dephosphorylation of T172 by protein phosphatases thereby 
allowing it to be maintained in its active conformation (Sanders et al., 2007; Suter et al., 2006; 
Xiao et al., 2011). The regulation of this cycle of phosphorylation and dephosphorylation 
seems likely to play an important role in the tissue specific function of AMPK. 
 
LKB1 is considered a “master” kinase which has been implicated in numerous important and 
clinically relevant processes from cell cycle regulation in haematopoietic stem cells (Nakada 
et al., 2010) to cell polarity in liver development (Woods et al., 2011). Also, early studies that 
showed LKB1 activating the AMPK-related kinases measured an increase in activity in the 
presence of LKB1 expression without taking into consideration other potential upstream 
kinases (Lizcano et al., 2004). Although this study provided various convincing pieces of data 
to show LKB1 activates the AMPK-related kinases, it did not conclusively show that 
phosphorylation by LKB1 is the only activating mechanism. 
 
Ca2+/calmodulin-dependent protein kinase kinase α and β (CaMKKα/β) are also capable of 
phosphorylating the key threonine residue on AMPK (Hawley et al., 2005; Hurley et al., 2005; 
Woods et al., 2005). CaMKKβ has been the focus of more attention in this area and is activated 
in response to a rise in intracellular calcium levels which in turn leads to an increase in AMPK 
activity. This means that AMPK is capable of responding to a change in cytosolic calcium as 
well as nucleotide levels. CaMKKβ is expressed mainly in neuronal cells but is also present in 
thymus, testis and T cells (Anderson and Kane, 1998). In cell types where both LKB1 and 
CaMKKβ are expressed, different stimuli may activate AMPK through different pathways 
(Stahmann et al., 2006; Tamas et al., 2006). 
 
The third upstream kinase for AMPK that has been reported is transforming growth factor-β 
(TGFβ)-activated kinase-1 (TAK1). This was identified using a screen for kinases that 
phosphorylate and activate the AMPK homologue sucrose non-fermenting protein 1 (SNF1) 
in yeast (Momcilovic et al., 2006). TAK1 has also been shown to activate AMPK in heart via an 
LKB1-dependent pathway (Xie et al., 2006). TAK1 has been researched from many different 
angles and appears to have a role in many different pathways. TAK1 has been shown to be 
involved in inflammatory response pathways (Sato et al., 2005) and similar to LKB1, TAK1 
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requires binding partners called TGFβ-activated kinase binding proteins 1-3 (TAB1-3) for its 
activation (Singhirunnusorn et al., 2005). The exact in vivo role of TAK1 activating AMPK is 
currently disputed despite several reports on this area (Chen et al., 2013b; Wang et al., 2013). 
 
1.1.3 AMPK and metabolism 
AMPK is generally activated by any metabolic stress that changes the AMP:ATP and ADP:ATP 
ratios, either by inhibiting ATP production or increasing ATP consumption. AMPK can also be 
activated by a number of extrinsic hormones and cytokines that can also influence cellular 
and whole body metabolism. AMPK was originally identified as an inhibitor of acetyl-CoA 
carboxylase 1 (ACC1) in rat liver (Carling et al., 1989). The effect of ACC1 inhibition is a 
reduction in the synthesis of fatty acids, a key ATP consuming biosynthetic pathway, and 
much of the research in the field since has focussed on the role of AMPK in metabolic 
pathways. Many studies, especially since the widespread use of animal models, have made 
observations about the involvement of AMPK in metabolic processes but in some cases the 
exact signalling pathway has yet to be clarified. Broadly, AMPK exerts its effect of switching 
off anabolic pathways by two mechanisms. Firstly it can directly phosphorylate and regulate 
the activity of key enzymes and co-factors involved in biosynthetic pathways such as glycogen 
synthase (Carling and Hardie, 1989; Jorgensen et al., 2004), regulatory-associated protein of 
mTOR (RAPTOR) (Gwinn et al., 2008) and 3‑hydroxy-3‑methylglutaryl CoA reductase (Clarke 
and Hardie, 1990). Through these and other pathways AMPK can directly reduce lipid, protein 
and carbohydrate synthesis, thereby reducing ATP consumption on a fairly immediate 
timescale to exert short-term control. However, AMPK can also exert a degree of long-term 
control by regulating the expression of proteins involved in these pathways over a longer time 
period. The exact transcriptional effect of AMPK is unclear but it is known to phosphorylate 
sterol regulatory element-binding protein 1C (SREBP1C) and inhibit its activity as a 
transcription factor (Li et al., 2011). AMPK can also regulate transcription directly by 
phosphorylation of CREB-regulated transcription co-activator 2 (CRTC2) (Koo et al., 2005) and 
indirectly via control of the localisation of the class IIa histone deacetylases, which in turn can 
control other transcription factors (Mihaylova and Shaw, 2011).  
 
  Chapter 1 - Introduction 
23 
 
Reducing the activity of anabolic pathways is one half of the role of AMPK and the other 
downstream effect is to increase catabolic pathways with the objective of increasing the ATP 
concentration in the cell back to a stable level. One way in which AMPK achieves this is by 
increasing glucose uptake during periods of stress such as muscle contraction. AMPK can 
mediate the same pathway as insulin by causing the translocation of glucose transporter 4 
(GLUT4) channels to the plasma membrane which increases glucose uptake. The key 
difference to insulin stimulated glucose uptake is that during times of stress, glucose is 
oxidised to make ATP rather than incorporated into glycogen, which is an anabolic process 
and would appear to defeat the purpose of activating AMPK to conserve ATP. The 
translocation of GLUT4 proteins involves signalling through several pathways including RAB 
family GTPase activating proteins (RAB-GAPs) such as TBC1D1, which AMPK can 
phosphorylate to promote the translocation of GLUT4 vesicles to the plasma membrane. Akt, 
a key kinase in the insulin signalling pathway can also phosphorylate RAB-GAPs (Treebak et 
al., 2009) and the distinct roles of these two pathways are currently unclear. Recent animal 
models have confirmed the role of AMPK in contraction stimulated glucose uptake, however 
there may be other downstream effectors besides the RAB-GAP family (O'Neill et al., 2011). 
AMPK also has the ability to regulate translocation of the transporter CD36, thereby 
increasing uptake of fatty acids which can be oxidised to produce ATP (Habets et al., 2009).  
AMPK also seems able to increase glucose uptake in cell types which express only glucose 
transporter 1 (GLUT1) by activating channels that are already part of the plasma membrane 
(Barnes et al., 2002). Not only can AMPK promote the uptake of molecules for ATP production, 
it can also stimulate glycolysis and the β-oxidation pathway via phosphorylation of 
6‑phosphofructo-2‑kinase/fructose‑2,6‑biphosphatase 2 (PFKFB2) in heart and acetyl-CoA 
carboxylase 2 (ACC2) in skeletal muscle respectively (Marsin et al., 2000; Merrill et al., 1997). 
 
Mitochondria are a key site of metabolism and it has been shown that AMPK can promote 
mitochondrial biogenesis to increase the cellular capacity for oxidative production of ATP. 
Treating rats with a known pharmacological activator of AMPK, 5‑aminoimidazole-
4‑carboxamide ribonucleoside (AICAR), produced an upregulation of mitochondrial genes in 
skeletal muscle (Winder et al., 2000). It has been suggested that AMPK regulates this response 
by targeting a central mitochondrial control gene, peroxisome proliferator-activated 
receptor‑γ co-activator 1α (PGC1α). Studies have suggested that AMPK is capable of directly 
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activating PGC1α by phosphorylation (Jager et al., 2007) or indirectly by changing the 
concentration of NAD+, which is required for the deacetylation of PGC1α (Canto and Auwerx, 
2010). Recent reports suggest that AMPK not only plays a role in the formation of new 
mitochondria, but is also involved in the removal of defective mitochondria by a process 
called mitophagy; a particular form of autophagy. This has been proposed on the basis that 
AMPK can phosphorylate and activate the mammalian orthologues of kinases responsible for 
autophagy in yeast (Egan et al., 2011).  
 
The key downstream targets and the metabolic processes that can be regulated by AMPK are 
summarised in Figure 1.2. The diversity of these target processes show how important AMPK 
is to maintaining cellular energy levels. By influencing systems to recruit energy sources to 
the cell, switch on ATP producing pathways, produce more mitochondria and remove faulty 
mitochondria it allows the cell to maintain ATP-generating capacity under conditions of stress. 
 
Another idea which has developed in recent years is the possibility that AMPK plays a key role 
in the whole body regulation of metabolism by affecting the arcuate nucleus feeding centre 
in the brain. Hormones known to stimulate or prevent feeding, such as grehlin and leptin, can 
activate or inhibit AMPK in key subsets of neurons (Andersson et al., 2004; Minokoshi et al., 
2004). While the exact downstream effect exerted by AMPK is unclear, indications that direct 
activation of AMPK can increase feeding (Andersson et al., 2004) would suggest that it does 
play a role in signalling pathways in the brain in response to hormonal cues. AMPK also 
appears to have a key function in a different set of neurons upstream of the feeding centre, 
which suggests that the role of AMPK in the brain may be much broader than originally 
thought (Yang et al., 2011).  
 
 
 
 
 
 
 
 
  Chapter 1 - Introduction 
25 
 
 
 
 
 
 
 
 
Figure 1.2 Downstream targets of AMPK in metabolism (modified from Hardie et al., 2012) 
AMPK has a diverse range of downstream targets involved in cell metabolism. The action of 
AMPK is broadly focussed around inhibiting anabolic pathways, such as fatty acid synthesis 
through ACC1 and activating catabolic pathways such as glycolysis through PFK. The exact 
interactions and pathways may vary between cell types but the pathways listed here are 
widely accepted as being affected by AMPK. Red indicates pathways involved in lipid 
metabolism, blue indicates pathways involved in glucose metabolism, green indicates 
pathways involved in protein metabolism and white for processes involved in mitochondrial 
biogenesis. 
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1.1.4 AMPK, cell proliferation and cancer 
With such wide ranging effects in cell metabolism, it is not surprising to find that changes in 
AMPK signalling can have significant effects on cell proliferation with implications for the 
treatment of cancers. LKB1 is well characterised as a bona fide tumour suppressor in humans 
(Hemminki et al., 1998) but it is also known to be upstream of the AMPK-related kinases 
(Lizcano et al., 2004), making it unclear exactly which other kinases are involved in mediating 
the tumour suppressor functions of LKB1. This is a short background just on the role of AMPK 
in cell proliferation. 
 
Because AMPK is such a ubiquitous and important signalling protein there have been a lot of 
conflicting reports regarding its function in either promoting or inhibiting cell growth and 
division. Many of these studies suggest that activating AMPK would reduce cell growth and 
proliferation, which is consistent with the role of the protein kinase in switching off anabolic 
pathways. Firstly, as most tumours have a high energy demand, it would be predicted that 
under conditions of limited energy availability, such as in tumour hypoxia, AMPK activation 
would reduce cell growth. However, to understand the wider effects of AMPK in this field it is 
important to consider other intracellular signalling pathways that regulate cell growth, 
particularly the mammalian target of rapamycin complex 1 (mTORC1) pathway. 
 
The mTORC1 pathway has been well characterised and, in its entirety, is incredibly complex 
and a recent attempt to map the whole pathway highlighted over 700 different interactions 
(Caron et al., 2010). To understand the involvement of AMPK I will focus on the key parts of 
the pathway highlighted in Figure 1.3. 
  Chapter 1 - Introduction 
27 
 
 
Figure 1.3 The mTOR pathway (adapted from Petroulakis et al., 2006)  
mTOR exists in two functionally different complexes, mTORC1 and mTORC2. The mTOR 
pathway is capable of integrating inputs from several different systems, including insulin and 
hormone signalling via the phosphoinositide 3-kinase (PI3K) pathway. This and the mitogen-
activated protein kinase (MAPK)/extracellular-signal regulated kinase (ERK) signalling 
pathway both act on the tuberous sclerosis 1 (TSC1)/tuberous sclerosis 2 (TSC2) complex. This 
behaves as a GTPase-activating protein (GAP), which can inhibit the function of the small 
GTPase RAS homologue enriched in brain (RHEB). This leads to an increase in the GTP-bound 
form of RHEB, which activates mTORC1, leading to a series of downstream effects which are 
generally pro-cell growth and proliferation. 
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The regulation of cell growth and proliferation is highly dependent on the metabolic status of 
the cell, so it would be logical for there to be a mechanism for integrating the energy sensing 
signal from AMPK into one of the key pathways for controlling cell growth. As an energy 
dependent process, cell division and growth should only occur under conditions of efficient 
energy availability. This means that the activity of the mTORC1 is opposite to that of AMPK, 
so that mTORC1 is active during times of nutrient availability compared to AMPK which is 
active during times of stress and energy depletion. Therefore, it would be expected that AMPK 
activation would inhibit mTORC1 to reinforce this control. AMPK can phosphorylate the mTOR 
partner protein RAPTOR, which reduces mTORC1 activity by promoting the binding of 14-3-3 
proteins (Gwinn et al., 2008). AMPK is also capable of directly phosphorylating mTOR which 
antagonises activation by Akt (Cheng et al., 2004). Finally, AMPK can signal to other 
components of the pathway, for example, by phosphorylating TSC2 leading to lower RHEB 
activity and consequently reduced mTORC1 activity (Inoki et al., 2003) (Figure 1.4A). 
 
Several cancers display high levels of de novo fatty acid synthesis and there are beneficial anti-
tumourigenic effects of inhibiting fatty acid synthase (FAS), which is a crucial enzyme in this 
process (Pizer et al., 1998). It has been established that AMPK activation can inhibit fatty acid 
synthesis, both indirectly via regulating FAS expression through SREBP1 and directly via ACC1 
inactivation (Chajes et al., 2006; Foretz et al., 1998) (Figure 1.4A). Consistent with this AMPK 
activators can inhibit fatty acid synthesis in cancer cell lines leading to reduced cell growth 
and increased apoptosis (Chajes et al., 2006; Xiang et al., 2004). 
 
The anti-cancer role of AMPK activation leading to inhibition of cell growth and proliferation 
would seem the most logical role of the kinase given the wider knowledge about how the 
pathways interact. However, recent data has suggested that the opposite may be the case, 
such that inhibition of AMPK could lead to reduced cell growth. Various screening studies 
have indicated that AMPK activity, and that of its upstream kinase CaMKKβ, is increased in 
prostate cancer cell lines (Frigo et al., 2011; Massie et al., 2011). Another study showed that 
a known AMPK inhibitor can reduce cancer cell proliferation (Park et al., 2009). AMPK may 
have a positive effect on cell growth simply by activating catabolic pathways such as glycolysis 
to produce more energy, as discussed previously (Figure 1.4B), but this may only be part of 
the story. Some other data has emerged recently, via novel screening techniques, to suggest 
  Chapter 1 - Introduction 
29 
 
how AMPK may exert this pro-proliferative effect by targeting components of the myosin 
phosphorylation pathway (see section 1.5 ).  
A 
 
B 
 
 
 
Figure 1.4 Actions of AMPK in cell proliferation and cancer (from Carling et al., 2012) 
Activating and inhibitory phosphorylation are shown in green and red respectively 
Various pathways which involve AMPK are highlighted as having either (A) an anti-
proliferative effect or (B) a pro-proliferative effect. In both cases AMPK could be activated by 
a variety of pathways, but specific activating mechanisms such as a change in the AMP:ATP 
or ADP:ATP ratios or increased expression of the upstream kinase CaMKKβ are proposed to 
be involved in certain conditions.  
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The potential anti-proliferative effects of AMPK could be mediated through several pathways. 
Activating phosphorylation of TSC2 inhibits RHEB, leading to inhibition of mTORC1. Direct 
phosphorylation of mTOR or phosphorylation of RAPTOR, thereby increasing 14-3-3 binding 
also both decrease mTORC1 activity. Also AMPK is known to down regulate de novo fatty acid 
synthesis by two mechanisms – firstly by directly phosphorylating and inhibiting ACC1 activity 
and secondly by suppressing SREBP1c expression leading to reduction in other genes involved 
in fatty acid synthesis (Figure 1.4). Similarly, the potential pro-proliferative effects of AMPK 
could involve two mechanisms. Firstly AMPK increases glycolysis by directly activating PFKFB2 
and PFKFB3, which would provide more energy for faster cell growth. Secondly, AMPK 
activation can lead to increased MLC phosphorylation, which leads to increased mitosis and 
cell migration (Figure 1.4, section 1.5 ).  
 
Currently the overall role of AMPK and its related pathways in cancer cell growth and 
proliferation is unclear and there are conflicting reports in the literature which are difficult to 
reconcile. Further investigation of the downstream targets and other proteins involved in 
signalling cascades may reveal cell-type specific roles or other mechanisms that allow 
differential control of AMPK activity in response to different conditions. It is possible that 
AMPK only influences mitosis in certain cells as there are several isoforms of the MYPT 
subunits and previous studies have shown that AMPK does not target all of the isoforms 
(Zagorska et al., 2010). There is also a possible role for related proteins involved in other 
signalling cascades to control separate parts of these pathways. 
 
1.2 AMPK-related kinases 
Data from the sequencing of the human kinome revealed a family of twelve protein kinases 
that are closely related to AMPK and share significant sequence homology within the catalytic 
α subunit (Manning et al., 2002) (Figure 1.5A). All the kinases listed are highly conserved and 
also show a high degree of homology across their mouse orthologues (Figure 1.5B). There are 
also eight other kinases that contain the same conserved threonine site within their T-loop 
sequence but do not have the same overall sequence homology with the other AMPK-related 
kinases (Jaleel et al., 2005). In this thesis, references made to “AMPK-related kinases” are 
consistent with the definition used in Manning et al. (2002). 
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AMPKα1     163 HRDLKPENVLLDAHMNAKIADFGLSNMMSD--GEFLRTSCGSPNYAAPEVISGRLYAGPE 
AMPKα2     137 HRDLKPENVLLDAHMNAKIADFGLSNMMSD--GEFLRTSCGSPNYAAPEVISGRLYAGPE 
NUAK1      176 HRDLKLENILLDDNCNIKIADFGLSNLYQK--DKFLQTFCGSPLYASPEIVNGRPYRGPE 
NUAK2      173 HRDLKLENILLDANGNIKIADFGLSNLYHQ--GKFLQTFCGSPLYASPEIVNGKPYTGPE 
MARK1      180 HRDLKAENLLLDGDMNIKIADFGFSNEFTV--GNKLDTFCGSPPYAAPELFQGKKYDGPE 
MARK2      140 HRDLKAENLLLDADMNIKIADFGFSNEFTF--GNKLDTFCGSPPYAAPELFQGKKYDGPE 
MARK3      176 HRDLKAENLLLDADMNIKIADFGFSNEFTV--GGKLDTFCGSPPYAAPELFQGKKYDGPE 
MARK4      179 HRDLKAENLLLDAEANIKIADFGFSNEFTL--GSKLDTFCGSPPYAAPELFQGKKYDGPE 
BRSK1      154 HRDLKPENLLLDEKNNIRIADFGMASLQVG--DSLLETSCGSPHYACPEVIKGEKYDGRR 
BRSK2      139 HRDLKPENLLLDEKNNIRIADFGMASLQVG--DSLLETSCGSPHYACPEVIRGEKYDGRK 
SIK1       147 HRDLKTENLLLDGNMDIKLADFGFGNFYKS--GEPLSTWCGSPPYAAPEVFEGKEYEGPQ 
SIK2       140 HRDLKAENLLLDNNMNIKIADFGFGNFFKS--GELLATWCGSPPYAAPEVFEGQQYEGPQ 
SIK3       128 HRDLKAENLLLDANLNIKIADFGFSNLFTP--GQLLKTWCGSPPYAAPELFEGKEYDGPK 
MELK       130 HRDLKPENLLFDEYHKLKLIDFGLCAKPKGNKDYHLQTCCGSLAYAAPELIQGKSYLGSE 
consensus  199 ***** **.*.*. ......***......   .  * *.***..**.**...*. *.*.. 
 
B 
 
AMPKα1     137 HRDLKPENVLLDAHMNAKIADFGLSNMMSD--GEFLRTSCGSPNYAAPEVISGRLYAGPE 
AMPKα2     137 HRDLKPENVLLDAQMNAKIADFGLSNMMSD--GEFLRTSCGSPNYAAPEVISGRLYAGPE 
NUAK1      177 HRDLKLENILLDDNCNIKIADFGLSNLYQK--DKFLQTFCGSPLYASPEIVNGRPYRGPE 
NUAK2      185 HRDLKLENILLDANGNIKIADFGLSNLYHK--GKFLQTFCGSPLYASPEIVNGKPYVGPE 
MARK1      180 HRDLKAENLLLDADMNIKIADFGFSNEFTV--GNKLDTFCGSPPYAAPELFQGKKYDGPE 
MARK2      173 HRDLKAENLLLDADMNIKIADFGFSNEFTF--GNKLDTFCGSPPYAAPELFQGKKYDGPE 
MARK3      176 HRDLKAENLLLDADMNIKIADFGFSNEFTV--GSKLDTFCGSPPYAAPELFQGKKYDGPE 
MARK4      179 HRDLKAENLLLDAEANIKIADFGFSNEFTL--GSKLDTFCGSPPYAAPELFQGKKYDGPE 
BRSK1      154 HRDLKPENLLLDEKNNIRIADFGMASLQVG--DSLLETSCGSPHYACPEVIKGEKYDGRR 
BRSK2      140 HRDLKPENLLLDERNNIRIADFGMASLQVG--DSLLETSCGSPHYACPEVIRGEKYDGRK 
SIK1       147 HRDLKTENLLLDSNMDIKLADFGFGNFYKP--GEPLSTWCGSPPYAAPEVFEGKEYEGPQ 
SIK2       140 HRDLKAENLLLDNNMNIKIADFGFGNFFKT--GELLATWCGSPPYAAPEVFEGQQYEGPQ 
SIK3       187 HRDLKAENLLLDANLNIKIADFGFSNLFTP--GQLLKTWCGSPPYAAPELFEGKEYDGPK 
MELK       130 HRDLKPENLLFDENHKLKLIDFGLCAKPKGNKDYHLQTCCGSLAYAAPELIQGKSYLGSE 
consensus  207 ***** **.*.*........***......   .  * *.***..**.**...*. *.*.. 
 
Figure 1.5 Sequence homology of the AMPK-related kinases 
(A) Alignment of the sequences of the human kinases with the critical threonine residue 
highlighted. (B) A sequence alignment of the kinases using sequences from the mouse 
reference genome. The homology within the kinase domain is clearly very high and also the 
homology between the human and mouse forms of the kinases is very evident.  
AMPK = AMP-activated protein kinase, NUAK1/2 = Nua (novel) kinase 1 and 2, MARK1-4 = 
Microtubule affinity-regulating kinases 1-4, BRSK1/2 = Brain-specific kinases 1 and 2, SIK1-3 = 
Salt-inducible kinases 1-3, MELK = Maternal embryonic leucine zipper kinase 
 
Critical 
threonine 
residue 
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1.2.1 Regulation of AMPK-related kinases by upstream kinases 
As described earlier there are three kinases (LKB1, CaMKKβ and TAK1) that have been well 
characterised as being upstream activators of AMPK. When they were first discovered, one of 
the defining features of the AMPK related kinases (with the exception of MELK) was that they 
share a common upstream kinase, LKB1 (Lizcano et al., 2004). The function of LKB1 has 
already been well defined in the literature as an activator of AMPK (Hawley et al., 2003; 
Woods et al., 2003) and certain known activators of AMPK such as metformin have been 
shown to act through phosphorylation by LKB1 (Shaw et al., 2005). No study since the original 
identification of the AMPK-related kinases has looked at all of them simultaneously but some 
data suggests that that the other AMPK upstream kinases may not activate the related 
kinases. Conflicting reports exist as to whether CaMKKβ can phosphorylate and activate brain-
specific kinases 1 and 2 (BRSK1 and BRSK2) (Bright et al., 2008; Fujimoto et al., 2008). 
Additionally these reports dispute the role of cyclic AMP-dependent protein kinase (PKA) 
upstream of the BRSKs, but other studies have indicated a role for PKA upstream of salt 
inducible kinase 1 (SIK1) (Takemori et al., 2002).  Some studies into the function of the AMPK-
related kinases have also suggested that they can be regulated by other pathways and that 
there may be similarities in the activation of sub-families of the related kinases (Bright et al., 
2009). The microtubule affinity-regulating kinase (MARK) group of kinases have been shown 
to be regulated by the TAO1 kinase (Hutchison et al., 1998) and glycogen synthase kinase-3β 
(GSK-3β) (Timm et al., 2008). There is also evidence that the SIK sub-family can be regulated 
by Akt2, leading to transcriptional control through degradation of CREB regulated 
transcription coactivator 2 (CRTC2) (Dentin et al., 2007) and by Ca2+/calmodulin-dependent 
kinase (CaMK) (Sjostrom et al., 2007). 
 
As with AMPK, it is probable that the balance between phosphorylation and 
dephosphorylation is a key determinant of AMPK-related kinase activity which would suggest 
that the regulation of inactivating phosphatases may also play an important role. This is 
particularly interesting as several studies have shown that members of the related kinase 
family have substrates that are part of protein phosphatase complexes (Sjostrom et al., 2007; 
Yamamoto et al., 2008; Zagorska et al., 2010) which raises the possibility of regulatory 
feedback loops.  
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1.2.2 Regulation of AMPK-related kinases by ubiquitination 
There have been reports that some members of the AMPK-related kinase family interact with, 
and may be regulated by, ubiquitin specific proteases USP9X and USP11 (Al-Hakim et al., 2008; 
Jaleel et al., 2006). The AMPK-related kinases are distinctive within the human kinome 
because most of them contain an ubiquitin associated (UBA) domain (Katajisto et al., 2007; 
Manning et al., 2002). Notably, the two related kinases that do not contain UBA domains are 
NUAK1 and NUAK2, meaning there could be key mechanisms of regulation linked to the 
absence of this domain (Figure 1.6). 
 
Figure 1.6 Domain comparison of AMPK-related kinases (from Katajisto et al., 2007) 
The domain structure of the human AMPK-related kinases is compared, aligned to the N-
terminal end of the kinase domain. The LKB1 phosphorylation site of a conserved threonine 
residue is highlighted in the kinase domain which is shown in red. Ubiquitin-associated 
domains (UBA) are shown in blue. Kinase associated domains, which are part of the MARK 
family and are of unknown function, are highlighted in orange. Domains which were identified 
in the SIK proteins contain an inhibitory PKA-phosphorylation site and can regulate subcellular 
localisation. Pfam-B domains conserved in human, Drosophila and C. elegans genomes are 
highlighted in grey.  
 
The UBA domains appear to be essential for activation, as a specific mutation within this 
region can prevent phosphorylation by LKB1 (Bright et al., 2008; Jaleel et al., 2006). 
Ubiquitination is a very important cellular process which can target proteins to various parts 
of the cell or mark them for degradation. The exact purpose of the ubiquitination of the 
AMPK-related kinases is not yet known, but may have an important role in controlling stability 
  Chapter 1 - Introduction 
34 
 
or activation by upstream kinases. Although domain identification programs do not detect a 
UBA in NUAK1 or NUAK2, sequence alignments show there is some homology between this 
region and the UBA domains on other AMPK-related kinases (Figure 1.7, (Jaleel et al., 2006). 
There is evidence that polyubiquitination may play a role in inhibiting NUAK1, as non-
ubiquitin specific protease 9X (USP9X) binding mutants were found to be hyperubiquitinated 
and inactive (Al-Hakim et al., 2008). MARK4 and NUAK2 have been shown to interact with 
USP9X and the binding site was identiﬁed as a tryptophan residue that is conserved in all the 
AMPK-related kinases. However, none of the other kinases showed any interaction with 
USP9X (Al-Hakim et al., 2008).  
 
AMPKα1     311 STMIDDEALKEVCEKFEC--S------EEEVLSCLYNRNHQDPLAVAYHLIIDNRRIMNE 
AMPKα2     285 ANVIDDEAVKEVCEKFEC--T------ESEVMNSLYSGDPQDQLAVAYHLIIDNRRIMNQ 
NUAK1      324 ESPL----LARIIDWHHR--STGLQADTEAKMKGLAKP------TT-SEVMLERQRSLKK 
NUAK2      321 GHPGSDSARASMADWLRR--SSRPLLENGAKVCSFFKQH-APGGGS-TTPGLERQHSLKK 
MARK1      327 DPDFNDTKRIDIMVTMGF--A------RDEINDALINQK-YDEVMATYILLGRKPPEFEG 
MARK2      287 LPDYKDPRRTELMVSMGY--T------REEIQDSLVGQR-YNEVMATYLLLGYKSSELEG 
MARK3      323 ELDISDQKRIDIMVGMGY--S------QEEIQESLSKMK-YDEITATYLLLGRKSSELDA 
MARK4      326 EEDFGDTKRIEVMVGMGY--T------REEIKESLTSQK-YNEVTATYLLLGRKTEEGGD 
BRSK1      311 SNGELDPDVLESMASLGCFRD------RERLHRELRSEE-ENQEKMIYYLLLDRKERYPS 
BRSK2      294 SLEDIDPDVLDSMHSLGCFRD------RNKLLQDLLSEE-ENQEKMIYFLLLDRKERYPS 
SIK1       300 NLGDYDEQALGIMQTLGV--D------RQRTVESLQNSS-YNHFAAIYYLLLERLKEYRN 
SIK2       292 SIGEFNEQVLRLMHSLGI--D------QQKTIESLQNKS-YNHFAAIYFLLVERLKSHRS 
SIK3       283 QVDPLNEDVLLAMEDMGL--D------KEQTLQSLRSDA-YDHYSAIYSLLCDRHKRHKT 
MELK       279 FIHLDDDCVTELSVHHRN--N------RQTMEDLISLWQ-YDHLTATYLLLLAKKARGKP 
consensus  361      .  .....  ..   .      .. .....     .  . . . ..... .   
   
Figure 1.7 Sequence alignment of UBA domains in AMPK-related kinases 
Alignment of the sequences of the human kinases across the UBA domains. The variation 
across this region within NUAK1 and NUAK2 is very evident. AMPK = AMP-activated protein 
kinase, NUAK1/2 = Nua (novel) kinase 1 and 2, MARK1-4 = Microtubule affinity-regulating 
kinases 1-4, BRSK1/2 = Brain-specific kinases 1 and 2, SIK1-3 = Salt-inducible kinases 1-3, MELK 
= Maternal embryonic leucine zipper kinase 
 
MELK, which is known to autophosphorylate, does not have a particularly high degree of 
homology across the UBA domain compared to the other related kinases. It shares some 
homology with NUAK1 across this region but this is unlikely to indicate that NUAK1 would 
share functional similarities with MELK (Figure 1.7). Polyubiquitination of NUAK1 prevented 
activation by LKB1 in vitro (Al-Hakim et al., 2008). A report investigating ubiquitination of 
AMPK-related kinases proposed a system of regulation based on the conformation of 
different domains within the protein. It was suggested that the kinase domain and Lys29/Lys33 
polyubiquitin chains compete for binding to the UBA domain (Al-Hakim et al., 2008). This 
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system of regulation also relates to previous data suggesting that the kinase domain binding 
to the UBA domain is important for LKB1 activation of other related kinases (Jaleel et al., 
2006). As identified by these previous studies, there are several other ways in which 
ubiquitination could affect kinase activity such as steric shielding of the critical threonine 
residue or other sites interacting with upstream kinases. Similarly, the presence of ubiquitin 
chains could promote dephosphorylation by phosphoprotein phosphatases (Al-Hakim et al., 
2008). The exact function of the UBA domain may vary depending on other factors, since 
ubiquitination is normally used as a method of targeting proteins for degradation but 
ubiquitination of NUAK1 does not seem to affect its stability (Al-Hakim et al., 2008). Another 
study on the UBA domain of MARK3 discovered it has intrinsic conformational instability 
which can cause it to unfold, affecting interactions with other proteins, which could in turn 
affect its activity (Murphy et al., 2007). 
 
1.2.3 AMPK-related kinases and 14-3-3 proteins 
14-3-3 proteins are small regulatory molecules which have been shown to bind to various 
AMPK-related kinases (Al-Hakim et al., 2005). The 14-3-3 protein family consists of 30 kDa 
acidic proteins which are widely expressed in most tissues. There are ﬁve major isoforms 
(which are named α – η). 14-3-3 proteins are functional dimers that can regulate interactions 
between other proteins. Over 200 known interacting partners exist and 14-3-3 proteins have 
been shown to be involved in a number of cellular processes, particularly trafficking, 
cytoskeletal structure, cell cycle progression and subcellular localisation (Aitken, 2006; Al-
Hakim et al., 2005; Morrison, 2009). The protein family is highly conserved across most 
mammalian species and all the isoforms are typically identical, but contain a few loci of 
variation. 14-3-3 homologues have been identified in a broad range of eukaryotic organisms. 
In terms of the AMPK-related kinases there is some contention over whether 14-3-3 proteins 
interact directly with the kinase or via another partner protein and whether they can directly 
affect the kinase activity. There could be a huge range of possibilities, including different 
partner proteins in different tissues and redundancy within the 14-3-3 isoforms. SIK1 and SIK3 
are known to interact with 14-3-3s after phosphorylation by LKB1 and in the case of the SIK 
kinases, the binding of 14-3-3s localises them to the cytoplasm and increases their catalytic 
activity (Al-Hakim et al., 2005). 14-3-3 proteins are known to interact with the PAR-1/MARK 
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enzymes (Brajenovic et al., 2004) and some data suggests phosphorylation of PAR-1/MARK 
by atypical protein kinase C (aPKC) favours 14-3-3 binding and can cause changes in 
subcellular localisation (Hurov et al., 2004; Kusakabe and Nishida, 2004; Suzuki et al., 2004b). 
Another study showed that this interaction with 14-3-3s is mediated by several 
phosphorylation sites (Goransson et al., 2006), but it has no apparent effect on catalytic 
activity (Al-Hakim et al., 2005). 
 
1.2.4 AMPK-related kinases and other signalling pathways 
Due to the interest in LKB1 and its downstream functions, recent effort has focussed on 
understanding the regulation of the AMPK-related kinases and other signalling pathways in 
which they are involved. Although research in this area is not as extensive as the work on 
AMPK itself, there are still some interesting indications of the function of the AMPK-related 
kinases and potential crosstalk with other well characterised pathways (Bright et al., 2009). 
There are broadly four subfamilies of kinases within the AMPK-related kinases (MARKs, 
BRSKs, SIKs and NUAKs) and of these, the MARKs have been studied most extensively.  
 
1.2.5 MARK/PAR family 
Microtubule affinity-regulating kinases (MARKs) were originally identiﬁed in the brain and so 
named because they are able to regulate the interaction of microtubule associated proteins 
(MAPs) and microtubules (Drewes et al., 1997). In particular, MARK phosphorylation of a well 
characterised microtubule organising protein tau causes dissociation from microtubules and 
destabilisation of the whole microtubule network (Stoothoff and Johnson, 2005). Tau is also 
known to have a role in controlling transport along the microtubule network by blocking 
interactions with motor proteins (Stamer et al., 2002). There is also an increasing body of 
evidence that tau plays a role in the development of neural pathologies such as Alzheimer’s 
disease and that dysregulation of associated pathways may be responsible for further neural 
damage (Weiner, 2013). In Drosophila, the neurotoxic effects of tau can be reduced by 
expressing tau protein mutated at two serine residues. These residues lie in the domain 
responsible for microtubule association and are phosphorylated by the Drosophila 
homologue of the MARK proteins, partitioning defective mutant 1 (PAR-1) (Nishimura et al., 
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2004). These mutations also prevented hyperphosphorylation of tau at different residues by 
other kinases and it has been suggested that phosphorylated tau may be cleaved and can 
then aggregate to form ﬁlaments and insoluble neuroﬁbrillary tangles seen in neuropathies 
such as Alzheimer’s disease (Gamblin et al., 2003). 
  
Studies investigating the MARK homologues in the PAR family of kinases in other model 
organisms such as Drosophila and C. elegans have revealed some additional functions. The 
family was originally identified as a regulator of embryonic polarity and partitioning in C. 
elegans (Kemphues et al., 1988). The PAR family have also been shown to be required for the 
establishment of cell polarity in a series of other model organisms (reviewed in Marx et al., 
2010). PAR proteins have been implicated in neuron growth, as overexpression of MARK2 
inhibits axon formation and polarization of neurones (Chen et al., 2006). Another study has 
provided links to calcium-dependent pathways as Ca2+/calmodulin dependent kinase I 
(CaMKI) is known to phosphorylate MARK2 and promote neurite outgrowth (Uboha et al., 
2007). Conflicting reports in different organisms have shown the PAR family interacting and 
controlling elements of the Wnt signalling pathways, thereby influencing cell growth and 
proliferation (Figure 1.8)  (Kusakabe and Nishida, 2004; Sun et al., 2001). Some reports 
suggest that different isoforms of PAR-1 (i.e. MARK1 – 4 in mammals) may control different 
parts of the Wnt signalling pathways (Mamidi et al., 2012; Ossipova et al., 2005). 
  
MARK1 might be involved in synaptic plasticity because potassium chloride-induced 
depolarization of neurons and neurotrophic factors increase MARK1 activity (Jeon et al., 
2005). MARK2 knockout mice models indicated a variety of functions such as fertility, 
metabolic processes and regulation of the immune system (Bessone et al., 1999; Hurov and 
Piwnica-Worms, 2007; Hurov et al., 2001). MARK3 has been shown to inactivate Cdc25 
phosphatase, important for the control of the cell cycle, which prevents activation of the 
Cdc2/cyclin B complex by dephosphorylation, which is required for entry into mitosis (Peng 
et al., 1998). MARK3 is also known to be downstream of Pim-1, regulating the same Cdc25 
signal at the G2/M cell cycle checkpoint (Bachmann et al., 2004). MARK3 has also been shown 
to interact with the Ras-MAPK pathway via the kinase suppressor of Raf-1 (KSR1) (Muller et 
al., 2001). One isoform of MARK4 is highly expressed in hepatocellular carcinomas (Beghini et 
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al., 2003; Kato et al., 2001), which suggests that it may play a role in tumour progression 
(Figure 1.8). 
 
1.2.6 BRSK family 
The BRSKs have the most tightly controlled expression of all the AMPK-related kinases as they 
are almost exclusively expressed in the brain, with a low level of expression detected in the 
testis and pancreas (Bright et al., 2008; Hezel et al., 2008; Inoue et al., 2006; Kishi et al., 2005). 
Homologues have been identified in Drosophila and C. elegans as Synapses of the Amphid 
Defective (SAD kinases) and shown to be regulators of neuronal polarity (Crump et al., 2001). 
Research into the area of SAD kinases in other model organisms (SAD-A = BRSK2, SAD-B = 
BRSK1) have revealed more information about the way they are regulated, but some recent 
studies have investigated BRSK proteins in mammalian systems. Mice with each kinase 
deleted individually were healthy, but double mutants showed poor responsiveness to 
physical stimulation and died shortly after birth, indicating that neuronal function was 
severely impaired and suggesting there may be redundancy within the BRSK family (Kishi et 
al., 2005). Double knockout mice have thinner cortices and individual neurones lack distinct 
neural outgrowths, possibly regulated by tau phosphorylation (Kishi et al., 2005). 
Interestingly, pyramidal neuron-specific LKB1 knockout mice showed a similar phenotype to 
the BRSK double knockout mice, indicating that the AMPK-related kinases probably play a role 
in regulating the tissue-specificity of the downstream functions of LKB1 (Barnes et al., 2007).  
  
Recent evidence has indicated a function for these kinases outside the brain, as BRSK2 has 
been shown to be a downstream mediator of mTOR signalling in the pancreas (Nie et al., 
2013). BRSK2 deletion leads to reduced glucose-stimulated insulin secretion from isolated β-
cells, similar to the phenotype of deletion of S6 kinase 1, a downstream target of mTORC1 
(Nie et al., 2013). BRSK2 expression can be stimulated by glucose and inhibited by rapamycin, 
implicating mTOR signalling and potential interaction with other metabolic processes (Figure 
1.3 and Figure 1.4). 
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1.2.7 SIK family 
The salt-inducible kinases (SIK) family of proteins were first identified from the adrenal glands 
of rats fed a high-salt diet, suggesting its involvement in gene expression after stimulation by 
the steroid adrenocorticotropic hormone (ACTH) (Wang et al., 1999). As the name would 
suggest, rises in intracellular sodium can increase expression of SIK1, which activates the 
Na+/K+ ATPase that in turn regulates various essential cell functions (Popov et al., 2011; 
Sjostrom et al., 2007). High sodium levels also increase calcium levels in the cell because ion 
pumps exchange sodium and calcium and the high calcium concentration activates CaMK 
which is thought to be able to phosphorylate and activate SIK1 (Sjostrom et al., 2007). There 
are thus multiple potential upstream kinases and the AMPK-related kinases may be involved 
in pathways decoding many extrinsic signals. SIK2 appears to be ubiquitously expressed (Xia 
et al., 2000) but particularly high expression has been shown in adipose tissue where it can 
phosphorylate insulin receptor substrate-1 (IRS1) (Horike et al., 2003). This phosphorylation 
is at the same site that is phosphorylated by AMPK (Jakobsen et al., 2001), which suggests 
SIK2 may be involved in insulin signal transduction and there could be some convergence 
between the AMPK and the AMPK-related kinase pathways (Figure 1.8). SIK2 also crosses over 
into other AMPK targets by phosphorylating CRTC2 at the AMPK site and preventing CREB-
activated transcription (Figure 1.4) (Screaton et al., 2004). SIK3 may interact with pathways 
regulating cell proliferation, as mitotic defects have been observed following knockdown of 
the Drosophila homologue, QSK (Bettencourt-Dias et al., 2004). 
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Figure 1.8 Functional roles and tissue specificity of AMPK-related kinases (adapted from 
Bright et al., 2009) 
The various roles of AMPK-related kinases (with homologue names in brackets) are shown 
alongside the predominant site of expression. The exact expression profile of some of the 
kinases is unclear and there is likely to be lower expression in other tissues. The broad range 
of functions of the AMPK-related kinases suggest their involvement in many signalling 
pathways. 
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1.3 NUAK1 
Nua (novel) kinase 1 (NUAK1) (also known as AMPK-related kinase 5, ARK5) is of particular 
interest, as various reports in the literature have indicated that it is involved tumour 
progression and senescence (Humbert et al., 2010; Kusakai et al., 2004a; Suzuki et al., 2003a; 
Suzuki et al., 2003b). Previous studies have suggested many interesting biological functions 
for NUAK1, however none of these observations provide coherent evidence for its function 
and regulation and there is little evidence for its role in cellular functions in vivo.  
 
1.3.1 NUAK1 homology, expression, structure and regulation 
The human NUAK1 protein is comprised of 661 amino acids (MW ≈ 76 kDa) and mouse NUAK1 
has 658 amino acids and 100% homology across the kinase domain compared to human 
NUAK1 (Figure 1.5 and Figure 1.9) with various orthologues identified in other species (Figure 
1.9). In a study to assess the global NUAK1 mouse knockout, expression was assessed by βgal 
inserted into the NUAK1 gene and by in situ hybridisation to look at mRNA levels (Hirano et 
al., 2006). The two methods correlated well, showing that mRNA levels should be an accurate 
indicator of protein expression in adult tissues. At embryonic day 9.5 βGal expression was 
found throughout the undifferentiated neuroectoderm and was ubiquitous in the epidermis 
but particularly highly expressed in the ventral body wall. At E14.5 and E18.5 βGal expression 
was only seen in differentiated areas of the cortex but not in other brain areas and was 
maintained in the epidermis of the whole body. 
 
An early study on NUAK1 activation in rat skeletal muscle investigated the expression profile 
in adult tissues and found mRNA present in heart, kidney, brain, liver, and skeletal muscle 
(Fisher et al., 2005). 
 
 
 
 
 
 
  Chapter 1 - Introduction 
42 
 
A 
 
B 
 
 
 
Figure 1.9 Homology of NUAK1 in various species (adapted from Hirano et al., 2006) 
(A) A phylogenetic tree of NUAK1 and NUAK2 orthologues from various species are shown, 
displaying the genetic divergence between the two NUAK family kinases and the distant 
relationship of the vertebrate orthologues to the C. elegans and Drosophila proteins. (B) The 
domain structure of various NUAK1 orthologues and the kinase domains are highlighted. The 
percentage figures show the level of homology to the mouse NUAK1 kinase domain and the 
numbers indicate the relevant residues within the protein. 
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Like all the AMPK-related kinases, NUAK1 has a highly conserved T loop and a critical 
threonine residue in the catalytic domain (Figure 1.5). The conserved threonine (residue 211 
in human NUAK1) can be phosphorylated and activated by LKB1 (Lizcano et al., 2004) and 
other reports have suggested that NUAK1 can be activated by phosphorylation on serine 600 
by Akt (Suzuki et al., 2004b).  
 
Initially, only a few laboratories studied the role of NUAK1 and various reports emerged from 
Hiroyasu Esumi’s group in Japan, including an initial report identifying NUAK1 by homology to 
the previously discovered NUAK2 (Suzuki et al., 2003b). However much of the biochemical 
analyses in these studies were carried out by observing cross-reaction with an antibody 
generated against a peptide from human NUAK2 (KKPRQRESGYYSSPEPS, residues 450 - 467). 
The group were interested in studying the connection of the AMPK family to metabolic 
processes in cancer cells, particularly the Akt pathway (Suzuki et al., 2003b). NUAK1 was an 
attractive candidate for this as it contains a conserved Akt consensus sequence (residues 595 
– 600), but there are concerns that the methods used would not conclusively rule out a role 
for other AMPK-related kinases (Suzuki et al., 2003b). Another report from the same group 
identified Nuclear Dbf2-Related Kinase 2 (NDR2) as a novel upstream kinase of NUAK1, 
capable of phosphorylating it on the critical T211 residue (Suzuki et al., 2006). NDR2 was 
identified by sequence homology to AMPK upstream kinases LKB1 and CaMKKβ but the 
confirmation of the role in vitro and the biochemical methods used are unclear, leading to 
concerns about the conclusions. Similarly reports that NUAK1 phosphorylation is stimulated 
by muscle contraction, insulin and AICAR have related issues with the methods, as much of 
the blotting data uses the same cross-reacting antibody and no significant difference in 
NUAK1 activity was measured (Fisher et al., 2005).  
 
Other reports in the literature have described a possible role for NUAK1 in controlling cell 
adhesion through regulating the phosphorylation of MYPT1 which, in a complex with PP1β, 
can dephosphorylate MLC (Zagorska et al., 2010). The proposed model involves 14-3-3 
binding to MYPT1 and reducing phosphatase activity but there may be many other aspects 
such as interaction with other partner proteins or other kinases affecting the system. This 
study also identified a conserved motif (Gly-Ile-Leu-Lys or GILK motif) that mediates the 
binding of NUAK1 to PP1β (Zagorska et al., 2010). Interestingly, NUAK2, which likewise 
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contains a GILK motif, has also been implicated in the phosphorylation of MYPT1 (Yamamoto 
et al., 2008). Taken together, there may be redundancy between these two protein kinases 
as the latter study confirmed that NUAK2 can interact with PP1β. NUAK1 and NUAK2 are the 
only AMPK-related kinases that contain GILK motifs and so this mechanism of myosin 
phosphatase regulation may be specific to them. Consistently, the involvement of the C. 
elegans homologue of the NUAK family (unc-82) in myosin organisation during development 
has been described (Hoppe et al., 2010). Another piece of supporting data from a large scale 
screen identified NUAK1 as one of two candidate loci for the determination of muscle 
strength, indicating an involvement in muscle development and myosin organisation 
(Windelinckx et al., 2011).  
 
It is currently unclear if NUAK1 requires dimerization or partner proteins for activity, like 
AMPK, but recent data regarding the structure and activation of members of the MARK/PAR 
family indicate that they are capable of autoactivation (Marx et al., 2010), and this may be 
true of other related kinases. Another AMPK-related kinase, MELK, has intrinsic activity and 
is capable of autophosphorylation with no involvement of LKB1 for activation (Lizcano et al., 
2004). 
 
Very recent data has emerged showing that NUAK1 may have other functions in different 
tissues, such as controlling axon branching by interfering with mitochondrial transport 
(Courchet et al., 2013). NUAK1 can be regulated by microRNAs, specifically miR-211 (Bell et 
al., 2013). The downregulation of NUAK1 by miR-211 led to increased cell adhesion in 
melanoma cells and provides another clue to the role of NUAK1. Importantly, all these data 
may link with the myosin organisation phenotype seen in C. elegans and may be modulated 
by components of the same pathways, meaning downstream effects of NUAK may converge 
on MYPT and PP1β (see section 1.5 ).  
 
All of the other information gathered to date regarding the function and regulation of NUAK1 
has come from screens looking at cancer progression and cell proliferation. Some of these 
data may link with the pathways identified above but more work will be required to confirm 
the functional relevance of NUAK1 in these pathways.  
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1.3.2 NUAK1 in cancer, cell proliferation and senescence 
Most of the earliest reports that NUAK1 is involved in regulating cell proliferation and possible 
cancer phenotypes also came from Hiroyasu Esumi’s group and they all suggested that NUAK1 
was pro-proliferative (Kusakai et al., 2004a; Kusakai et al., 2004b; Suzuki et al., 2005). 
Increased NUAK1 mRNA was detected in human cancer biopsies and cell lines. However, there 
was no evidence of increased NUAK1 kinase activity. The only suggested downstream 
mechanism for how NUAK1 promoted cell proliferation and invasion was by regulation of 
caspase-6, indicated by coincident expression in colorectal cancer cells (Suzuki et al., 2004a). 
While this is a possible mechanism, NUAK1 is a protein kinase whose downstream targets 
would not be regulated by changes in their expression but by changes in their 
phosphorylation. 
 
Contrary to these reports, data emerged from our laboratory, in collaboration with others, 
that downregulation of NUAK1 leads to an increase in replicative lifespan and a reduction in 
senescence (Humbert et al., 2010). This report also showed a requirement for LKB1 activation 
of NUAK1, consistent with previous reports that this is an upstream kinase for NUAK1 (Lizcano 
et al., 2004). The mechanism proposed for the effect on senescence was regulation of large 
tumour suppressor kinase 1 (LATS1) as NUAK1 was shown to phosphorylate it directly and a 
dominant-negative version had the same phenotypic effect as NUAK1 knockdown (Humbert 
et al., 2010). Another report investigating cancer models with deregulated MYC expression 
found that NUAK1 depletion prolonged cell survival by maintaining metabolic homeostasis 
(Liu et al., 2012). However, the mechanism proposed for this was partly via direct 
phosphorylation and regulation of AMPK and mTORC1 (Figure 1.3), which has not been 
reported by any other group despite numerous studies on AMPK activation (Hardie, 2008).  
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Figure 1.10 The Hippo pathway (from Pan, 2010) 
The Hippo pathway is a growth regulating signalling pathway first identified in Drosophila but 
the components of the cascade are highly conserved in mammals. Known direct interactions 
are shown by solid lines or as proteins in direct contact with each other. Dashed lines indicate 
potential interactions identified by homology from the Drosophila pathway but for which 
there is currently no evidence.  
 
 
The finding that NUAK1 can phosphorylate and activate LATS1 links it to a highly conserved 
growth regulating signalling pathway, Hippo, known to be involved in the control of organ size 
(Pan, 2010). The main end target of the Hippo pathway is the inactivation of transcriptional 
coactivators Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding 
motif (TAZ), which in turn regulate the expression of a number of genes as shown in Figure 
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1.10. Overexpression of YAP is capable of mimicking loss of Hippo signalling and producing 
vastly oversized organs, also leading to hepatocellular carcinoma when overexpressed in 
mouse liver (Dong et al., 2007). Reports that NUAK1 can phosphorylate and reduce expression 
of LATS1 would suggest that it can control the Hippo pathway to activate YAP/TAZ, leading to 
an increase in proliferation and organ size. This suggests that the presence of NUAK1 would 
be pro-proliferative but other studies in human cell lines have suggested that LATS1 
downregulation causes irreversible cell cycle arrest in normal human cells, implicating an anti-
proliferative role for NUAK1 (Humbert et al., 2010; Takahashi et al., 2006). 
 
To further complicate the situation, several other reports have appeared in the past two years 
supporting the initial hypothesis that NUAK1 activity promotes proliferation, at least in certain 
cancer models including breast (Chang et al., 2012), glioma (Lu et al., 2013), non-small cell 
lung cancer (Chen et al., 2013a) and hepatocellular carcinoma (Cui et al., 2013). An isolated 
study also reported that NUAK1 was capable of directly phosphorylating and regulating p53, 
leading to cell cycle arrest (Hou et al., 2011). However, no such mechanism has since been 
reported despite many other validated upstream kinases of p53 and numerous reports 
studying its role in cell proliferation (Carvajal and Manfredi, 2013). NUAK1 can regulate 
adhesion in melanoma cells and may function to control the balance between tumour growth 
and metastasis, but it is unclear if it has a direct pro or anti-proliferative effect (Bell et al., 
2013). 
  
1.3.3 NUAK1 global knockout and omphalocele  
Efforts to identify novel genes involved in brain development in mice led to the creation of a 
global NUAK1 knockout, then termed omphalocele kinase 1 (Omphk1), due to the phenotype 
created by the deletion of the gene (Hirano et al., 2006). Despite the interest in the gene due 
to its expression in the brain, the main phenotype was in the ventral body wall. The knockout 
was generated by inserting the lacZ gene just after the translation initiation site to investigate 
expression by βgal staining and knockout was confirmed by RT-PCR. No live NUAK1 knockout 
embryos were born and the embryos displayed an omphalocele phenotype by embryonic day 
14.5, showing it much more markedly by day 18.5 (Hirano et al., 2006). NUAK1 was expressed 
in both sternal and abdominal bands, but the latter failed to fuse properly across the central 
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abdomen. Prior to embryonic day 12.5, the knockout embryos were normal and the area 
covered by the primary body wall was shown to express NUAK1 (Hirano et al., 2006). The 
pathways involved in mediating this phenotype were not investigated and it was highlighted 
that several screening studies previously showed other kinases are expressed in the ventral 
body wall (Carninci et al., 2005; Okazaki et al., 2002; Stopka and Skoultchi, 2003).  
 
An omphalocele phenotype is an abdominal wall defect, where various internal organs remain 
outside the abdomen surrounded by a membrane because of a defect in the closure of the 
abdominal wall. These sorts of malformations are one of the primary forms of physical human 
birth defects and are present in about 1 in every 2000 – 4000 live births (Brewer and Williams, 
2004a). In humans there is a high rate of mortality (25%) and often other associated 
pathologies such as neural tube defects. In a small proportion of human cases, chromosomal 
abnormalities have been detected but the exact pathways involved in this phenotype are 
unclear (Brewer and Williams, 2004a). Some cases have been linked to trisomy 18 (Kanagawa 
et al., 2002) and trisomy 13 (Yatsenko et al., 2003). NUAK1 is located on human chromosome 
12 (12q23.3) and therefore is unlikely that the omphalocele phenotype has the same 
underlying cause that produces the effect in NUAK1 knockout mice. Recent data from mouse 
knockouts have also provided some clues as to the pathways involved, as the following 
transgenic models all display ventral body wall defects: AP-2α (Brewer and Williams, 2004b), 
Hoxb2/b4 double mutant (Manley et al., 2001), Tgfβ2/β3 double mutant (Dunker and 
Krieglstein, 2002), Mab21l2 (Yamada et al., 2004) and ROCK-I/ROCK-II double knockout 
(Thumkeo et al., 2005). 
 
Recent data from Shinichi Aizawa’s laboratory has shown the mouse global knockout of 
NUAK1 and NUAK2 displays similar embryonic lethality due to exencephaly, facial clefting, 
and spina biﬁda in addition to failure of the ventral body wall to close (Ohmura et al., 2012). 
The report showed changes in the accumulation of various cytoskeletal components including 
phosphorylated MLC, F-actin, and cortactin in the developing neural plate, indicating possible 
downstream targets (Ohmura et al., 2012). 
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1.3.4 NUAK1 muscle specific knockout 
Due to the embryonic lethality of NUAK1 global knockout mice, it has been impossible to 
assess the physiological role of the kinase in adult tissues so studies have been conducted 
using conditional tissue-specific deletions. Only one report to date has shown a skeletal 
muscle-specific knockout of NUAK1 by deleting the kinase using cre-recombinase under the 
control of the muscle creatine kinase (MCK) promoter (Inazuka et al., 2012). The choice of 
skeletal muscle as a target tissue was based on previous expression data from the same group 
(Fisher et al., 2005). No basal phenotype was observed, suggesting that there is no significant 
developmental effect of deleting NUAK1 in muscle. However, on a high fat diet, muscle-
specific NUAK1 knockout mice had lower fasting blood glucose levels, improved glucose 
tolerance and increased muscle glycogen (Inazuka et al., 2012). The suggested mechanism for 
this was by controlling phosphorylation of insulin receptor substrate 1 (IRS1), although no 
direct interaction was shown, only evidence for increased phosphorylation in knockouts. 
These data, combined with previous inconsistent reports from the same laboratory (Fisher et 
al., 2005) could suggest that NUAK1 is affecting IRS1 phosphorylation via activation or 
inhibition of other pathways, rather than by any direct binding to the substrate. 
 
1.4 LKB1 
1.4.1 LKB1 structure and regulation 
LKB1 was first identified after looking for the genetic determinant of the human cancer pre-
disposition condition called Peutz-Jeghers syndrome (PJS). The gene or genes responsible 
were first narrowed down to a locus on chromosome 19 (Hemminki et al., 1997). After various 
attempts to identify mutations in genes from this region that were linked to PJS it was 
narrowed down to a kinase that had previously been identified as part of a genetic screen 
(Hemminki et al., 1998; Su et al., 1996). A parallel study also identified mutations that 
correlated with PJS and termed the kinase serine threonine kinase 11 (STK11) (Jenne et al., 
1998). The initial screen that identified LKB1 showed that it has a high degree of homology 
with XEEK1 which is known to be expressed in early Xenopus embryos and is phosphorylated 
by PKA (Su et al., 1996). 
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A systematic study of the entire human kinome after the publication of the human genome 
showed that there is only one LKB1 gene in humans, which is composed of ten exons (nine 
coding exons) and spans 23kb. Recent data has shown that there are two LKB1 splice variants, 
termed LKB1 long (LKB1L) and LKB1 short (LKB1S) (Denison et al., 2009; Towler et al., 2008). 
The short form of LKB1 has restricted tissue distribution and appears to be predominantly 
expressed in the testis, whereas the LKB1L form appears to be expressed ubiquitously (Alessi 
et al., 2006; Denison et al., 2009). The only function that has been described for LKB1S is a 
role in spermatogenesis (Denison et al., 2011; Towler et al., 2008) and although there is not 
yet any evidence for it, this variant could play a role in regulating the AMPK-related kinases. 
 
Human LKB1 consists of 433 residues and the catalytic domain (residues 49–309) shares some 
sequence identity with AMPK and its related kinases (Figure 1.11C) (Manning et al., 2002; 
Zeqiraj et al., 2009). The non-catalytic regions of the kinase do not seem to share homology 
with any other proteins and do not contain any known functional domains, although there is 
a farnesylation site at the C-terminus of the long form. Expression analyses show that it 
appears to be ubiquitously expressed across all the adult and foetal tissues that were 
examined (Hemminki et al., 1998). Various biochemical studies since the initial discovery have 
determined that LKB1 forms a complex in mammalian cells with two other proteins called 
STE20-related adaptor (STRAD) and mouse protein 25 (MO25) (Figure 1.11). Both these 
partner proteins are required for maximal LKB1 activity and STRAD has been identified as a 
pseudokinase, which may be a vestigial upstream kinase that evolved to become a scaffold. 
Also, various cell based studies have shown that changes in STRAD and MO25 expression can 
influence the binding and sub cellular localisation of LKB1 (Boudeau et al., 2003). Numerous 
studies have showed that LKB1 is constitutively active in all the cell types it has been found 
in, by immunoprecipitation of LKB1 complexes from tissue and cell extracts and through 
observing no change in LKB1 activity under conditions known to activate its downstream 
target AMPK (Sakamoto et al., 2004; Woods et al., 2003). 
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LKB1      173 VHKDIKPGNLLLTTGGTLKISDLGVAEALHPFAADDTCRTSQGSPAFQPPEIANGLDTFSG 
AMPKα1    162 VHRDLKPENVLLDAHMNAKIADFGLSNM---MSDGEFLRTSCGSPNYAAPEVISGR-LYAG 
NUAK1     175 VHRDLKLENILLDDNCNIKIADFGLSNL---YQKDKFLQTFCGSPLYASPEIVNGR-PYRG 
consensus 198 VHrDlKpeNlLLd   nlKIaDfGlsnm   f  ddflrTscGSP ya PEiinGr  y G 
 
Figure 1.11 Structure and sequence homology of the LKB1 complex (adapted from Zeqiraj 
et al., 2009) 
(A) Domain structure of LKB1, STRADα and MO25α (B) Surface representation of the three 
dimensional crystal structure of the LKB1 complex, showing a potential function of MO25 in 
holding the complex together. (C) Sequence alignment of the human kinase domains of LKB1 
(the catalytic part of the LKB1 complex), AMPKα1 and NUAK1 showing the sequence similarity 
between the three kinases. 
 
T172 in AMPK equivalent 
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1.4.2 LKB1 as a tumour suppressor 
Early biochemical studies of the role of LKB1 quickly suggested that it may have a key role in 
cell cycle progression and cell proliferation, because overexpression of active LKB1 in cell lines 
known not to express LKB1 endogenously, such as HeLa, caused a G1 cell cycle arrest (Tiainen 
et al., 1999). In the same study catalytically inactive mutants, including known PJS mutations, 
were found not to arrest the cell cycle despite similar over expression. 
 
Before tissue specific knockouts of LKB1 were developed there were studies using 
heterozygous germ line deletions of LKB1 investigating the effect of partial loss of activity in 
vivo. Given the involvement of LKB1 in PJS and potential tumour suppressor effects, much of 
the focus was on the incidence of cancer within this model. The most striking observation was 
the high level of hepatocellular carcinomas (HCC), particularly in male mice (Nakau et al., 
2002). In terms of LKB1 activity, conflicting reports have been made about whether total or 
partial loss of LKB1 can lead to formation of polyps and tumours. Various groups showed that 
LKB1 expression in polyps from PJS patients was approximately half the normal level, 
suggesting that the heterozygosity gene dosage effect was enough to form tumours (Jishage 
et al., 2002; Miyoshi et al., 2002; Rossi et al., 2002). A parallel report also showed that many 
polyps isolated from heterozygous LKB1 mice showed total loss of LKB1 expression, either 
through gene inactivation or loss of the wild-type allele (Bardeesy et al., 2002). These studies 
did not look at the biochemical basis for this effect, but it suggests that loss or lower activity 
of LKB1 and pathways downstream of it may be responsible for the increased incidence of 
polyps and hepatocellular carcinomas.  
 
 
1.4.3 LKB1 heart-specific mouse knockout  
Due to the role of LKB1 as a tumour suppressor and being upstream of AMPK there has been 
significant interest in studying the in vivo role of the kinase using mouse knockout models. 
Early attempts to use gene targeting to delete the gene throughout the entire body caused 
embryonic lethality in mid-gestation due to death of mesenchymal cells, defects in vascular 
development and malformations of the neural tube (Ylikorkala et al., 2001). In recent years it 
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has become more feasible to use conditional gene targeting technology such as FLP 
recombinase and tissue specific expression of cre recombinase to alter the expression of 
genes in individual tissues. This allows much more detailed analysis of the physiological role 
within certain cell types and provides a mechanism to study the role of genes, such as LKB1, 
that cause embryonic lethality when knocked out in the entire organism.   
 
A recent study used cre recombinase under the control of the α myosin heavy chain (αMHC) 
promoter to delete LKB1 specifically in cardiac myocytes (Ikeda et al., 2009). Previous models 
to study cardiac-specific deletion of LKB1 had used cre recombinase under the control of the 
muscle creatine kinase (MCK) promoter but other work has highlighted various issues with 
incomplete gene deletion using the MCK-cre strategy (Sakamoto et al., 2006; Shield et al., 
1996).  
 
Cardiac-specific LKB1 knockout mice showed cardiac dysfunction characterised by atrial 
enlargement and fibrillation in younger mice. Left ventricular hypertrophy was seen in older 
mice but not in younger mice and the cardiac dysfunction led to death within 6 months of 
birth (Ikeda et al., 2009). This study also looked at effectors downstream of LKB1 to determine 
the pathways involved in mediating this effect. Collagen I and III mRNA levels were higher, 
along with an increase in atrial fibrosis while phosphorylation of AMPK was reduced. 
However, mTOR and p70S6 kinase phosphorylation were both higher (Ikeda et al., 2009). 
While this indicates that AMPK and mTOR pathways discussed earlier may be involved in this 
effect, it does not rule out the involvement of other effectors downstream of LKB1. 
 
As one of the main downstream signalling targets of LKB1, the role of AMPK in the heart has 
been extensively studied using mouse knockouts. A study investigating the deletion of 
AMPKα2, the predominant catalytic subunit in the heart, showed it does not cause any basal 
functional or morphological adaptations, but impairs glucose uptake and consequently 
glycogen production (Carvajal et al., 2007). Also, overexpression of a dominant-negative form 
of AMPKα2 was shown to cause a decrease in basal cardiac contractility (Li et al., 2004). 
Conflicting reports highlight the difficulty of interpreting results and the inherent problems 
with using different background strains and experimental conditions (Viollet et al., 2009). 
Also, various mutations in the AMPKγ subunit are known to increase glycogen storage and 
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cause a cardiomyopathy called Wolff-Parkinson-White (WPW) syndrome. Transgenic mouse 
models of these mutations in the heart have been thoroughly characterised and show the 
importance of these signalling pathways in cardiac development and metabolism (Dyck and 
Lopaschuk, 2006). 
 
The contrast between the phenotype of the LKB1 heart knockout and the absence of a basal 
contractility phenotype in the AMPKα2 heart knockout indicate that there may be a significant 
role for other pathways influenced by LKB1, such as the AMPK-related kinases. 
 
1.4.4 LKB1 liver-specific mouse knockout 
Given the strong association with AMPK and the key role of AMPK in metabolism, various 
studies have investigated the role of LKB1 in the liver. The liver plays a key role in several 
metabolic functions including bile production and regulation of glucose and lipid levels. 
Deletion of LKB1 in the liver of adult mice caused an almost complete loss of AMPK activity, 
indicating that LKB1 is the major pathway for AMPK activation in this organ (Shaw et al., 2005). 
The functional effect was severe hyperglycaemia and an increase in expression of genes 
involved in glucose and lipid synthesis. Another interesting metabolic effect was the 
dephosphorylation of CRTC2, increasing the expression of PGC-1α, which plays a key role in 
increasing gluconeogenesis (Shaw et al., 2005). Another important finding in this report was 
that the action of metformin, a pharmacological activator of AMPK, requires the presence of 
LKB1 in vivo (Shaw et al., 2005). This suggests that metformin acts via LKB1 and therefore may 
affect other downstream pathways. However the effect of metformin could be due to ATP 
depletion and therefore be specific to AMPK.  
 
Other functional effects of the loss of LKB1 in the liver, particularly with reference to cellular 
processes not directly linked to AMPK, have been investigated. A role for LKB1 in sub cellular 
organisation and targeting proteins to the cell membrane has been highlighted (Fu et al., 
2010). A similar LKB1 liver-specific knockout mouse model displayed malformed bile ducts 
and canaliculi, which results in poor bile acid clearance and build-up of bile acids in the liver 
and serum (Woods et al., 2011). The basis for this effect is the mis-localisation of a key 
membrane transporter bile salt export pump (BSEP). The observation that LKB1 is involved in 
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establishing cell polarity is backed up by other reports (Baas et al., 2004) and indicates that 
there may be other mechanisms downstream of LKB1 controlling this effect. 
  
1.5 Myosin organisation and regulation in cell division 
Cellular myosin II is a key component of the cytoskeleton and plays an important role in cell 
division. The regulation of myosin contractility is therefore important for controlling 
proliferation and cell growth. Functionally, myosin II is made up of heavy and light chains and 
is activated by phosphorylation of the regulatory light chain (MLC) at either T18 or S19 
(Moussavi et al., 1993). The phosphorylation of these residues promotes interaction with 
actin to form an actomyosin complex, thereby increasing contraction. The activation of MLC 
by phosphorylation also promotes the formation of myosin filaments which are important in 
the formation of filopodia and lamellipodia (Ikebe et al., 1988; Scholey et al., 1980). 
 
Several kinases are known to phosphorylate MLC at the activating residues in vitro or in vivo 
(Figure 1.12). All of these kinases are themselves part of wider regulatory networks and can 
be controlled by various upstream proteins or external signalling molecules. This range of 
activators of MLC seems to be important for the spatial subcellular control of MLC activation. 
In the case of MLCK and ROCK, phosphorylation of MLC occurs in different parts of the cell 
(Totsukawa et al., 2000). 
 
The processes controlling dephosphorylation of MLC are equally important for regulating its 
activity. The primary myosin phosphatase consists of three subunits: a large regulatory 
subunit called  PPP1R12A (MYPT1), a catalytic subunit which is an isoform of PP1C and 
another smaller subunit whose role is unclear (Hartshorne et al., 2004). MYPT1 acts as a 
partner protein and helps to target the catalytic subunit of PP1C to the myosin (Alessi et al., 
1992). It is important to bear in mind that several of the upstream activators which cause MLC 
phosphorylation can also exert an effect on the phosphatase (Figure 1.12). 
 
AMPK can target PAK2, an upstream kinase of MLC, which plays a crucial role in regulating 
cytoskeletal organisation. An inactivating mutation of the AMPK target site on PAK2 led to 
decreased phosphorylation of MLC in response to AMPK activation (Banko et al., 2011). The 
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same study also showed AMPK can phosphorylate PPP1R12C, another of the myosin 
phosphatase targeting (MYPT) family. This subunit forms an active complex with PP1Cβ and 
14-3-3 proteins. Mutation of the AMPK site abolished interaction with 14-3-3 but did not 
change the interaction with PP1Cβ (Banko et al., 2011). Another study reported 
phosphorylation of MYPT1 by NUAK1 (Zagorska et al., 2010). This study by Zagorska and 
colleagues suggested that binding of 14-3-3s to the MYPT1–PP1β complex reduced its ability 
to dephosphorylate MLC in vitro. Their data showed that although AMPK could phosphorylate 
the same MYPT1 residues as NUAK1 in vitro, regulation by AMPK was not physiologically 
important in vivo. Although no direct evidence was shown, the action of AMPK on PPP1R12C 
could inhibit phosphoprotein phosphatase PP1β, leading to a further increase in 
phosphorylated MLC (Figure 1.4B). Therefore, AMPK activation can affect MLC 
phosphorylation from two angles, both by increasing the activity of an upstream kinase, PAK2, 
and by inhibiting dephosphorylation, suggesting that AMPK has some role in the control of 
mitosis (Carling et al., 2012). This is supported by a study showing that AMPK-knockout 
Drosophila embryos had defects in polarity and cell division (Lee et al., 2007).  
 
The activity of myosin phosphatase can be inhibited by phosphorylation of MYPT1 at a critical 
threonine residue (T695) by kinases including ROCK (Kimura et al., 1996) and other kinases 
listed in the diagram. ROCK can also have another activating effect by phosphorylating MYPT1 
at T850 causing myosin to dissociate from the phosphatase complex.  
 
  Chapter 1 - Introduction 
57 
 
 
Figure 1.12 Control of MLC phosphorylation (adapted from Matsumura et al., 2005)  
Positive regulatory mechanisms are shown in green and negative effects are shown in red.  
There are various kinases that are known to phosphorylate and activate MLC and these can 
be regulated by a series of upstream molecules. Several of the positive regulators of MLC 
phosphorylation cause this effect by inhibiting the myosin phosphatase complex.  
MLCK = Myosin light chain kinase, ROCK = Rho-associated protein kinase, Citron-K = citron 
kinase, PAK = p21-activated protein kinase, MRCK = myotonic dystrophy protein kinase-
related cdc42-binding kinase, DAK = death-associated kinase, ILK = integrin-linked kinase, ZIPK 
= ZIP-like kinase, CaM = calmodulin, MAPK = mitogen-activated protein kinase, PKA = protein 
kinase A, PKC = protein kinase C, CPI-17 = inhibitory phosphoprotein of smooth muscle myosin 
phosphatase. 
 
Cell detachment can increase NUAK1 activity, which phosphorylates MYPT1, thereby 
inhibiting myosin phosphatase and leading to enhanced phosphorylation of MLC (Zagorska et 
al., 2010). NUAK1 could therefore be a novel regulator of MLC phosphorylation and some of 
the associated cellular functions and pathologies. 
 
1.6 Liver damage and hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is a major disease burden across the whole world and has 
been rising in several Western countries in recent years (El-Serag, 2011; El-Serag and Mason, 
1999). The occurrence of HCC is higher in the Middle East and North Africa, as the incidence 
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of hepatitis B and C is higher in these regions and can play a role in the development of the 
cancer (El-Serag, 2004). Patients with pre-existing liver problems, primarily cirrhosis, are more 
likely to develop HCC. Several studies in Western countries showed that up to 40% of patients 
being treated for HCC did not have chronic infection with hepatitis B or C which demonstrates 
that there must be other underlying causes. Some of these patients did show signs of having 
a fatty liver, consistent with some of them being obese and other studies have shown an 
increased risk of HCC in type II diabetic patients (Calle et al., 2003; El-Serag et al., 2006). There 
are certain rarer causes of HCC, but the majority of cases can be accounted for by cirrhosis, 
hepatitis B or C infection, or adaptations caused by obesity and development of a fatty liver. 
The common factor in all these cases is that they cause chronic liver damage. It is known that 
mature hepatocytes can upregulate growth factor signalling in response to various forms of 
liver damage (including the Ras-Raf-MEK-ERK and PI3K-Akt-mTOR pathways). If the damage 
is chronic then this upregulation will carry on, leading to continual activation of such 
pathways, which could play a key role in uncontrolled cell growth (Minguez et al., 2009; 
Villanueva et al., 2007).  
 
For many years, models of chronic liver damage in rodents have been studied and various 
diets have been developed that recapitulate various forms of human liver disease. The first 
of these is chronic feeding of diethyl 1,4-dihydro-2,4,6,-trimethyl-3,5-pyridinedicarboxylate 
(DDC) (Magnus et al., 1969) and also a choline deficient ethionine supplemented diet (CDE) 
(Shinozuka et al., 1978). Both these models have been analysed in more detail and are known 
to produce liver progenitor cells, known as “oval” cells, which play a key role in liver 
regeneration (Akhurst et al., 2001; Fickert et al., 2007). These oval cells are produced in 
response to cholestasis, cholangitis and biliary fibrosis (Fickert et al., 2007). Recently more 
evidence has shown that the proliferation of oval cells plays a role in the development of HCC 
and pathways involved in the growth of these cells may provide novel therapeutic targets 
(Shen and Cao, 2012).  
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1.7 Cardiac hypertrophy and the renin-angiotensin system 
Cardiac hypertrophy is a physiological response to changes in the cardiovascular system that 
requires the heart to pump harder, thereby inducing growth of cardiac myocytes and 
thickening of the cardiac muscle (Kohli et al., 2011). Cardiac hypertrophy can occur in 
response to normal stimuli such as exercise or pregnancy (Zaidi and Sharma, 2013), but is 
more commonly associated with various pathological states. It is often a secondary pathology 
induced by stresses such as hypertension, myocardial infarction, or imbalances in hormonal 
systems. There are also various known genetic variations that can cause congenital 
cardiomyopathies that result in hypertrophy (Tousoulis et al., 2013). Pathological cardiac 
hypertrophy leads to an increase in muscle mass without increasing its pumping ability, which 
can cause fibrosis and scarring of the cardiac tissue (Moreno-Moral et al., 2013).  
 
There are several interlinked regulatory systems that maintain healthy blood pressure and 
normal cardiac function. One key hormonal regulator is the renin-angiotensin system of 
hormonal feedback. Angiotensin is a peptide hormone that has wide ranging effects causing 
a rise in blood pressure. When blood pressure is low, the kidneys secrete an enzyme called 
renin into the bloodstream which converts the liver-derived hormone precursor 
angiotensinogen into angiotensin I. Angiotensin I is then converted to angiotensin II by the 
angiotensin converting enzyme (ACE) expressed by pulmonary endothelial cells (Nguyen Dinh 
Cat and Touyz, 2011). Angiotensin II is the major active component of the system and triggers 
mechanisms to increase blood pressure such as vasoconstriction and secretion of the 
hormone aldosterone from the adrenal cortex. Aldosterone causes the kidneys to reabsorb 
more sodium and water, thereby increasing the volume of fluid in the bloodstream, which 
also raises blood pressure (Nguyen Dinh Cat and Touyz, 2011). In addition to producing 
angiotensin II, ACE also converts bradykinin (BK), a known vasodilator into various inactive 
metabolites, further increasing its effect to raise blood pressure (Carey and Siragy, 2003). The 
effects of angiotensin II are mediated by two receptors, type 1 and type 2 (AT1 and AT2) that 
appear to cause opposite effects. The main receptor is AT1 and causes the production of 
second messengers such as inositol trisphosphate (IP3) and activation of various protein 
kinases such as MAPK, p70S6K and PKC (Higuchi et al., 2007). Most of the downstream effects 
of angiotensin II are mediated through AT1 receptors, including vasoconstriction, aldosterone 
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secretion and cardiovascular inflammation, fibrosis and hypertrophy (Figure 1.13) (Nguyen 
Dinh Cat and Touyz, 2011; Savoia et al., 2011). The AT2 receptor has partial homology (34%) 
with the AT1 receptor and is the main angiotensin II signalling mechanism in the foetus (Grady 
et al., 1991). It is only expressed at low levels in adult tissues, but acts to partially antagonise 
the effects of the AT1 receptor (Horiuchi et al., 1999). The AT2 receptor stimulates 
vasodilation, anti-inflammatory mechanisms and inhibition of cell growth via activation of 
protein phosphatases and generation of nitric oxide (Figure 1.13) (Lemarie and Schiffrin, 
2010; Savoia et al., 2011). Recent insights into the renin-angiotensin system have revealed a 
homologue of the angiotensin converting enzyme, ACE2 which can breakdown angiotensin I 
and II to produce other peptides Ang-(1-9) and Ang-(1-7), which represent fragments of the 
original decapeptide, angiotensin I. These peptides also contribute to effects antagonising the 
primary effect of the AT1 receptor via the G protein-coupled receptor Mas (Figure 1.13) 
(Dantas and Sandberg, 2005; Ferrario, 2011; Santos et al., 2003). 
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Figure 1.13 The renin-angiotensin system (from Nguyen Dinh Cat and Touyz, 2011) 
Liver-derived angiotensinogen is broken down to angiotensin I by the enzyme renin which is 
secreted from the kidney. Angiotensin II and other related peptides are then formed by the 
angiotensin converting enzymes (ACE and ACE2). These angiotensin derived peptides then 
have a series of antagonising downstream effects via the AT1 and AT2 receptors. ACE can also 
inactivate bradykinin which reduces its effect on vasodilation, thereby helping to increase 
blood pressure.  
 
Angiotensin II has been widely studied in a variety of clinical settings, animal models and 
transgenic rodent systems to assess effects on vascular and cardiac processes. Administration 
of purified angiotensin II peptide via intravenous injection or a subcutaneous pump is 
commonly used as a way of inducing hypertension to create a generic cardiovascular stress 
which induces physiological changes in blood vessels and the heart (Horiuchi et al., 2012; Qin, 
2008). Angiotensin II has been proposed to elicit some of its effect on hypertrophy by 
increasing the production of reactive oxygen species (ROS) in mitochondria (Dai and 
Rabinovitch, 2011). The exact role of the mitochondrial ROS in causing hypertrophy is unclear, 
but protein kinases such as ERK are sensitive to activation by ROS and may be involved. 
Angiotensin II is often used in animals to exacerbate small differences in a cardiac phenotype 
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or induce hypertrophy in transgenic models and observe effects of genetic alterations 
(McDermott-Roe et al., 2011). 
 
1.8 Summary and Aims  
This project seeks to further the investigation of NUAK1 within the wider context of AMPK 
regulation and provide answers to some of the questions raised by previous studies. The 
functions of NUAK1 are not fully understood and indications that NUAK1 may be a potential 
therapeutic target for the treatment of cancer and metabolic disorders need further 
validation using in vivo models. 
 
This study aims to increase the understanding of NUAK1 regulation by upstream kinases and 
binding proteins, such as 14-3-3s. Another objective of this study is to use mass spectrometry 
approaches to identify novel interaction partners and possible links to other signalling 
pathways.  
 
Prior to this project there was very little data from in vivo models regarding the role of NUAK1 
and this study aims to investigate the role of NUAK1 in liver and heart using transgenic mouse 
models. The data from these studies will seek to clarify the physiological function of NUAK1 
and the biochemical mechanisms involved. The in vivo data will aim to further understand the 
role of NUAK1 in pathological conditions and provide more information to interpret its 
possible therapeutic potential.  
 
Observations from this study also aim to contribute more knowledge to the wider field of 
LKB1 signalling and AMPK-related kinases. This research will contribute to a currently 
disparate set of evidence of NUAK1 function and regulation, while providing a summary and 
aiming to explain some of the inconsistencies in the existing knowledge. 
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2  Materials and Methods 
2.1 Materials 
2.1.1 General reagents 
Adenosine monophosphate (AMP), Adenosine triphosphate (ATP), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), Tris(hydroxymethyl)aminomethane (Tris), ammonium 
persulphate (APS), magnesium chloride (MgCl2), sodium fluoride (NaF), sodium 
pyrophosphate (Na4P2O7), dithiothreitol (DTT), N,N,N’,N’-tetramethylethylenedamine 
(TEMED), protein A/G-sepharose, β-mercaptoethanol, agarose, N-cyclohexyl-3-
aminopropanesulfonic acid (CAPS), Taq DNA polymerase, ampicillin, Dimethyl sulfoxide 
(DMSO), Triton X-100, phenylmethylsulphonyl fluoride (PMSF) and trypan blue dye were 
obtained from Sigma (Poole, UK).  Glucose oxidase kit and BSA protein standards were 
obtained from Thermo Fisher Scientific (Leicestershire, UK). 10x Tris/Glycine/SDS buffer, 
ProtoGel bisacrylamide and Ecoscint scintillant were purchased from National Diagnostics 
(Yorkshire, UK). Polyvinylidene difluoride (PVDF) membrane was from Millipore (Watford, 
UK). Primers were generated by Sigma-Genosys (Haverhill, UK).  Cal Phos transfection kit was 
from Clontech (Saint-Germain-en-Laye, France). NaOH, sodium lauryl sulfate (SDS), NaCl, 
Tween 20, glycerol, ethylenediaminetetraacetic acid (EDTA), ethanol, methanol, KCl, KH2PO4, 
chloroform and glucose were from VWR (West Sussex, UK). Plasmid miniprep, maxiprep and 
gel purification kits, QIAquick gel extraction kit, RNeasy column and GelPilot DNA Loading Dye 
were from Qiagen (Crawley, UK). 3MM chromatography paper and P81 phosphocellulose 
paper were obtained from Whatman (Maidstone, UK). DMEM, Penicillin/Streptomycin and 
sodium pyruvate were from Gibco (Paisley, UK). Complete EDTA free protease inhibitor 
cocktail was from Roche (Burgess Hill, UK). TRIzol was from Invitrogen (Paisley, UK). PageRuler 
Plus Prestained protein marker was from Fermentas (York, UK). DC Protein assay kit was from 
Bio-Rad (Hertfordshire, UK). LNR, LATS, SAMS and AMARA peptides were synthesised in house 
by the peptide synthesis facility (Clinical Sciences Centre). [γ-32P]ATP (6000 Ci/mmol) was 
obtained from Perkin Elmer (Amersham, UK). 
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2.1.2 Buffers 
SDS-PAGE buffer – 50mM Tris-HCl, pH8.4, 400mM glycine, 0.1% (w/v) SDS  
TBS-T (Tris buffered saline with Tween) buffer – 20mM Tris-HCl, pH7.4, 0.5M NaCl, 0.5% (v/v) 
Tween20.  
Protein binding buffer – 50 M HEPES, pH7.4, 300mM NaCl, 10mM Imidazole.  
Protein washing buffer - 50mM HEPES, pH7.4, 300mM NaCl, 25mM Imidazole. 
Protein elution buffer – 50mM HEPES, pH 7.4, 300mM NaCl, 250mM Imidazole.  
Gel filtration buffer – 50mM HEPES, pH 7.4, 300mM NaCl and 1mM Tris(2-carboxyethyl) 
phosphine hydrochloride (TCEP).  
HGE – 50mM HEPES, pH 7.4, 10% (v/v) glycerol, 1mM EDTA.  
Cell Lysis Buffer – 50mM HEPES, pH7.4, 10% (v/v) glycerol, 1mM EDTA, 1mM benzamidine, 
0.1mM PMSF and 4μg/ml trypsin inhibitor, 0.5% (v/v) Triton.  
Homogenisation Buffer - 50mM Tris, pH 7.4, 50mM NaF, 5mM Na4P2O7, 1mM EDTA, 250mM 
sucrose, 1mM dithiothreitol, 4μg/ml trypsin inhibitor, 0.1mM phenylmethylsulfonyl fluoride, 
1mM benzamidine. 
Western blot buffer – 10mM N-Cyclohexyl-3-aminopropanesulfonic acid (CAPS), pH 11, 10% 
methanol.  
Phosphate-buffered Saline (PBS-A) – 137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 1.4mM 
KH2PO4, pH 7.4  
Perfusion buffer - 138mM NaCl, 50mM HEPES, 5.56mM glucose, 0.5mM EGTA, 5.4mM KCl, 
0.338mM Na2PO4, 0.44mM KH2PO4, 4.17mM NaHCO3, carboxygenated, pH 7.4 
TAE (Tris, acetic acid, EDTA) – 40mM Tris, 20mM acetic acid, 1mM EDTA, pH 8.0.  
Luria broth (LB) – 1% (w/v) tryptone, 0.5% yeast extract, 0.5% (w/v) NaCl  
SOC media – 2% (w/v) tryptone, 0.5% yeast extract, 0.05% (w/v) NaCl, 20mM glucose 
10% buffered formalin – 4% (v/v) formaldehyde in PBS-A 
Methacarn fixative – 60% (v/v) methanol, 30% (v/v) chloroform, 10% (v/v) glacial acetic acid 
 
2.1.3 Bacterial strains 
E. coli strain JM109 (endA1, recA1, gyrA96, thi, hsdR17 (rk-, mk+), relA1, supE44, Δ(lac-proAB), 
[F’ traD36, proAB, laqIqZΔM15]) competent cells were obtained from Promega (Sussex, UK). 
These were used for the transformation and amplification of plasmid DNA. The (endA) 
endonuclease deficiency allows high quality plasmid DNA to be produced and the (recA) 
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recombinase deficiency improves insert stability. The hsdR mutation prevents cleavage of the 
plasmid DNA by the EcoK endonucleases system.  
E. coli strain BL21-Codon-Plus (DE3)-RIL (B F-, ompT, hsdS(rB- mB-), dcm+, Tetr, gal λ(DE3), 
endA, Hte [argU ileY leuW Camr]) competent cells from Agilent (Waldbronn, Germany) were 
used for expression of recombinant proteins and grown in LB supplemented with appropriate 
antibiotics. These cells are naturally deficient in the Lon protease and are engineered to be 
deficient in the ompT protease, reducing the risk of degradation of expressed proteins. The 
DE3 designation means the strains contain the λ DE3 lysogen and carries the gene for T7 RNA 
polymerase under the control of the lacUV5 promoter allowing high levels of protein 
expression following induction with isopropyl-1-thio-b-D-galactopyranoside (IPTG). The RIL 
strain of cells also contains plasmids encoding extra copies of the argU, ileY and leuW tRNA 
genes which are rare in E. coli, the lack of which can lead to the formation of truncated and 
degraded protein products. 
 
2.1.4 Mammalian cells 
CCL13 cells (Human liver epithelial cells), HEK293T cells (Human embryonic kidney cells 
carrying the large T antigen) and COS7 (African Green Monkey SV40-transformed kidney 
fibroblasts) were obtained from American Cell Type Culture Collection (Middlesex, UK) and 
maintained at 37oC, 5% CO2 in Dulbecco’s Modified Eagle’s Medium (DMEM with sodium 
pyruvate, 4500mg/L glucose and pyridoxine) (Invitrogen) supplemented with 10% (v/v) foetal 
calf serum, 2mM N-glutamine and 0.5mg/ml penicillin-streptomycin. Cells were passaged 
before reaching confluency using trypsin-EDTA (Invitrogen). 
Wild-type and NUAK1 knockout primary Mouse Embryonic Fibroblasts (MEFs) were isolated 
under the supervision of Dr Naveenan Navaratnam (MRC Clinical Sciences Centre), see section 
2.2.12 . Primary mouse hepatocytes were isolated with the assistance of Dr Alicia Garcia (MRC 
Clinical Sciences Centre), see section 2.2.17 . 
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2.1.5 Proteins 
Recombinant AMPK complex (α1β1γ1) was expressed in Escherichia coli and purified by Dr 
David Carmena (Clinical Sciences Centre) as previously described (Sanders et al., 2007). 
Recombinant CaMKKβ and LKB1 complex, obtained by the co-expression of human His-LKB1, 
STRADα and MO25α, were expressed in Escherichia coli and purified by Dr David Carmena. 
Recombinant human his-tagged PP2Cα protein was expressed and purified by Dr David 
Carmena.  
 
2.1.6 Antibodies 
T211 phosphorylation was determined using rabbit monoclonal antibodies raised against 
AMPK phospho-T172 from Cell Signalling (#2535). His-tagged proteins were detected using 
mouse monoclonal anti-His antibodies from Qiagen (34660). Anti-FLAG tag antibodies were 
from Cell Signalling (Rabbit, #2368) or Sigma (Mouse, F1804). Anti-FLAG M2 affinity gel was 
from Sigma (A2220). Anti-pan 14-3-3 rabbit antibody was from Santa Cruz Biotechnology (K-
19). Anti-α/β-tubulin rabbit antibody was from Cell Signalling (#2148). Anti-NUAK1 rabbit 
antibody was sourced from Cell Signalling (#4458). Anti-phospho-(Ser/Thr) casein kinase 2 
substrate (P-S/T3-100) rabbit monoclonal antibody was from Cell Signalling (#8738). A pan-
AMPK β subunit rabbit antibody (Sip2) was raised in house against a β-GST fusion protein 
(lacking the N-terminal 68 amino acids). 
Secondary antibodies for use with the LI-COR scanner were used for all immunodetection of 
western blots. IRDye800 goat anti-mouse and goat anti-rabbit were from LI-COR Biosciences 
UK Ltd (Cambridge, UK). AlexaFluor 680 goat anti-mouse and goat anti-rabbit antibodies were 
from Invitrogen. 
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2.1.7 Plasmids 
pET15b (Novagen) plasmid containing the full length wild-type human NUAK1 cDNA and pRSF-
Duet1 plasmid containing full length wild-type human 14-3-3ε were kindly provided by Dr 
Naveenan Navaratnam. pcDNA3.1/V5-His-TOPO® vector was from Invitrogen (K4900-01). 
 
2.2 Methods   
2.2.1 Animals 
Embryonic stem cells (ES) carrying a transgenic construct for NUAK1 (CSD Knockout First, 
promoter driven) were generated by the trans-NIH Knock-Out Mouse Project (KOMP) and 
obtained from the KOMP Repository (www.komp.org). NIH grants to Velocigene at Regeneron 
Inc. (U01HG004085) and the CSD Consortium (U01HG004080) funded the generation of gene-
targeted ES cells for 8500 genes in the KOMP Program and archived and distributed by the 
KOMP Repository at UC Davis and CHORI (U42RR024244). 
Mice carrying this construct were re-derived on a C57-Bl6 background by Zoe Webster 
(Clinical Sciences Centre, Transgenic Facility). To produce the appropriate conditional 
knockouts, the animals were crossed with transgenic mice carrying the FLP recombinase 
(Jackson Laboratory), cre recombinase under the control of the albumin promoter (Jackson 
Laboratory) and cre recombinase under the control of the α myosin heavy chain (αMHC) (a 
gift of Prof. Michael Schneider, National Heart and Lung Institute).  
 
2.2.1.1 Housing conditions 
All mice were bred and maintained by myself and Phillip Muckett according to Home Office 
regulations as defined by the Animal (Scientific Procedures) Act, 1986. Mice were stocked at 
a maximum density of 7 animals per cage, or 4 animals per cage over 30g bodyweight, in 
Allentown XJ individually ventilated cages (IVCs). Environmental conditions were maintained 
within strict limits; temperature 21oC ± 2oC, humidity 55% ± 10% and light conditions were 
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kept on 12hour light/12 hour dark cycles. Unless otherwise stated mice were fed on Special 
Diet Services (SDS) Rat and Mouse No.3 Breeding diet. 
 
2.2.1.2 Genotyping 
Ear clipping was used to identify individual mice and to obtain tissue for genetic identification. 
DNA was purified from ear clips by heating at 100oC for 20 minutes in 50μl of 200mM NaOH 
with occasional vortexing. This was then neutralised with 25μl of 1M Tris pH8. The resulting 
solution was used in polymerase chain reaction (PCR) experiments to determine the genotype 
of the animal. Reddymix PCR mix (Thermo Scientific, #AB-0575/DC/LD/A) or MyTaq™ HS Red 
Mix (Bioline, BIO-25047) were used according to the manufacturer’s instructions with the 
relevant primers listed in the appendix. Tail tips were taken for post mortem genotyping and 
DNA was extracted in the same way for use in PCR reactions to confirm the identity and 
genotype of animals used in each experiment. 
 
2.2.1.3 Echo-MRI 
Body composition of animals at the age indicated in the figure was determined by a trained, 
genotype-blinded operator using an EchoMRI-100V machine. This instrument calculates body 
composition by using nuclear magnetic resonance (NMR) to create contrast between soft 
tissues based on the differences in relaxation times of the hydrogen proton spins in water in 
different environments. The method does not require the animals to be anaesthetised, which 
reduces the risk of harm to the mice. 
 
2.2.1.4 Intra-peritoneal glucose tolerance test (ipGTT) 
Mice were fasted overnight prior to administration of glucose by intra-peritoneal injection 
(1g/kg of body weight). Blood samples from the tail were taken at 0, +15, +30, +60, +120 
minutes after glucose dosing. Blood glucose levels were measured with an Accu-Chek 
Compact Plus glucometer. 
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2.2.1.5 Comprehensive Laboratory Animal Monitoring System 
(CLAMS) 
Mice were housed individually for at least a week prior to going into the CLAMS system to 
allow for acclimatisation to single housing. Experiments were limited to 5 days to ensure that 
animals were never left unattended for more than an overnight period thereby reducing any 
possible harm.  
The CLAMS system is a monitoring system that allows multi parameter assessment of many 
animals simultaneously. Cohorts of 12 – 16 mice were placed in the system which measures 
oxygen consumption, carbon dioxide production and food and water intake. The calorimetric 
data is then calculated indirectly from the gases flowing in and out of the animal chamber. 
Heat is derived by looking at the exchange of oxygen for carbon dioxide that occurs during 
the metabolism of an energy source. The relationship between the volume of oxygen 
consumed and the amount of carbon dioxide produced reveals the energy content of the 
energy source the animal is using. This calorific value is then linked with the volume of gases 
exchanged to compute heat. 
Animals were monitored several times daily by a trained, genotype-blinded operator and 
experiments were terminated early if they were having an adverse effect on the animal. 
 
2.2.1.6 Echocardiography 
Mice were anaesthetised with 4% (v/v) isoflurane and arranged in a supine position on a 
bench-mounted heat pad. The chest wall was shaved to allow application of pre-warmed 
ultrasound gel and anaesthesia was maintained with 1.5% (v/v) isoflurane in 100% oxygen 
administered via a mask. Echocardiography images were taken using a Vevo 770 Imaging 
System (VisualSonics) and analysed without prior knowledge of the genotype. Parameters 
were measured using VisualSonics EKV software and then raw data exported to Microsoft 
Excel and GraphPad Prism for analysis. Mice were euthanised after echocardiography and 
appropriate tissues harvested for analysis.  
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2.2.1.7 Angiotensin II treatment 
Mice were dosed with angiotensin II peptide (Sigma) dissolved in 0.9% (w/v) sterile saline 
solution. The concentration of the peptide solution was calculated based on body weights 
taken the day prior to the start of the experiment such that each mouse would receive 
1.2mg/kg/day of angiotensin II. Delivery was by micro-osmotic minipumps (Azlet, model 
1002). Surgery was carried out under sterile conditions, according to Home Office guidance. 
Mice were anaesthetised with 4% isoflurane and maintained with 1.5% (v/v) isoflurane in 
100% oxygen administered via a mask. Baseline measurements of body weight, food intake 
and water intake were recorded for at least a week prior to the diet change and during the 
course of the experiment. Any animals that lost more than 20% of their body weight were 
immediately euthanised to prevent suffering. 
 
2.2.1.8 Tissue harvesting 
Mice of the age and sex specified in the figure were culled by cervical dislocation. Tissues 
were harvested and immediately frozen in liquid nitrogen. Prior to analysis, tissues were 
roughly chopped in two volumes of ice-cold homogenisation buffer and then briefly 
homogenized with a rotor-stator homogenizer. The homogenates were then centrifuged at 
16000 x g for 15 min to remove insoluble material. 
 
2.2.1.9 Serum metabolite analysis 
Mice of the age and sex indicated in the figure were culled by decapitation and whole blood 
was drained into heparinised collection tubes (Sarstedt). Blood was immediately centrifuged 
at 2000 x g for 10 min to separate red cells and clotting factors. Serum was then drawn off 
and stored at -80oC until analysis. Samples were then sent to the Core Biochemical Assay 
Laboratory, Cambridge University for analysis.  
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2.2.1.10 CDE Diet and panCK staining 
Mice of the age and sex indicated in the figure were maintained on a normal chow diet and 
changed to a choline deficient, ethionine supplemented (CDE) diet for a maximum of three 
weeks before being culled by cervical dislocation. Diet was from Harlan Laboratories (Teklad 
TD.90262). DL-Ethionine (Sigma) was dissolved in drinking water at a concentration of 0.15% 
(w/v) and supplemented with 10% (v/v) Robinson’s Sugar Free Orange Squash to make it more 
palatable. Baseline measurements of body weight, food intake and water intake were 
recorded for at least a week prior to the diet change and during the course of the experiment. 
Any animals that lost more than 20% of their body weight were immediately euthanised to 
prevent suffering. 
Livers were harvested immediately following cervical dislocation and lobes were fixed in 10% 
(v/v) buffered formalin or methacarn overnight. Liver lobes were then dehydrated through a 
series of alcohol grades (see section 2.2.2) before wax embedding. The wax embedded 
samples were then sent to our collaborators at Edinburgh University (Prof. Stuart Forbes et 
al.) for sectioning, staining and imaging. 
 
2.2.2 Histology 
Samples were immediately fixed after harvesting in 10% (v/v) formalin, methacarn or 4% (v/v) 
paraformaldehyde depending on the tissue and staining protocol in question. The tissue was 
left in the fixative overnight at 4oC and was then transferred into 70% (v/v) ethanol. The 
tissues were then put through a series of dehydration steps before immersion in clearing 
agent and wax: 
 90% (v/v) Ethanol – 1 hour 
 95% (v/v) Ethanol – 1 hour 
 100% (v/v) Ethanol – 1 hour 
 100% (v/v) Ethanol – 1 hour 
 Histo-clear II – 1 hour 
 Histo-clear II – 1 hour 
 Molten paraffin wax – 1 hour 
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Samples were then embedded on histology cassettes using a Leica EG1160 embedder. 
All sectioning and staining was conducted by Mahrokh Nohadani (C & C Laboratory Services 
Ltd.). 
 
2.2.2.1 Haematoxylin & Eosin staining (H&E) 
Briefly, sections were deparaffinised by washing in xylene and rehydrated in descending 
dilutions of alcohol. Sections were then stained with haematoxylin solution for 8 – 10 minutes. 
Sections were washed with water before being counterstained in eosin solution for 30 
seconds to 1 minute. Sections were then dehydrated through ascending alcohol dilutions 
before being mounted on slides. 
 
2.2.2.2 Periodic Acid Schiff staining (PAS) 
Briefly, sections were deparaffinised by washing in xylene and rehydrated in descending 
dilutions of alcohol. Sections were then oxidised in 0.5% (w/v) periodic acid solution for 5 
minutes. Sections were washed in distilled water before being stained with Schiff reagent for 
15 minutes. Sections were then counterstained in haematoxylin for 1 minute before being 
dehydrated through ascending alcohol dilutions and mounted on slides. 
 
2.2.2.3 Sirius red staining 
Briefly, sections were deparaffinised by washing in xylene and rehydrated in descending 
dilutions of alcohol. Nuclei were then stained with haematoxylin for 8 – 10 minutes. Sections 
were washed in distilled water before being stained with picro-sirius red (1% (w/v) solution 
of Sirius red in saturated picric acid) for 1 hour. Sections were then washed with acidified 
water before being dehydrated through ascending alcohol dilutions and mounted on slides. 
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2.2.3 Cloning  
Site-specific point mutations were generated using the QuikChange® site-directed 
mutagenesis kit (Stratagene) according to the manufacturer’s protocol. This method was 
performed using Phusion DNA polymerase which replicates both plasmid strands with high 
fidelity without displacing the mutant oligonucleotide primers. Briefly, the procedure uses a 
vector DNA with the insert of interest and two synthetic oligonucleotide primers containing 
the desired mutation. Primers used in this project were synthesised by Sigma Genosys and 
are listed in the appendix. PCR extension occurs from the annealed primers resulting in the 
generation of new plasmids containing the mutated codon. Mutagenesis was carried out in a 
50μl reaction volume containing: 50ng plasmid DNA, 10ng of forward and reverse primer, 
0.2mM dNTPs, 1% (v/v) DMSO, and Pfu Ultra buffer containing 2mM MgCl2, and 1 unit of Pfu 
Ultra enzyme. A polymerase chain reaction (PCR) was programmed for an initial heating step 
of 1 min at 95oC followed by 20 cycles of denaturation step at 95oC for 1 min, annealing step 
at 60oC for 1 min and extension step at 68oC for 7 min and then a final extension step of 68oC 
for 10 min. Following PCR, 10μl of the reaction was incubated in another 50μl reaction with 2 
units of DpnI endonuclease (specific for methylated DNA) at 37oC for 1h to digest the original 
DNA. This relies on the fact that the template DNA, having been purified from bacteria, is 
methylated whereas the mutated products of the PCR reaction are unmethylated. The 
product vector DNA incorporating the desired mutations was then transformed into E. coli 
JM-109 competent cells and the DNA was prepared from small-scale cultures from isolated 
colonies using either the plasmid mini-prep or maxi-prep kit (Qiagen). The introduction of the 
desired mutations, and confirmation of no unwanted changes, was verified by sequencing 
performed by the Sequencing Service, MRC Clinical Sciences Centre using vector primers. 
 
2.2.4 Plasmid DNA purification 
Plasmid DNA was purified from 5 ml or 250 ml bacterial cultures using a Qiagen miniprep or 
maxiprep kit following the manufacturer’s instructions. Briefly, cells were centrifuged and the 
cell pellet was lysed using appropriate lysis buffer. Proteins and genomic DNA were 
precipitated using the buffers in the kit. Following centrifugation, the supernatant containing 
plasmid DNA was passed through the appropriate column and then washed with buffer. 
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Plasmid DNA was eluted and precipitated with isopropanol. Following centrifugation at 15000 
x g for 40 minutes the supernatant was discarded and the DNA pellet was washed with 70% 
(v/v) ethanol. After further centrifugation, plasmid DNA was resuspended in an appropriate 
volume of distilled water. DNA concentration was measured on an Amersham Biosciences 
Ultrospec 2100pro. Sequencing was performed by the Sequencing Service at MRC Clinical 
Sciences Centre using vector primers. 
 
2.2.5 Agarose gel electrophoresis 
DNA samples were diluted in Qiagen GelPilot DNA Loading Dye and analysed by 
electrophoresis at 120V for 1 hour on a 2% (w/v) agarose gel. Bands were visualised by UV 
exposure on Syngene Gene Genius transilluminator. 
 
2.2.6 Bacterial transformations and culture 
Competent JM109 cells were thawed on ice. Cells were mixed gently with DNA and incubated 
on ice for 30 min before undergoing heat shock for 50 seconds at 42C. Transformation 
reactions were cooled on ice for 2 minutes before addition of 900μl SOB media (2% (w/v) 
tryptone, 0.5% (w/v) Yeast extract, 10mM NaCl, 2.5mM KCl) and incubation at 37C for 1 hour. 
Cells were pelleted by centrifugation and resuspended in Luria broth (LB) (1% (w/v) tryptone, 
0.5% (w/v) yeast extract, 0.05% (w/v) NaCl) and plated on LB plates (LB broth with 1.5% (w/v) 
agar) with appropriate antibiotic (100μg/ml ampicillin or 50μg/ml kanamycin). Plates were 
incubated overnight at 37C and single colonies were used to inoculate liquid cultures. 
 
2.2.7 Protein expression 
Recombinant NUAK1 was expressed and purified from E. coli. Briefly, BL21-Codon-Plus (DE3)-
RIL competent cells were transformed with the plasmid of interest and colonies selected by 
growth on agar plates supplemented with the appropriate antibiotic. A single clone was 
selected and grown in LB containing the appropriate antibiotic overnight at 37oC in a shaking 
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incubator. This overnight culture was used to inoculate a larger culture (4 x 500ml) in LB 
medium and grown at 37oC until an optical density at 600nm of 1.0 was reached. 
Subsequently, the culture was transferred to a shaking incubator at room temperature and 
protein expression was induced with a final concentration of 0.4mM IPTG for an additional 16 
hours. Cells were harvested by centrifugation and lysed by sonication in lysis buffer (50mM 
HEPES, 300mM NaCl, 10mM imidazole, pH 8.0). His-tagged proteins were isolated from the 
lysate using nickel affinity chromatography on an AKTApurifier system (GE Healthcare). After 
elution the appropriate fractions containing useable protein (assessed by SDS-PAGE) were 
pooled and concentrated using centrifugal VivaSpin 20 concentrators (30000 MWCO) 
(Millipore). Concentrated protein was then size separated on a Sepharose column (Superdex 
200, GE Healthcare) using an AKTA purifier system and appropriate fractions concentrated to 
produce the final protein solution. Quality of the concentrated protein was assessed by SDS-
PAGE. 
 
2.2.8 Protein determination 
Protein assays were carried out using the Bio-Rad DC kit according to the manufacturer’s 
instructions, against BSA protein standards (Thermo Scientific). Absorbance at 750nm was 
read using the Spectromax 340pc plate reader. 
 
2.2.9 Western blotting 
Samples for SDS-PAGE were denatured for 5 minutes at 95°C in sample buffer (250mM Tris, 
pH6.8, 8% (w/v) SDS, 30% (v/v) glycerol, 10% (v/v) β-mercaptoethanol, 0.04% (w/v) 
bromophenol blue) before loading into a 10% (w/v) polyacrylamide gel and run for 1 hour at 
200 V in Tris-Glycine buffer (25mM Tris, 192mM glycine, 0.1% (w/v) SDS). Proteins were 
transferred to a polyvinylidene difluoride (PVDF) membrane in transfer buffer (5mM CAPS, 
pH 11, 10% (v/v) methanol) at 60 V for 4 hours. Membranes were blocked in 5% (w/v) milk 
powder (CoffeeMate) in TBS-T (20mM Tris pH 8, 150mM NaCl, 0.5% (v/v) Tween 20) before 
incubation with primary antibody at an appropriate dilution for a minimum of 2 hours. 
Following three washes in TBS-T, membranes were incubated for an hour with the 
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appropriate fluorescently conjugated secondary antibody at a dilution of 1:10,000. 
Membranes were then washed three times with TBS-T before detecting on the LICOR Odyssey 
scanner using 700nm and 800nm wavelengths to detect the fluorescent dyes. 
 
2.2.10 Radiolabelling kinase assays 
AMPK was assayed as previously described (Davies et al., 1989). A similar technique and 
buffer was used to measure NUAK1 activity. Details are shown in the results (Figure 3.4) 
regarding the peptide substrate specificity of NUAK1. The specific activity of the radioactive 
ATP was measured during each set of assays. 
 
2.2.10.1 AMPK assays 
Recombinant AMPK or immunoprecipitated protein bound to resin was incubated at 37°C 
whilst shaking for 20 minutes with 200μM AMP, 200μM SAMS peptide 
(HMRSAMSGLHLVKRR), 10mM HEPES, 0.2% (v/v) Triton X-100, and 200μM [γ-32P]ATP in a 
total volume of 25μl. The reaction mix (20μl) was spotted onto a P81 paper and washed 
thoroughly in 1% (v/v) orthophosphoric acid to remove radioactive ATP. Samples were 
submerged in EcoScint fluid and counted in a TriCarb 2800TR scintillation counter.  
 
2.2.10.2 NUAK1 assays 
Recombinant NUAK1 or immunoprecipitated protein bound to resin was incubated at 37°C 
whilst shaking for 20 minutes with 5mM MgCl2, 200μM ATP, 200μM of the indicated peptide, 
10mM HEPES, 0.2% (v/v) Triton X-100 and 200μM [γ-32P]ATP in a total volume of 25μl. The 
reaction mix (20μl) was spotted onto a P81 paper and washed thoroughly in 1% (v/v) 
orthophosphoric acid to remove radioactive ATP. Samples were submerged in EcoScint fluid 
and counted in a TriCarb 2800TR scintillation counter.  
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2.2.11 Mammalian cell transfection 
The day before transfection, cells were seeded at an appropriate level to be 60% confluent 
on the day of transfection. Transfection was carried out using the CalPhos mammalian 
transfection kit (Clontech) according to the manufacturer’s instructions. Briefly, 30μg DNA 
was combined with 0.124M CaCl2 and HEPES-buffered saline and was incubated for 30 
minutes at room temperature before adding drop-wise to the cell culture medium. The cell 
culture medium was changed the following morning. Cells were harvested 48 hours post-
transfection or as described in the figure legends.  
 
2.2.12 Mouse Embryonic Fibroblast (MEF) isolation 
Isolation of wild-type and NUAK1 null MEFs was performed at embryonic days 11.5 - 13.5. 
The embryos were removed from the uterus and thoroughly washed with PBS. The head, 
spleen and liver were removed and the rest of the embryo was chopped and digested for an 
hour with trypsin before passing through a 70μM cell sieve. The cells were thoroughly 
resuspended and cultured in DMEM supplemented with 10% (v/v) FCS and 
penicillin/streptomycin.  
 
2.2.12.1 Cell counting 
Cells were counted for the purposes of plating density for transfections and for determining 
the number of cells present at different stages of growth. Cells were detached from the 
culture plate or flask by treatment with trypsin-EDTA (Invitrogen). Detachment was confirmed 
by observing the remaining attached cells using a light microscope. Cells were then 
centrifuged at 1300 x g and the supernatant discarded. The cells were resuspended in an 
appropriate volume of DMEM and an aliquot was diluted at an appropriate ratio with more 
DMEM and finally at a 1:1 ratio with trypan blue dye (Sigma). Cells were counted using a 
Neubauer Improved haemocytometer on a light microscope and multiplied by the 
appropriate ratios to establish the cell density.  
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2.2.13 Cell lysis 
Cells were washed with PBS and immediately scraped into lysis buffer (10mM HEPES, 100mM 
NaCl, 2.5mM MgCl2, 1mM dithiothreitol (DTT), 5mM Na2P2O7, 50mM NaF, 0.5% (v/v) Triton 
X-100, complete protease inhibitor cocktail). Samples were incubated for 15 minutes on ice 
before centrifugation at 21000 x g at 4°C. Supernatants were stored at -80°C until further use. 
 
2.2.14 Immunoprecipitation  
Proteins were immunoprecipitated from cell lysates for kinase assays or western blotting. 
Equal amounts of protein were made up to a volume of 100μl with lysis buffer and incubated 
at 4°C for at least 2 hours with 15μl of 50% (v/v) protein A/G Sepharose slurry and 0.5μl of 
the appropriate antibody as described in the figure legends. The immunoprecipitates were 
then washed 3 times with HEPES buffer A (50mM HEPES, 1mM EDTA, 10% (v/v) glycerol, 1mM 
DTT, 1% (v/v) Triton X-100, protease inhibitor cocktail).   
 
2.2.15 RNA extraction 
Cells were washed thoroughly with PBS and scraped into 500µl TRIzol and incubated for 5 
minutes at room temperature before addition of 100μl chloroform. For tissue RNA extraction 
100mg of material was homogenised in 500μl of TRIzol and then treated in the same way. 
After adding chloroform, samples were inverted for 15 seconds before a further three minute 
incubation. Samples were centrifuged at 12000 x g for 15 minutes to separate the RNA 
fraction in the upper aqueous phase. 0.53% (v/v) ethanol was added before loading onto an 
RNeasy column. The column was washed with Buffers RW1 and PPE and RNA was eluted in 
RNase-free water. RNA concentration was measured by absorbance at 260 nm in an 
Amersham Biosciences Ultrospec 2100pro and samples were stored at -80°C.  
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2.2.16 Quantitative PCR (qPCR) 
mRNA was isolated from cells or tissues as described in 2.2.15. cDNA was then produced from 
this material using SuperScript® II Reverse Transcriptase (Invitrogen, 18064-014) according to 
the manufacturer’s instructions. cDNA concentration was determined by absorbance at 
260nm using a NanoDrop® ND-1000 UV-Vis spectrophotometer. qPCR reactions were carried 
out on the Opticon DNA engine 2 using the Qiagen SYBR Green kit according to the 
manufacturer’s instructions. 10ng of total cDNA was incubated with SYBR green RT-PCR 
master mix, RT mix and appropriate primers and put through 40 cycles of extension. All cDNA 
expression values are shown as cDNA expression relative to a house keeping gene as 
described in the figure legends and all primers were tested to show they gave linear results 
before being used.  
 
2.2.17 Mouse primary hepatocyte isolation  
Primary hepatocyte isolation was carried out as previously described (Foretz et al., 1998) with 
some amendments. Perfusions were carried out by Dr Alicia Garcia. Mice were anaesthetised 
with 200μl/100g of body weight using a solution of 0.286% (w/v) xylazine (Rompun®) and 
42.9mg/ml  ketamine (Ketaset®) in distilled water. Mice were canulated in the inferior vena 
cava and the liver was perfused with perfusion buffer at 37°C (138mM NaCl, 50mM HEPES, 
5.56mM glucose, 0.5mM EGTA, 5.4mM KCl, 0.338mM Na2PO4, 0.44mM KH2PO4, 4.17mM 
NaHCO3, carboxygenated, pH 7.4). After washing with perfusion buffer for 15 minutes the 
liver was digested with collagenase buffer (perfusion buffer minus EGTA, 5mM CaCl2 with 
0.025% (w/v) collagenase H). Digested livers were removed and hepatocytes were released 
and filtered, and washed twice with ice cold perfusion buffer followed by washing with ice 
cold M199. Cells were plated onto collagen coated plates in plating medium (M199, 
Penicillin/Streptomycin, 10% (v/v) bovine serum albumin (BSA), Ultrosero G, 100nM T3, 
100nM dexamethasone, 100nM insulin). Plating medium was removed 4 hours later and 
replaced with overnight medium (M199, Penicillin/Streptomycin, 100nM dexamethasone, 
1nM insulin) and cells were cultured for at least 16 hours in this medium. The following day, 
the medium was changed to M199 supplemented only with penicillin and streptomycin at 
least 2 hours before treatment or harvesting. 
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2.2.18 Hepatic glucose production 
Mouse hepatocytes were treated on the day following isolation as described in the figure 
legends. Following the required treatment time, media were removed and cells were washed 
twice with PBS before addition of 1 ml Hepatic Glucose Production medium per 6 well plate 
well (DMEM minus phenol red, supplemented with 2mM sodium pyruvate, 20mM sodium 
lactate). Samples of the culture media were taken 2 hours, 4 hours and 6 hours following the 
medium change. Glucose concentration was read in a 96 well plate using the TRACE DMA 
glucose oxidase kit compared to glucose standards read on the Spectromax 340pc at 490 nm.  
 
2.2.19 Extracellular flux analysis (Seahorse) 
Wild-type and NUAK1 knockout hepatocytes were seeded onto XF24 Cell Culture Microplates 
at the same density (2 x 105 cells per well) after harvesting and analysed the following day 
(see section 2.2.17). The cells were analysed on a XF24 Extracellular Flux Analyser (Seahorse 
Biosciences) by Dr Alicia Garcia. This machine takes real-time measurements of oxygen 
consumption rate (OCR) and extracellular acidification rate (ECAR). OCR is an indicator of 
mitochondrial respiration, and ECAR can be used to indicate glycolytic capacity. The cells were 
subjected to treatment with drugs in the XF Mito Stress Kit according to the manufacturer’s 
instructions. The different drugs allow the measurement of four key parameters of 
mitochondrial function: basal respiration, ATP turnover, proton leak, and maximal 
respiration.  
 
2.2.20 Immunofluorescence 
For immunofluorescence analysis, 10-20000 cells were seeded on poly-lysine coated glass 
cover slips overnight and transfected with appropriate plasmids, as listed in the figure 
legends. After 36-48 hours, the cells were fixed with methanol or 4% (v/v) paraformaldehyde 
(PFA) for 10min. PFA fixed cells were permeabilised with 0.2-0.5% (w/v) Triton in PBS for 2-3 
min and washed 3 times, 10 minutes each, with PBS at room temperature. Washed cells were 
blocked with 0.5% (w/v) fish gelatine in PBS for 2-3 hours and incubated with the primary 
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antibody (1:100-1:300 dilution) overnight. After overnight incubation, coverslips were 
washed with PBS as before and incubated with appropriate fluorescently conjugated 
secondary antibody (1:200 dilution) for 30 min. Secondary antibody was removed and cells 
were washed 3 times in PBS and mounted on glass coverslips using Vectashield with DAPI and 
imaged using a Leica SP5 microscope. Images were captured with Leica LAS AF and further 
analysed using Metamorph software. 
 
2.2.21 Mass spectrometry methods 
2.2.21.1 Stable Isotope Labelling by Amino Acids in Cell Culture 
(SILAC) 
This experiment was kindly conducted by Dr Naveenan Navaratnam (Clinical Sciences Centre). 
Stable isotope labelling by amino acids in cell culture (SILAC) is a method for in vivo 
incorporation of a label into proteins for quantitative mass spectrometry proteomics. SILAC 
relies on incorporation of a so called ‘light’ or ‘heavy’ form of an amino acid into proteins in a 
cell which can then be distinguished by mass spectrometry analysis. Wild-type MEFs were 
grown on ‘light’ DMEM media lacking arginine and lysine and specifically supplemented with 
‘normal’ arginine and lysine and dialysed foetal bovine serum. NUAK1 knockout MEFs were 
grown on ‘heavy’ media containing 13C arginine and 15N lysine. 
Equal quantities of cells were harvested and lysed in the same way (see 2.2.13). The lysates 
were normalised to ensure the same amount of total protein was used and then the mixed 
lysates were digested with trypsin for analysis by mass spectrometry using an LTQ Orbitrap 
XL machine. 
 
2.2.21.2 Neuronal phosphoscreen 
This experiment was kindly conducted by Dr Nicola Bright (Clinical Sciences Centre). Lysate 
from wild-type primary embryonic mouse cortical neurons were harvested and equal 
quantities were incubated with varying amounts of active recombinant NUAK1 or AMPK (0μg, 
1μg and 5μg) for different times. The method relies on a high specific activity recombinant 
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kinase phosphorylating downstream targets in the lysate in a time-dependent manner. 
Phosphopeptides were generated by trypsin digestion and concentrated on a titanium 
dioxide column and the resulting material was analysed by mass spectrometry. By comparing 
the rate of phosphorylation, this method can identify specific phosphopeptides 
phosphorylated by the recombinant kinase. The method has been used in published reports 
(Casado et al., 2013).  
  
2.2.21.3 FLAG tagged SILAC immunoprecipitation 
This experiment was kindly conducted by Dr Naveenan Navaratnam (Clinical Sciences Centre). 
FLAG-tagged full-length NUAK1 was over expressed in HEK293T cells and grown on ‘heavy’ 
SILAC media as before. Control cells with vector only transfection were grown under similar 
conditions on ‘light’ SILAC media. Cells were harvested and NUAK1 protein 
immunoprecipitated using an anti-FLAG resin and eluted with flag peptide. The resulting 
material from transfected and un-transfected cells was then mixed, separated by SDS-PAGE 
and analysed by mass spectrometry to identify any proteins that co-immunoprecipitated with 
NUAK1.  
  
2.2.21.4 Mass spectrometry analysis 
Data was generated from the different mass spectrometry screens in the form of lists of 
proteins, ordered either by hierarchy of quantity of the peptide detected or the degree of 
change compared to the relevant control sample. Some data was compared using peptide 
fingerprints but where this was not available, protein data was converted into consistent gene 
acronyms using the Database for Annotation, Visualization and Integrated Discovery (DAVID) 
(http://david.abcc.ncifcrf.gov). By comparing the consistent index of gene acronyms, a list of 
all the proteins that appeared in at least two of the different methods was determined. These 
lists were then analysed using the gene ontology search resources provided by the Lewis-
Sigler Institute for Integrative Genomics, Princeton University (http://go.princeton.edu/).  
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2.2.22 Statistical analysis  
Data are expressed as the mean ± standard error of the mean (S.E.M.). The Student’s t-test 
or an ANOVA followed by an appropriate posthoc test was used to determine statistical 
significance. The means were considered to be significantly different if a value of p<0.05 was 
obtained. 
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3  In vitro and cellular characterisation of NUAK1 
3.1 Introduction 
Previous studies investigating the role of NUAK1 have only looked at very specific aspects of 
the activation and control of the kinase (Lizcano et al., 2004) or have identified the kinase as 
part of wider screens looking at a specific pathology or role of another kinase (Suzuki et al., 
2004b). The first study to take an overall view of the field of AMPK-related kinases identified 
LKB1 as a common upstream kinase and other consistent features such as their lack of 
activation by AICAR (Lizcano et al., 2004). However, given that LKB1 has previously been 
suggested to be constitutively active (Alessi et al., 2006) this raised further questions about 
how the activity of the related kinases are controlled. Another study from the same group 
identified the presence of a conserved UBA domain and linked this to the regulation of AMPK-
related kinase phosphorylation by LKB1 (Jaleel et al., 2006). Aside from these data, there have 
been only a few other studies that have indicated potential mechanisms of NUAK1 regulation 
and many of these have provided contradictory evidence. Part of this study seeks to identify 
and clarify regulatory features of NUAK1 in vitro which may be linked to the functional role of 
the kinase in vivo. Reports have linked NUAK1 to a several pathways, but a consistent 
appraisal of its function remains elusive. 
In this chapter, recombinant protein and over-expression in cell lines are used to study the 
control and activation of NUAK1. Mass spectrometry screens have also been undertaken to 
provide a larger scale insight into possible pathways and interaction partners of NUAK1. 
Previous studies (unpublished) in our laboratory have shown that NUAK1 interacts with 14-3-
3 (Appendix 3) and this interaction is explored further. 
 
3.2 Results 
3.2.1 Recombinant NUAK1 expression 
Only one previous study to date has used recombinant NUAK1 to investigate its function 
(Lizcano et al., 2004). This previous report used the human NUAK1 sequence cloned from a 
brain cDNA library and expressed the protein in a pGEX constructs with a GST-HA tag. BL21 E. 
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coli cells were used for expression but it is not stated exactly which cells were used. This study 
reported that recombinant NUAK1 required activation by the LKB1 complex. To confirm these 
findings a similar strategy was used. 
 
 
A 
 
 
B 
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Figure 3.1 Purification of recombinant NUAK1 
(A) Recombinant NUAK1 was purified from whole cell extract of E. coli competent cells 
transformed with pRSF-Duet1 vector containing His/FLAG tagged human NUAK1 and induced 
overnight with 0.4mM IPTG. The protein was purified by Ni2+-Sepharose affinity 
chromatography. The purification was carried out on an AKTApurifier (GE Healthcare) and 
eluted protein was monitored by absorption at 280nm. The different stages of purification – 
loading, washing and elution are shown in panel A. The peak of purified protein is eluted 
between 40 and 50ml. (B) Purified protein was collected in 1ml fractions during the elution 
phase and resolved on a 10% SDS-PAGE Tris-Glycine gel and stained with SimplyBlue stain. (C) 
Peak fractions were then pooled and concentrated before further purification by size 
exclusion on a gel-filtration column (Superdex 200, GE Healthcare) and 1ml fractions were 
collected. These fractions were then resolved on a 10% SDS-PAGE Tris-Glycine gel and stained 
as before. 
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Recombinant human NUAK1 expressed well in E. coli and was purified in reasonable 
quantities (approximately 1mg per litre of bacterial culture) (Figure 3.1). Therefore, various 
manipulations were made to NUAK1 to investigate how changes in the sequence would affect 
the expression and activity. Mutations were made in key residues to investigate the role of 
previously identified aspects of kinase regulation. Firstly, the conserved threonine residue in 
the activation loop (T211 in human NUAK1), previously identified by other studies of the 
AMPK-related kinases (Lizcano et al., 2004; Manning et al., 2002) was mutated to alanine, 
which should ablate activity. NUAK1 also contains the highly conserved DFG motif, common 
to many kinases, immediately N-terminal to the activation loop. Crucially, two residues, an 
aspartic acid (D196 in human NUAK1) and a lysine (K84 in human NUAK1) are required for 
binding the Mg2+ ion that co-ordinates β and γ phosphates of Mg2+-ATP in the active site. By 
mutating these residues to alanine, this prevents the binding of Mg2+-ATP rendering the 
kinase inactive. These are well characterised mutations that have been shown to eliminate 
activity in many kinases, including AMPK (Johnson et al., 1996) and have previously been used 
in studies of NUAK1 (Humbert et al., 2010). This is because the kinase domain and active site 
of many kinases is highly conserved (Figure 1.6). Also, as several previous reports have 
indicated that various members of the AMPK-related kinase family interact with 14-3-3 
proteins (Al-Hakim et al., 2005; Brajenovic et al., 2004), NUAK1 was co-expressed with 14-3-
3ε in the same recombinant system. The 14-3-3ε isoform was chosen, as our previous data 
(Appendix 3) and another report had suggested that this was the most likely to interact with 
NUAK1 (Ballif et al., 2006). 
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Figure 3.2 Expression of recombinant NUAK1 with 14-3-3ε 
Recombinant NUAK1 was purified from whole cell extract of E. coli cells transformed with 
pRSF-Duet1 vector containing His/FLAG tagged NUAK1 and untagged 14-3-3ε controlled by a 
separate promoter and induced overnight with 0.4mM IPTG. Protein was purified in the same 
way as in Figure 3.1 using an AKTApurifier. (A) Purified protein was collected in 1ml fractions 
during the elution phase and resolved on a 10% SDS-PAGE Tris-Glycine gel and stained as 
before. (B) The protein was then concentrated and further purified by gel-filtration on a 
Superdex column and 1ml fractions collected. These fractions were then resolved on a 10% 
SDS-PAGE Tris-Glycine gel and stained as before. (C) Several mutant forms of NUAK1 were 
produced by site directed mutagenesis and purified in the same way using the pRSF-Duet1 
vector system. Concentrated protein was resolved on a 10% SDS-PAGE Tris-Glycine gel and 
stained as before. The molecular weight markers are indicated on the left (kDa) and the 
identity of the bands is indicated on the right.  
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Recombinant NUAK1 could be co-expressed with 14-3-3ε and clearly formed a strong enough 
complex to survive purification (Figure 3.2B). The 14-3-3ε was untagged so could only be 
purified by Ni2+-sepharose affinity chromatography by associating with the his-tagged NUAK1. 
Mutant forms of NUAK1 (T211A and D196A) could both be expressed and both still associated 
with 14-3-3ε (Figure 3.2C). During expression of both mutants the protein yield was 
substantially lower but sufficient quantities of protein were obtained for further experiments. 
The NUAK1 mutant proteins gave around half the yield of the wild-type, approximately 0.5mg 
per litre of bacterial culture. 
 
3.2.2 Recombinant NUAK1 activity 
A previous report (Lizcano et al., 2004) had used a modified version of the AMPK radiolabeling 
kinase assay (Davies et al., 1989) to measure the activity of recombinant NUAK1. A similar 
assay was optimised in our laboratory (see section 2.2.10.2 and used to assess the activity of 
the various forms of recombinant protein. 
 
Figure 3.3 Activity of recombinant NUAK1 
Recombinant wild-type NUAK1, mutated NUAK1 and NUAK1 co-expressed with 14-3-3ε was 
assayed by incubation with γ32P-ATP and synthetic AMARA peptide substrate. Activities are 
shown as mean ± S.E.M. from three independent experiments and are plotted as specific 
activity (picomoles of phosphate incorporated per minute per microgram of protein, 
pmol/min/μg). 
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Interestingly, the wild-type full length protein as expressed in E. coli clearly had some basal 
activity without the need for incubation with LKB1 (Figure 3.3), which contradicts previous 
reports (Lizcano et al., 2004). The wild-type protein co-expressed with 14-3-3ε also had some 
activity but significantly lower than NUAK1 expressed alone. As expected, the T211A and 
D196A mutants showed no activity (Figure 3.3). 
 
The radiolabelling peptide assay was adapted from the AMPK assay in which the AMARA 
peptide was the substrate, based on optimum recognition motifs of known downstream 
targets for AMPK (Dale et al., 1995). The AMARA peptide has been shown to work as a 
synthetic substrate for many kinases but there is no way to predict the optimum substrate 
for NUAK1, as very few downstream targets have been verified. In order to test the activity 
of NUAK1 towards different peptides, a series of previously identified substrates were tested 
to see if NUAK1 could phosphorylate them in vitro. In addition to the AMARA peptide, LNR 
peptide was tested, as it is known to be a suitable substrate for activity measurements of 
several serine/threonine-specific kinases (Ross et al., 2002). The SAMS peptide was tested as 
it is the original peptide substrate for AMPK (Davies et al., 1989) and a novel LATS_N1 peptide, 
based on the sequence of human LATS1 protein, was tested as it was shown to be 
phosphorylated by NUAK1 (Humbert et al., 2010). 
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Figure 3.4 Substrate specificity of recombinant NUAK1 
(A) 0.1 or 0.5μg of wild-type recombinant NUAK1 expressed without 14-3-3ε was incubated 
with the indicated peptide substrate and γ32P-ATP in identical reaction buffers to detect any 
variation in substrate specificity. T211A and D196A mutated NUAK1 are shown as negative 
controls. (B) Various mutations in the LATS1 peptide as shown are incubated with equal 
amounts of recombinant NUAK1 in the same radiolabelling buffers and activities are shown 
as a percentage of the LATS_N1 peptide which is based on the N-terminal sequence of wild-
type human LATS1 protein. Activities are shown as mean ± S.E.M. from three independent 
experiments. (C) The sequence of the peptides used are shown with key residues highlighted. 
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This demonstrated that NUAK1 shows maximal activity when assayed using the AMARA 
peptide with very little activity towards the SAMS peptide, as previosuly reported (Lizcano et 
al., 2004). This previous study of recombinant NUAK1 activity also reported it preferentially 
phosphortylating the LNR peptide but this does not seem to be the case in my experiment 
(Figure 3.4). LATS_N1 peptide showed similar levels of activity as the AMARA peptide but as 
LATS1 protein was a known downstream target of NUAK1 in vivo (Humbert et al., 2010), it 
was possible to mutate the targeted serine residues to assess possible variations in substrate 
specificity. Figure 3.4B clearly shows similar activity levels towards AMARA and LATS_N1 from 
equal amounts of protein but mutation of either of the serine residues to alanine in the LATS 
peptide reduces this activity significantly. 
 
 
Figure 3.5 Western blot detection of recombinant NUAK1 and phosphorylation status of the 
T-loop 
Equal volumes of eluate from bacterially expressed recombinant wild-type and T211A 
mutated NUAK1 was resolved on a 10% SDS-PAGE Tris-Glycine gel and transferred to 
Immobilon FL PVDF membrane for immunodetection. The membrane was incubated with the 
indicated primary antibodies followed by fluorescence conjugated secondary antibodies for 
multiplex detection. The membrane was scanned using a LI-COR Odyssey scanner. 
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As the conserved threonine residue (T211 in human NUAK1) has been shown to be critical for 
activity of the kinase, it is useful to determine if this phosphorylation can be detected by 
western blotting for further analysis of the protein in vivo. As shown in Figure 3.5, the 
recombinant protein, as expressed in E. coli without LKB1, can be detected on a western blot 
using an antibody against the His-tag. The phosphorylation status can also be detected by 
cross-reaction with the AMPK phospho-T172 antibody, which is the equivalent residue to 
T211 in NUAK1. This cross-reaction has been reported previously and provides a useful 
reagent for assessing the phosphorylation status of NUAK1. As expected, Figure 3.5 shows 
that no phosphorylation of the T211A mutant is detectable and that the expression level 
seems to be lower for equivalent E. coli culture volumes, approximately half that of the wild-
type protein. 
 
3.2.3 Cell based expression, activity and regulation of NUAK1 
Assessing the activity of a kinase in vitro with purified recombinant protein is clearly a very 
artificial method that does not permit the complexities of other signalling pathways that may 
impact on the activity occurring in vivo or in cells. By expressing NUAK1 in mammalian cells it 
is possible to assess the activity of the kinase in a more physiologically relevant system. The 
same His/FLAG tagged NUAK1 construct and the T211A mutant used for bacterial expression 
were cloned into pCDNA3.1 vectors for transfection into mammalian cell lines. Initially COS7 
cells were used as they are a readily transfectable cell line that have been shown to express 
LKB1.  
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Figure 3.6 Overexpression and activity in COS7 cells  
(A) Wild-type and T211A mutated NUAK1 was cloned into a pcDNA3.1 vector and transfected 
into COS7 cells using calcium phosphate precipitation. Cells were rapidly lysed and crude 
lysates were resolved on a 10% SDS-PAGE Tris-Glycine gel and transferred to Immobilon FL 
PVDF membrane for immunodetection. The membrane was incubated with the indicated 
primary antibodies followed by fluorescence conjugated secondary antibodies for multiplex 
detection. (B) Expressed protein from COS7 cells was purified using FLAG-affinity resin and 
activity was detected by incubation with γ32P-ATP and synthetic AMARA peptide substrate. 
Activities are shown as mean ± S.E.M. from three independent experiments and are plotted 
as specific activity. 
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NUAK1 protein can clearly be overexpressed in COS7 cells and mutated T211A protein clearly 
shows as similar degree of expression but no phosphorylation of the threonine residue, as 
expected (Figure 3.6). Protein from cells transfected with either wild-type or T211A mutated 
NUAK1 was then purified using FLAG affinity resin in order to be able to assess the activity of 
the protein expressed in mammalian cells. As shown in Figure 3.6B, the phosphorylation 
status of T211 correlates with the activity of the protein, as expected and as shown in a 
recombinant system in Figure 3.3 and Figure 3.5. The immunoprecipitated wild-type protein 
displayed similar NUAK activity to bacterially expressed recombinant protein, but COS7 cells 
express endogenous LKB1 and it is not clear if this basal activity is a result of phosphorylation 
by LKB1. 
 
As a mammalian cell expression system provides a more physiologically relevant context for 
regulation, it is a good opportunity to test some point mutations to better understand 
previous reports regarding the regulation of NUAK1. A previous study reported that NUAK1 
was phosphorylated on S600 by Akt and that this resulted in activation of NUAK1 (Suzuki et 
al., 2004b). By mutating this and other residues it is possible to assess their effect on NUAK1 
activity. 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 3  - In vitro and cellular characterisation of NUAK1 
97 
 
A 
 
 
B 
 
 
Figure 3.7 Effect of point mutations on recombinant NUAK1 activity 
Point mutations of key residues in NUAK1 were created by site-directed mutagenesis and 
confirmed by sequencing. The protein was expressed by transfecting the relevant vector into 
HEK-293T cells and purified using a FLAG affinity resin. (A) The protein was eluted off the resin 
by competition with a FLAG peptide and resolved on a 10% SDS-PAGE Tris-Glycine gel and 
transferred to Immobilon FL PVDF membrane for immunodetection with the indicated 
antibodies, as before. (B) The activity of recombinant protein carrying the indicated mutation 
was determined by incubation with γ32P-ATP and synthetic AMARA peptide substrate. 
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Wild-type NUAK1 and various mutants can also be expressed in HEK293T cells and as before 
the phosphorylation status of T211 correlates with the activity. Consistent with the results 
obtained previously in COS7 cells, the T211A mutant has very low activity (Figure 3.6 and 
Figure 3.7). The K84R mutant is another form of kinase-inactive NUAK1 that has been used 
previously (Humbert et al., 2010) and shows almost no activity. Importantly, the activity of 
NUAK1 harbouring the S600A mutation was similar to that of the wild-type, suggesting that 
Akt signalling may not play a role in NUAK1 activity, at least in HEK cells.  
 
To assess if the over-expression of LKB1 and 14-3-3ε have any effect on NUAK1 activity in 
cells, these were both cloned into pcDNA3 vectors for co-expression in the same cell lines. 
For LKB1, three different vectors were used to co-express LKB1, STRADα (both carrying FLAG-
tags) and MO25 (with a myc-tag). 14-3-3ε was expressed carrying a V5 tag. 
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Figure 3.8 Co-expression of NUAK1 with LKB1 and 14-3-3 in cells 
NUAK1 was co-expressed in COS7 cells with either full-length human LKB1 (along with MO25 
and STRADα in separate vectors to ensure activity) or 14-3-3ε. (A) FLAG affinity purified 
protein was resolved on a 10% SDS-PAGE Tris-Glycine gel and transferred to Immobilon FL 
PVDF membrane for immunodetection. The membrane was incubated with the indicated 
primary antibodies followed by fluorescence conjugated secondary antibodies for multiplex 
detection. (B) Protein was purified using FLAG-affinity resin and activity of the 
immunocomplex was detected by incubation with γ32P-ATP and synthetic AMARA peptide 
substrate. Activities are shown as mean ± S.E.M. from three independent experiments and 
are plotted as specific activity. LKB1 was also FLAG-tagged but has negligible activity towards 
the AMARA peptide (data not shown).  
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NUAK1 can clearly be overexpressed alongside LKB1 and 14-3-3ε in cells and these proteins 
can be purified using FLAG affinity resin. 14-3-3ε was expressed with a V5 tag and therefore 
must have co-purified with either NUAK1 or LKB1 (Figure 3.8). Similar to the recombinant 
system, LKB1 does seem capable of increasing NUAK1 activity slightly and co-expression with 
14-3-3ε does seem to reduce activity to around half of the basal level (Figure 3.3 and Figure 
3.8B). Interestingly, co-expression with both 14-3-3ε and LKB1 appears to restore the NUAK1 
activity to around basal levels, suggesting they may have antagonistic effects. 
 
3.2.4 Role of upstream kinases 
To clarify the role of LKB1 and determine if there was any additional role of the upstream 
kinase in the activation of NUAK1, various activity measurements were performed using 
bacterially expressed recombinant proteins.  
 
Figure 3.9 Partial activation by LKB1 but no activation by CaMKKβ of recombinant NUAK1 
Recombinant NUAK1 and AMPK activity was measured using a radioactive kinase assay by 
incubation with γ32P-ATP and synthetic AMARA peptide substrate. Bacterial recombinant 
NUAK1 expressed without 14-3-3 was incubated in the presence of LKB1 or CaMKKβ and 
MgATP to detect any effect on NUAK1 activity. Recombinant AMPK was used as a control to 
detect activity of recombinant LKB1 and CaMKKβ (kindly provided by Dr David Carmena). 
Activities are shown as mean ± S.E.M. from three independent experiments and are plotted 
as specific activity. 
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LKB1 or CaMKKβ alone have negligible activity on the AMARA peptide so the readout is solely 
for NUAK1. Recombinant LKB1 was expressed as an active complex with STRADα and MO25 
in E. coli and its activity was demonstrated by activation of the human wild-type AMPK 
complex (α1β1γ1) as previously reported (Neumann et al., 2003). Similarly, active CaMKKβ 
was expressed in E. coli and activity was confirmed by activation of wild-type AMPK. Based on 
their activation of AMPK, the same amounts of active LKB1 and CaMKKβ were then incubated 
with recombinant NUAK1 for an assay with the AMARA peptide. CaMKKβ caused no change 
in activity but incubation with LKB1 caused a modest, but significant, increase in activity, 
around 80% more than the basal activity (Figure 3.9). T211A, the T-loop mutant of NUAK1 
was used as a negative control and clearly shows no activity when incubated with LKB1. 
 
The variation in activity of wild-type NUAK1 observed between different experiments (Figure 
3.3, 3.6 and 3.9) may be attributed to differences in the degree of autophosphorylation during 
the purification, or to unknown differences in cellular conditions that affect the activity of the 
kinase. 
 
Only one previous report has indicated any compounds or endogenous molecules that may 
activate or inhibit NUAK1 activity (Fisher et al., 2005). This report suggests that insulin and a 
known AMPK activator, AICAR, can activate NUAK1 based on immunoprecipitating NUAK1 
from incubated rat muscles. To examine whether any other molecules may have an effect on 
NUAK1, recombinant and cell-based assays were conducted to try and modulate the activity 
of the kinase with known activators of other AMPK-related kinases, specifically salt and AMP. 
Salt has been shown to activate the SIK family kinases and AMP is a well-known allosteric 
activator of AMPK. To test the effect of known AMPK family activators, bacterially expressed 
recombinant NUAK1 was incubated with 0.2mM AMP and COS7 cells overexpressing NUAK1 
were incubated with 0.5M sodium chloride 
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Figure 3.10 No activation of NUAK1 by known AMPK allosteric activator AMP or salt 
(A) Recombinant NUAK1 expressed without 14-3-3ε was incubated with 0.2mM AMP during 
a kinase assay and compared to activity of the untreated protein determined by incubation 
with γ32P-ATP and synthetic AMARA peptide substrate. (B) COS7 cells expressing His-tagged 
NUAK1 were treated with 0.5M sodium chloride, added to the culture medium for 10 minutes 
before rapid lysis. The activity of the protein was determined by immunoprecipitation using 
an anti-His antibody followed by incubation with γ32P-ATP and synthetic AMARA peptide 
substrate. (C) and (D) Lysates from the treated cells were resolved on a 10% SDS-PAGE Tris-
Glycine gel and transferred to Immobilon FL PVDF membrane for immunodetection, as 
before. The percentage of phosphorylated protein was determined using the LI-COR Image 
Studio software. 
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Clearly neither salt (in cells) nor AMP (direct addition to the kinase assay) have any significant 
effect on the activity of NUAK1 (Figure 3.10), suggesting there must be several different 
mechanisms of regulation within the AMPK-related kinase family. As before, the 
phosphorylation status of T211 broadly correlates with activity and using densitometry on the 
western blot, it is possible to establish that under basal conditions only around 35% of NUAK1 
in cells is phosphorylated and active. This shows that there is a pool of unphosphorylated 
protein that could be activated by upstream signals. 
 
3.2.5 Autophosphorylation of NUAK1 
The fact that basal levels of activity can be detected in recombinant protein expressed in 
bacteria without the presence of LKB1 suggests that there must be other activating 
mechanisms. One possibility is that NUAK1 is capable of activation by autophosphorylation, a 
mechanisms previously described for another AMPK-related kinase, MELK (Lizcano et al., 
2004). Autophosphorylated MELK was maximally active and unable to be further 
phosphorylated by LKB1. Also, some members of the MARK/PAR family may be capable of 
autoactivation (Marx et al., 2010). Therefore, there may be conserved mechanisms of 
activation by autophosphorylation amongst AMPK-related kinase family members. 
 
Many kinase systems are a balance between phosphorylation and dephosphorylation, which 
is controlled by a series of phosphatases. Some kinases are constitutively active, but many 
respond to activation by phosphorylation, often as part of signal transduction pathways. 
While several well characterised kinases, notably AMPK, do not have a clearly defined 
phosphatase, it is crucial for the regulation of most systems to have a robust mechanism of 
dephosphorylation. The identity of the in vivo phosphatase of NUAK1 is unknown but 
recombinant protein phosphatase 2C (PP2C) can be used as a generic phosphatase and is 
capable of dephosphorylating a number of kinases. It is routinely used in in vitro AMPK 
dephosphorylation assays (Sanders et al., 2007). 
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Figure 3.11 Autophosphorylation and dephosphorylation of recombinant NUAK1 
(A) Various amounts of wild-type and T211A mutated bacterially expressed recombinant 
NUAK1 were incubated with γ32P-ATP in an appropriate buffer and resolved on a 10% SDS-
PAGE Tris-Glycine gel. The gel was exposed to a phosphorimager plate and imaged using a 
Fuji FLA-9000 phosphorimager.  (B) Wild-type bacterially expressed recombinant NUAK1 was 
bound to FLAG-affinity resin and incubated with recombinant PP2C (non-FLAG tagged) and 
the activity determined by incubation with γ32P-ATP and synthetic AMARA peptide substrate. 
Equal amounts of the PP2C treated protein bound to resin was also washed and treated with 
either MgATP or recombinant LKB1 and MgATP and used in the same radioactive kinase assay 
as before. 
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The fact that wild-type protein but not the non-activateable form (T211A) can incorporate 
32PO4 clearly shows that NUAK1 can autophosphorylate (Figure 3.11A). The T211A mutant 
renders the kinase inactive, therefore eliminating its ability to autophosphorylate but it is 
possible that active NUAK1 can autophosphorylate on other residues and this may play a role 
in its regulation or interaction with other proteins.   
 
This autophosphorylation is likely to be the reason for the basal level of activity observed in 
the bacterially expressed recombinant protein. To analyse if the activity can be reduced by 
dephosphorylation, active NUAK1 was treated with recombinant PP2C and showed a 
significant drop in activity to around 30% of the basal level (Figure 3.11B). Because NUAK1 is 
capable of autophosphorylation, it was of interest to see if, when PP2C was removed from 
the assay and the protein bound to the FLAG resin was reincubated with MgATP, the protein 
could reactivate. The recombinant PP2C was not FLAG tagged so could be washed out, leaving 
just the NUAK1 bound to the resin. After incubation with MgATP no increase in activity was 
observed. Dephosphorylated NUAK1 bound to the FLAG resin was also reincubated with 
active recombinant LKB1, but no increase in activity was observed (Figure 3.11B).  
 
3.2.6 Subcellular localisation of NUAK1 
The data described above suggest that while LKB1 may have some role in determining the 
activity of NUAK1, there is likely to be some basal level of autoactivation, potentially meaning 
the kinase is constitutively active. If there is a constitutive level of activity then the function 
of the kinase may be controlled by subcellular localisation. To investigate this, 
immunofluoresence experiments were carried out using tagged forms of NUAK1. 
 
 
 
 
 Chapter 3  - In vitro and cellular characterisation of NUAK1 
106 
 
 
 
 
 
 
 
 
A 
 
   
 
       
B 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
GFP-NUAK1 DAPI Merged 
GFP-NUAK1 DAPI Merged 
 Chapter 3  - In vitro and cellular characterisation of NUAK1 
107 
 
 
 
C 
 
Figure 3.12 Subcellular localisation of NUAK1 in LKB1 expressing cells 
(A) and (B) NUAK1 tagged with green fluorescent protein was expressed in HEK293T cells and 
fixed for fluorescence microscopy. Images are shown of DAPI stained transfected cells and 
the merged image for confirmation of subcellular localisation. (C) COS7 cells transfected with 
FLAG-tagged NUAK1 were fixed and stained with immunofluorescence antibodies against 
FLAG and tubulin. The DAPI stained and merged image are shown for confirmation of 
subcellular localisation. 
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Figure 3.13 Subcellular localisation of NUAK1 in LKB1 null cells 
NUAK1 tagged with green fluorescent protein was expressed in HeLa cells and fixed for 
fluorescence microscopy. Images are shown of DAPI stained transfected cells and the merged 
image for confirmation of subcellular localisation. 
 
The subcellular localisation of NUAK1 is clearly highly regulated as some of the images show 
punctate regions of NUAK1 localisation in the nucleus (Figure 3.12A and B), whereas panel C 
shows NUAK1 to be localised entirely in the nucleus. It is possible that the subcellular 
localisation varies during different parts of the cell cycle as the cell in Figure 3.12C has just 
divided and all the NUAK1 appears to be localised in the cytoplasm. Also, Figure 3.12A and B 
both show HEK293T cells with different patterns of expression, possibly at different stages of 
the cell cycle. Interestingly, the cells in Figure 3.13 are HeLa cells, which lack LKB1 expression, 
yet the subcellular localisation of NUAK1 is similar to that shown in HEK293T cells in Figure 
3.12A. This suggests that any role LKB1 plays in the activation of NUAK1 may not affect its 
subcellular localisation. Although NUAK1 clearly can translocate into the nucleus, the function 
of the kinase in nuclear signalling is unclear, although previous reports have linked NUAK1 to 
senescence and cell cycle control (Humbert et al., 2010). The nuclear role of NUAK1 may be 
linked to its function of phosphorylating LATS1 as part of the Hippo pathway (Figure 1.10), 
however it is not currently clear where this phosphorylation takes place.  
 
3.2.7 NUAK1 knockout mouse embryonic fibroblasts (MEFs) 
Later on in this project, as part of the knockout mouse breeding strategy (Figure 4.1 and Figure 
4.2), NUAK1 knockout mouse embryonic fibroblasts (MEFs) became available, providing a 
very useful resource for analysing the potential role of the kinase as well as providing a useful 
negative control. 
GFP-NUAK1 DAPI Merged 
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Figure 3.14 Establishment of MEFs and confirmation of NUAK1 knockout 
(A) Embryonic fibroblasts were established from wild-type, heterozygous and homozygous 
NUAK1 knockout mouse embryos (Figure 4.1 and  
Figure 4.2). mRNA was purified from wild-type and homozygous NUAK1 knockout cells and 
used to make cDNA. The expression level of NUAK1 was confirmed by quantitative PCR and is 
shown as a percentage of the wild-type MEF expression. (B) Total lysates from wild-type and 
knockout MEFs were resolved on a 10% SDS-PAGE Tris-Glycine gel and transferred to 
Immobilon FL PVDF membrane for immunodetection with anti-NUAK1 antibody (Cell 
Signalling). (C) NUAK2 expression levels were tested by quantitative RT-PCR to confirm that 
the knockout was specific and expression of similar proteins was unaffected. All qPCR figures 
are normalised to the expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
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MEFs were established from wild-type, heterozygous and homozygous global NUAK1 
knockout embryo littermates. NUAK1 deletion was confirmed by quantitative PCR and 
western blotting with the best available commercial NUAK1 antibody (see Figure 4.5), 
showing total deletion in the knockout MEFs (Figure 3.14). Also, the heterozygous global 
NUAK1 knockout MEFs showed approximately 50% of the wild-type expression levels, as 
expected. To ensure the knockout was specific, quantitative PCR was performed using specific 
primers designed against NUAK2, the closest homologous protein to NUAK1. As shown in 
Figure 3.14C there was no change in NUAK2 mRNA levels, suggesting the NUAK1 knockout 
strategy is specific. 
 
Although there have been relatively few studies into the function of NUAK1, one obvious 
inconsistency in the literature is whether NUAK1 is pro or anti-proliferative. Several reports 
from Hiroyasu Esumi’s group and others have suggested that the presence or over-expression 
of NUAK1 is pro-proliferative (Chang et al., 2012; Kusakai et al., 2004a; Suzuki et al., 2004b). 
However, a report from our laboratory and others recently showed that NUAK1 knockdown 
in cells was pro-proliferative (Humbert et al., 2010), contradicting these previous reports. 
Knockout and wild-type MEFs provide an ideal experimental system for investigating the role 
of NUAK1 in cell proliferation. 
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Figure 3.15 Increased growth rate in NUAK1 knockout MEFs 
(A) Equal numbers (1 x 105 cells) of MEFs of each genotype were seeded onto 10cm tissue 
culture plates and grown in identical culture medium. Plates were harvested every 24 hours 
and total cell number was calculated from an average of three replicate plates. (B) Equal 
numbers of cells from wild-type and homozygous NUAK1 knockout MEFs were seeded on 6 
well plates and grown for the indicated number of days before being fixed with 4% 
paraformaldehyde and stained with crystal violet. 
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Using two different methods it is clear that NUAK1 null MEFs grow faster than their wild-type 
equivalents (Figure 3.15). Interestingly, the heterozygous NUAK1 MEFs showed an 
intermediate growth phenotype indicating that partial loss of NUAK1 activity may affect 
whichever pathways mediate this phenotype. This supports the idea that NUAK1 has an anti-
proliferative role or may control some mechanism in the cell cycle which contributes towards 
senescence. This observation could be confirmed by investigating 3H thymidine incorporation 
to accurately quantify any increase in cell proliferation. Anecdotal evidence from handling 
NUAK1 knockout MEF cultures also suggests that they are more adherant, although no data 
is shown as a suitable assay was not performed. This is consistent with recent evidence 
showing NUAK1 can phosphorylate MYPT1 and regulate myosin light chain (MLC) 
phosphorylation, leading to cells being more adherant (Zagorska et al., 2010). 
 
Part of the initial hypothesis behind investigating the role of NUAK1 was that it could be 
involved in aspects of metabolic regulation, given the important role AMPK and its 
downstream pathways play in metabolism. Given the higher growth rate of the NUAK1 null 
MEFs it was possible that there could be an upregulation of metabolic processes to provide 
the energy to drive cell proliferation. Changes in AMPK subunit mRNA levels and two key 
mitochondrial genes, cytochrome c oxidase subunit VIb (Cox6b) and NADH dehydrogenase 
protein 4 (Ndufs4) were assessed by quantitative PCR. 
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Figure 3.16 Quantitative PCR of NUAK1 knockout MEFs 
mRNA purified from wild-type and homozygous NUAK1 knockout MEFs was converted to 
cDNA and used to determine the expression of AMPK subunits and two important 
mitochondrial genes. The values are shown as a fold change against the wild-type values and 
are an average of at least three biological replicates. (A) AMPK α1 subunit, (B) AMPK α2 
subunit, (C) AMPK β1 subunit, (D) AMPK γ1 subunit, (E) Cox6b (F) Ndufs4 All figures are 
normalised to the expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
Significance was analysed using the student’s t-test and indicated on the graph (* = p<0.05). 
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No changes were observed in AMPK α or γ subunit levels but a significant increase in β subunit 
levels was seen. This increase would not affect AMPK activity levels as the 1:1:1 stoichoimetric 
ratio of subunits would mean that the number of active AMPK complexes in the cell would be 
determined by the lowest common denominator, which would be the α or γ subunit levels, 
which are unchanged (Figure 3.16). Interestingly, there was a significant increase in the mRNA 
levels of both Cox6b and Ndufs4, suggesting that mitochondrial genes may be upregulated as 
a result of reduced NUAK1 activity (Figure 3.16). 
 
Figure 3.17 AMPK activity is unchanged in NUAK1 knockout MEFs 
Endogenous AMPK complexes were immunoprecipitated from both wild-type and 
homozygous NUAK1 knockout MEFs using a pan-AMPKβ antibody. The activity of AMPK in the 
immune complex was determined by incubation with γ32P-ATP and synthetic AMARA peptide 
substrate. No significant difference (p>0.05) was observed between wild-type and knockout 
MEFs when analysed using the student’s t-test. 
 
As expected from the qPCR data, there is no change in the activity of AMPK in NUAK1 
knockout MEFs compared to their wild-type equivalents (Figure 3.17). This is another piece 
of evidence that the NUAK1 knockout is specific and is not having off target effects on other 
components of the AMPK-related kinase family. 
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3.2.8 NUAK1 mass spectrometry studies 
Given the great experimental potential of having NUAK1 knockout MEFs and without any 
clear indication of what processes or pathways the kinase may be targeting, it was useful to 
take a wider approach and use an un-biased, large scale method to identify possible 
downstream targets. The most efficient method available for looking at changes in expression 
and phosphorylation of proteins on a large scale is mass spectrometry. Given the high 
possibility of getting false positive results, a decision was made to use three different methods 
and compare the results to minimise the number of false positives. The experimental basis 
for each method is explained in Figure 3.18A. 
A 
 
 
B 
 
Gene 
Ontology 
term 
Cluster 
frequency 
Genome 
frequency 
Corrected 
P-value 
FDR 
False 
Positives 
Genes 
annotated 
to the term 
Transcytosis 
2 of 4 genes, 
50.0% 
9 of 25496 
genes, 0.0% 
5.64e-05 0.00% 0.00 USO1, SRC 
Positive 
regulation of 
protein 
complex 
assembly 
2 of 4 genes, 
50.0% 
102 of 25496 
genes, 0.4% 
0.00804 9.00% 0.18 CHIP, SRC 
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C 
 
Gene 
Ontology 
term 
Cluster 
frequency 
Genome 
frequency 
Corrected 
P-value 
FDR 
False 
Positives 
Genes annotated to 
the term 
Organelle 
organization 
11 of 20 
genes, 
55.0% 
2183 of 
25496 
genes, 
8.6% 
3.58e-05 0.00% 0.00 
CLIP1, NSUN2, 
MAP1S, NUDC, 
MAP2, STMN1, 
RTN4, CRK, USO1, 
HUWE1, SRC 
Microtubule 
bundle 
formation 
3 of 20 
genes, 
15.0% 
33 of 
25496 
genes, 
0.1% 
0.00055 0.00% 0.00 
CLIP1, MAP1S, 
MAP2 
Cellular 
component 
organization 
12 of 20 
genes, 
60.0% 
3853 of 
25496 
genes, 
15.1% 
0.00133 0.00% 0.00 
CLIP1, NSUN2, 
MAP1S, CHIP, 
NUDC, MAP2, 
STMN1, RTN4, CRK, 
USO1, HUWE1, 
SRC 
Cellular 
component 
organization 
or biogenesis 
12 of 20 
genes, 
60.0% 
3983 of 
25496 
genes, 
15.6% 
0.00190 0.00% 0.00 
CLIP1, NSUN2, 
MAP1S, CHIP, 
NUDC, MAP2, 
STMN1, RTN4, CRK, 
USO1, HUWE1, 
SRC 
Regulation of 
protein 
complex 
assembly 
4 of 20 
genes, 
20.0% 
210 of 
25496 
genes, 
0.8% 
0.00488 0.80% 0.04 
CLIP1, STMN1, 
CHIP, SRC 
Transcytosis 
2 of 20 
genes, 
10.0% 
9 of 
25496 
genes, 
0.0% 
0.00524 1.00% 0.06 USO1, SRC 
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D 
 
Gene 
Ontology 
term 
Cluster 
frequency 
Genome 
frequency 
Corrected 
P-value 
FDR 
False 
Positives 
Genes annotated to the 
term 
Nuclear 
division 
5 of 25 
genes, 
20.0% 
326 of 
25496 
genes, 
1.3% 
0.00440 0.00% 0.00 
MYPT1, AKAP8, CDC16, 
KIF2A, USP9X 
Mitosis 
5 of 25 
genes, 
20.0% 
326 of 
25496 
genes, 
1.3% 
0.00440 0.00% 0.00 
MYPT1, AKAP8, CDC16, 
KIF2A, USP9X 
Organelle 
fission 
5 of 25 
genes, 
20.0% 
354 of 
25496 
genes, 
1.4% 
0.00655 0.00% 0.00 
MYPT1, AKAP8, CDC16, 
KIF2A, USP9X 
Cellular 
component 
organization 
or biogenesis 
13 of 25 
genes, 
52.0% 
3983 of 
25496 
genes, 
15.6% 
0.00807 0.00% 0.00 
MYPT1, AP3D1, CDC16, 
KIF2A, HNRPK, CHIP, 
NOP56, AKAP8, MYH9, 
USO1, USP9X, SRC, 
MARK2 
 
 
E 
 
Gene 
Ontology 
term 
Cluster 
frequency 
Genome 
frequency 
Corrected 
P-value 
FDR 
False 
Positives 
Genes annotated to the 
term 
Unannotated 
15 of 59 
genes, 
25.4% 
716 of 
25496 
genes, 2.8% 
4.02e-08 0.00% 0.00 
MRLC2, FOR, NCBP, ADE2, 
SEC61, TPM3, RAB, CAB, 
DNAJ, DSH, FKBP59, 
AKAP, FAR, UAP56, NATA 
Cellular protein 
metabolic process 
22 of 59 
genes, 
37.3% 
2981 of 
25496 
genes, 
11.7% 
0.00023 0.00% 0.00 
FMR1, RIG, MMS2, FYN, 
FAT, RHO, NEDD8, 
IQGAP1, HSP40, FGFR2, 
RAS, HSPB1, EIF3, FGR, 
MAK, RAD50, ACP1, 
FKBP4, CAND1, UBC12, 
PP1, LYN 
Protein metabolic 
process 
23 of 59 
genes, 
39.0% 
3720 of 
25496 
genes, 
14.6% 
0.00261 0.00% 0.00 
PAI1, FMR1, RIG, MMS2, 
FYN, FAT, RHO, NEDD8, 
IQGAP1, HSP40, FGFR2, 
RAS, HSPB1, EIF3, FGR, 
MAK, RAD50, ACP1, 
FKBP4, CAND1, UBC12, 
PP1, LYN 
Protein auto-
phosphorylation 
6 of 59 
genes, 
10.2% 
185 of 
25496 
genes, 0.7% 
0.00303 0.00% 0.00 
FGR, MAK, FGFR2, RAD50, 
LYN, FYN 
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Gene 
Ontology 
term 
Cluster 
frequency 
Genome 
frequency 
Corrected 
P-value 
FDR 
False 
Positives 
Genes annotated to the 
term 
Cellular protein 
modification 
process 
17 of 59 
genes, 
28.8% 
2302 of 
25496 
genes, 9.0% 
0.00793 0.40% 0.02 
FYN, FAT, RHO, NEDD8, 
IQGAP1, FGFR2, RAS, 
HSPB1, FGR, MAK, 
RAD50, ACP1, FKBP4, 
CAND1, UBC12, PP1, LYN 
Protein 
modification 
process 
17 of 59 
genes, 
28.8% 
2302 of 
25496 
genes, 9.0% 
0.00793 0.33% 0.02 
FYN, FAT, RHO, NEDD8, 
IQGAP1, FGFR2, RAS, 
HSPB1, FGR, MAK, 
RAD50, ACP1, FKBP4, 
CAND1, UBC12, PP1, LYN 
 
 
Figure 3.18 Summary of NUAK1 mass spectrometry screens 
Various mass spectrometry screens were used to identify possible interaction partners for 
NUAK1 with the assistance of the CSC Mass Spectrometry Facility (Bram Snidjers and Pedro 
Rodriguez Cutillas). (A) An explanatory flowchart explains what different methods were used. 
For further information see section 2.2.21. By using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) comparisons were made between the results 
for each different screen. In each case Gene Ontology searches were carried out on those 
genes that were found in more than one screen. (B) This table shows the gene ontology for 
genes found in all three sets of results. (C) This table shows the gene ontology for genes found 
in both the MEF SILAC and neuronal phosphoscreen experiments.  (D) This table shows the 
gene ontology for genes found in both the neuronal phosphoscreen and the FLAG-tagged 
immunoprecipitation experiments.  (E) This table shows the gene ontology for genes found in 
both the FLAG-tagged immunoprecipitation and MEF SILAC experiments. 
The False Discovery Rate (FDR) is a value for how often a p-value generated from random data 
is as good as or better than a p-value generated from the real data for that ontology term.     
p-value<0.01 was chosen as the cutoff and the false positives column is an indication of the 
expected number of false positive results that would appear, if that particular ontology term 
was chosen as the cutoff. 
 
The three different mass spectrometry screens generated a huge amount of data and crucially 
provided some confirmation of previously reported proteins that interact with NUAK1, 
specifically USP9X and MYPT1 (Figure 3.18D) (Al-Hakim et al., 2008; Zagorska et al., 2010). 
The data shows that the proteins interacting with NUAK1 and those that show changes in 
phosphorylation between NUAK1 knockout and wild-type MEFs are involved in various 
processes including microtubule organisation, mitosis and metabolism. These data provide 
possible links to the downstream pathways that are controlling the increased proliferation in 
NUAK1 null MEFs and increase in metabolic gene expression. 
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Gene 
Ontology 
term 
Cluster 
frequency 
Genome 
frequency 
Corrected 
P-value 
FDR 
False 
Positives 
Genes annotated to the 
term 
Microtubule 
cytoskeleton 
organization 
5 of 11 genes, 
45.5% 
286 of 25496 
genes, 1.1% 
1.24e-05 0.00% 0.00 
Map4, Map1b, Map1s, 
Mapt, Map2 
Microtubule bundle 
formation 
3 of 11 genes, 
27.3% 
33 of 25496 
genes, 0.1% 
5.37e-05 0.00% 0.00 Map1b, Map1s, Map2 
Microtubule-based 
process 
5 of 11 genes, 
45.5% 
418 of 25496 
genes, 1.6% 
8.17e-05 0.00% 0.00 
Map4, Map1b, Map1s, 
Mapt, Map2 
Establishment of 
mitochondrion 
localization, 
microtubule-
mediated 
2 of 11 genes, 
18.2% 
5 of 25496 
genes, 0.0% 
0.00028 0.00% 0.00 Map1b, Mapt 
Mitochondrion 
transport along 
microtubule 
2 of 11 genes, 
18.2% 
5 of 25496 
genes, 0.0% 
0.00028 0.00% 0.00 Map1b, Mapt 
Establishment of 
mitochondrion 
localization 
2 of 11 genes, 
18.2% 
7 of 25496 
genes, 0.0% 
0.00058 0.00% 0.00 Map1b, Mapt 
Cytoskeleton 
organization 
5 of 11 genes, 
45.5% 
771 of 25496 
genes, 3.0% 
0.00164 0.00% 0.00 
Map4, Map1b, Map1s, 
Mapt, Map2 
Positive regulation 
of microtubule 
polymerization 
2 of 11 genes, 
18.2% 
14 of 25496 
genes, 0.1% 
0.00254 0.00% 0.00 Map1b, Mapt 
Neuron projection 
morphogenesis 
4 of 11 genes, 
36.4% 
412 of 25496 
genes, 1.6% 
0.00336 0.00% 0.00 
Map1b, Map1s, Mapt, 
Map2 
Microtubule-based 
movement 
3 of 11 genes, 
27.3% 
138 of 25496 
genes, 0.5% 
0.00411 0.00% 0.00 Map4, Map1b, Mapt 
Positive regulation 
of microtubule 
polymerization or 
depolymerisation 
2 of 11 genes, 
18.2% 
18 of 25496 
genes, 0.1% 
0.00428 0.00% 0.00 Map1b, Mapt 
Establishment of 
organelle 
localization 
3 of 11 genes, 
27.3% 
148 of 25496 
genes, 0.6% 
0.00507 0.00% 0.00 Map4, Map1b, Mapt 
Mitochondrion 
localization 
2 of 11 genes, 
18.2% 
20 of 25496 
genes, 0.1% 
0.00531 0.00% 0.00 Map1b, Mapt 
Regulation of 
microtubule 
polymerization 
2 of 11 genes, 
18.2% 
24 of 25496 
genes, 0.1% 
0.00771 0.00% 0.00 Map1b, Mapt 
Organelle transport 
along microtubule 
2 of 11 genes, 
18.2% 
24 of 25496 
genes, 0.1% 
0.00771 0.00% 0.00 Map1b, Mapt 
Positive regulation 
of axon extension 
2 of 11 genes, 
18.2% 
25 of 25496 
genes, 0.1% 
0.00838 0.00% 0.00 Map1b, Mapt 
Cell projection 
morphogenesis 
4 of 11 genes, 
36.4% 
535 of 25496 
genes, 2.1% 
0.00934 0.00% 0.00 
Map1b, Map1s, Mapt, 
Map2 
 
Figure 3.19 Comparison of AMPK and NUAK1 neuronal lysate phosphoscreens 
An identical experiment to the neuronal lysate phosphoscreen described in Figure 3.18A was 
carried out using recombinant AMPK instead of NUAK1. The results from these two 
experiments were compared and common genes were analysed using a gene ontology search. 
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In a parallel experiment to the NUAK1 phosphoscreen, an identical experiment was 
conducted using recombinant AMPK. By comparing the results from this screen to the NUAK1 
screen, a degree of specificity can be determined (Figure 3.19). Clearly many of the proteins 
common to both the AMPK and NUAK1 screens are regulating microtubule function and 
cytoskeletal organisation, suggesting there may be redundancy in the AMPK-related kinase 
family in controlling these functions, especially as the MARK family are known to regulate 
similar processes (Bright et al., 2009). Comparing the results from this screen to the overall 
summary of the NUAK1 mass spectrometry experiments, it may suggest that the specific roles 
of NUAK1 are more focussed on mitosis and metabolism rather than microtubule regulation. 
 
Raw data from the phosphoscreens indicated a lot of proteins with acidic residues having 
altered phosphorylation levels or protein levels in the NUAK1 wild-types compared to the 
knockouts (data shown in Appendix 2). Casein kinase 2 (CK2) is a well known upstream kinase 
of various acidic proteins and it was hypothesised that NUAK1 may be modulating the role of 
CK2 in some way given the number of acidic proteins that were changed in the mass 
spectrometry data. 
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Figure 3.20 Casein kinase 2 substrate phosphorylation is unaffected by NUAK1 knockout in 
liver 
Total tissue lysate from wild-type and homozygous NUAK1 knockout livers were resolved on 
a 10% SDS-PAGE Tris-Glycine gel and transferred to Immobilon FL PVDF membrane for 
immunodetection. The membrane was incubated with a phospho-CK2 substrate primary 
antibody. Various bands were quantified using the LI-COR software and no significant 
difference in any of the bands was observed (data not shown). 
 
Although the blot was probed with a phospho-CK2 substrate antibody that identifies a generic 
CK2 recognition motif, it clearly shows there is no obvious change in CK2 substrate 
phosphorylation (Figure 3.20). If there were large scale changes in CK2 activity it would be 
reasonable to expect to see some change in phosphorylation using this antibody so it is likely 
that there is no change in CK2 activity as a result of NUAK1 deletion. 
 
3.3 Discussion 
The fields of NUAK1 and AMPK-related kinases in general have been sparsely researched and 
few reports exist in published literature regarding the role and regulation of these kinases. 
This presents a challenge and an opportunity simultaneously as there are many possibilities 
for novel findings but there is also insufficient evidence to support a coherent model of 
NUAK1 function.  
Several findings described in this chapter contradict published reports of NUAK1 regulation 
and clearly it is difficult to determine the reason for the observed differences and combine 
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the data to produce a cohesive story. As with any emerging field, more research will be 
required to establish a consistent picture of the role of NUAK1 in wider signalling pathways. 
 
Only one previous report has investigated the activity of recombinant NUAK1 expressed in E. 
coli (Lizcano et al., 2004). Their data showed that wild-type human recombinant NUAK1 has 
no intrinsic activity, however in my study a small but measurable amount of activity is seen 
when the same protein is expressed. The only significant difference in the experimental 
method that produced these two opposing results was the tag used to purify the expressed 
protein. The previous study used GST-HA tags, although no details were shown regarding 
where the tags were located. GST is a large 26 kDa tag and the method did not mention that 
the tag was cleaved off prior to assaying for activity (Lizcano et al., 2004 – supplementary 
section). The presence of the large GST tag and data suggesting that the presence of the tag 
can cause proteins to dimerize in solution (Terpe, 2003) may explain why no catalytic activity 
was observed. The precise three-dimensional structure of kinases is crucial for their activity 
and if the active site was obstructed this could lead to a drop in activity. The GST tag may also 
lead to misfolding or aggregation of the expressed protein which would still be detectable by 
western blotting but would not have activity. The purification tag used in my study was a His-
FLAG tag, both on the N-terminal end of the protein, with a total size of 1.84 kDa. This tag 
would be much less likely to obstruct any intrinsic activity. To support the evidence in this 
report that other members of the AMPK-related kinase family may show intrinsic activity in 
the absence of LKB1, the report that first identified SIK1 expressed a GST tagged form that 
showed a basal level of activity, presumed to be via autophosphorylation (Wang et al., 1999). 
This report also supports the hypothesis that some of the AMPK-related kinases may possess 
intrinsic activity. 
 
The finding that NUAK1 has measurable basal kinase activity without the need for 
phosphorylation by LKB1 opens up the possibility and requirement for other mechanisms of 
regulation. The data shown here suggest that although LKB1 is not required for NUAK1 
activity, the presence of LKB1 can increase the activity (Figure 3.8 and Figure 3.9). This may 
suggest that a basal level of NUAK1 is required for some functions but that further 
phosphorylation by LKB1 could increase its activity in the presence of certain stimuli.  
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This discovery that LKB1 can still be an activating upstream kinase raises the question of other 
methods of regulation that can modulate NUAK1 activity in response to relevant stimuli. From 
the data regarding NUAK1 generated during this study (Appendix 3) and from other data 
regarding similar AMPK-related kinases (Al-Hakim et al., 2005), it was known that 14-3-3 can 
bind and potentially regulate NUAK1 activity. The previous study reported that 14-3-3 
proteins can bind to the AMPK-related kinases SIK1 and SIK3 (QSK) and increase their activity. 
Their data also suggested that 14-3-3 binds directly to the T-loop and allows activation by 
LKB1 (Al-Hakim et al., 2005). To date, there have been no other reports of proteins that can 
bind directly to the T-loop of AMPK-related kinases and preliminary indications from 
sequence analysis suggest that 14-3-3 probably binds to NUAK1 in the C-terminal portion of 
the protein (data not shown), which may mean it regulates the activity differently. Also, data 
from bacterial expression shows that the conserved threonine residue in the active site 
probably plays no role in binding 14-3-3 as mutation to alanine did not abolish the binding 
(Figure 3.2). There is no evidence that 14-3-3s bind to the S600 residue of NUAK1, as binding 
was still observed with expression of the S600A mutant protein (data not shown). Another 
function that 14-3-3 may be regulating is subcellular localisation, as numerous reports have 
demonstrated that the binding of 14-3-3 proteins can control the targeting of proteins within 
the cell (reviewed in Aitken, 2006). In the case of SIK3, 14-3-3 binding localised the kinase to 
punctate structures within the cytosol (Al-Hakim et al., 2005). Interestingly, this localisation 
was not seen in LKB1 deficient HeLa cells, suggesting there may be a co-operative mechanism 
controlling localisation and activity. 14-3-3 proteins are known to be able to bind two 
substrate proteins simultaneously and these results led the authors of this report to 
hypothesise that 14-3-3 may function as a scaffolding complex to allow the interaction of the 
kinases with other 14-3-3 binding partners. 
 
The results presented in this thesis partially contradict the report on SIK1 and SIK3 because it 
was observed that 14-3-3s binding to NUAK1 reduced its activity in vitro and in cells (Figure 
3.3 and Figure 3.8). There are several possible explanations for this observation. Firstly, 
different AMPK-related kinases may bind 14-3-3 by different mechanisms, leading to diverse 
structural changes and consequently different effects on kinase activity. Also, different          
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14-3-3 isoforms may have contrasting effects on their binding partners. The study looking at 
SIK1 and SIK3 reported interaction with 14-3-3ζ, whereas NUAK1 appears to primarily bind to        
14-3-3ε (Appendix 3 and Ballif et al., 2006). Interestingly, looking at the subcellular localisation 
of NUAK1, there was no difference seen between LKB1 expressing cells and LKB1 null cells 
(Figure 3.12A and Figure 3.13). This may suggest that LKB1 expression does not influence the 
localisation of NUAK1 in the same way as SIK1 and SIK3. The localisation of NUAK1 could still 
be controlled by 14-3-3s and some evidence from this report suggests that it may also be 
involved in regulating its activity. Basal activity of NUAK1 was reduced in the presence of       
14-3-3ε in bacterial cells, indicating that it may be responsible for inactivating and 
sequestering the kinase in a part of the cell when its activity is not required. The fact that 
activity was increased to around basal levels in the presence of LKB1 and 14-3-3 (Figure 3.3 
and Figure 3.8) points to the possibility that there may be a co-operative mechanism for 
regulating NUAK1 activity, similar to that reported for SIK1 and SIK3. However, rather than 
localising LKB1 with its substrate to increase activity, it appears that LKB1 and 14-3-3s may 
act in an antagonistic manner to regulate NUAK1 activity.  
 
Looking further at the subcellular localisation, it is possible that 14-3-3s and LKB1 act to 
modulate the activity of NUAK1 at different phases of the cell cycle. The finding that NUAK1 
is not maximally phosphorylated (Figure 3.10D) suggests the possibility that by binding of      
14-3-3s and phosphorylation by LKB1, the partial basal activity of the kinase could be 
controlled in response to stimuli. It is possible that the subcellular localisation varies during 
different phases of the cell cycle, as the cell in Figure 3.12C has just undergone division and 
all the NUAK1 appears to be diffusely localised in the cytoplasm. This transition may be 
mediated by association and dissociation of 14-3-3s, as these proteins are known to bind 
phosphorylated residues and influence localisation (Mackintosh, 2004). NUAK1 is seen to 
autophosphorylate (Figure 3.11) and some of the residues it phosphorylates may be 
important for binding 14-3-3s. Further studies using mass spectrometry approaches to 
identify the autophosphorylation sites would allow these residues to be mutated to assess 
the effect on 14-3-3 binding. Although no firm evidence is provided in this thesis to support 
the hypothesis that the localisation of NUAK1 varies with specific cues in the cell cycle, it is an 
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interesting idea that may support some of the phenotypes observed in NUAK1 knockout cells 
and animal models.  
 
During this project several attempts were made to express NUAK1 in LKB1 null cell lines such 
as HeLa and CCL13, but very little protein was detected, despite control proteins being readily 
expressed (data not shown). Although occasionally it was possible to transfect NUAK1 into 
LKB1 null cells with some success (Figure 3.13), it is possible that the presence of LKB1 has 
some effect on the localisation or stablilty of the protein in a cellular environment, hence the 
low expression observed in LKB1 null cells. Although NUAK1 is capable of 
autophosphorylation in vitro (Figure 3.11), LKB1 may still be responsible for stability and 
localised activity within mammalian cells.  
 
Contrary to this finding, recombinant LKB1 was not seen to reactivate dephosphorylated 
NUAK1 in vitro (Figure 3.11B). This lack of reactivation could be due to limitations of the assay 
technique if a small amount of PP2C remained in the assay or if the binding of NUAK1 to the 
resin somehow interfered with acess to LKB1 to prevent phosphorylation and reactivation. 
However, it may also suggest that the activity of NUAK1 requires a co-ordinated combination 
of LKB1, or another upstream kinase, and autophosphorylation to be fully active. 
 
This study also sought to clarify findings of previous reports, particularly the involvement of 
other potential upstream kinases for NUAK1. A previous report indicated that Akt was capable 
of phosphorylating NUAK1 on S600 leading to activation (Suzuki et al., 2004b). However, 
when NUAK1 harbouring a mutation of S600 to alanine was overexpressed in HEK293T cells, 
no change in the activity was seen (Figure 3.7). It is possible that under basal conditions, S600 
might not be phosphorylated so no effect would be observed by simply mutating the residue 
and it may be more indicative to stimulate the cells with an agonist that would activate the 
Akt pathway, such as insulin. However, the previous study reported that an overexpression 
of the S600A mutant in PANC-1 cells completely ablated activity (Suzuki et al., 2004b), which 
was not seen in my experiment. The previous study measured activity against a GST-tagged 
SAMS peptide which could explain the variability in observations given that in my hands, 
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recombinant NUAK1 appears to show better activity against the AMARA and LATS1 peptides 
(Figure 3.4). The inactivity of K84R and D196A mutants indicate that the predicited structural 
similarities of NUAK1 to other kinases are correct (Figure 3.7). Similarities such as these may 
be used to provide some insight into the structure and regulation of NUAK1 when compared 
to the structure of other similar proteins, such as the MARKs, which are also known to 
autophosphorylate (Marx et al., 2010). 
 
Although the activity of NUAK1 may share these similarities with other kinases, the finding 
that neither AMP or salt are capable of activating NUAK1 (Figure 3.10) suggests that there are 
disparate mechanisms of activation within the family of AMPK-related kinases and if there are 
any small molecules that are found to activate NUAK1, these may play a role in its subcellular 
localisation or control of its autophosphorylation. One important issue concerning the 
regulation of NUAK1 is that there are very few indications of conditions that can activate or 
inhibit NUAK1 in vivo. One report has indicated that phosphorylation of known NUAK1 targets 
is increased by cell detachment (Zagorska et al., 2010), but no mechanism for this increase 
was suggested. Establishing phsyiological or pathological conditions that alter NUAK1 activity  
will be key to understanding its regulation. Various other stresses could be used to establish 
mechanisms of NUAK1 activation, such as ATP depletion with 2-deoxyglucose, oligomycin or 
metformin. 
 
As previously mentioned, a major inconsistency in the literature is whether NUAK1 is pro or 
anti-proliferative. Several reports have implicated it in pro-proliferative mechanisms (Chen et 
al., 2013a; Kusakai et al., 2004a; Lu et al., 2013) but other reports have indicated the presence 
of NUAK1 to be anti-proliferative (Humbert et al., 2010). The finding in this report that NUAK1 
null MEFs grow significantly faster than wild-type MEFs (Figure 3.15) would support the 
finding that NUAK1 is anti-proliferative. This could be due to the regulation of LATS1 discussed 
in Humbert et al. but could also be due to another downstream mechanism, such as 
downregulating mTOR signalling. To investigate this further it would be interesting to assess 
S6K and 4E-BP1 phosphorylation. The finding that downregulation of LATS1 is involved in the 
maintenance of senesence links NUAK1 to key regulators of cell cycle control (Takahashi et 
al., 2006). However, LATS1 is also involved in the Hippo pathway (Figure 1.10) and NUAK1 
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reducing expression of LATS1 would have pro-proliferative effects. This opens up the 
interesting possibility that NUAK1 could have two cell-stage dependent functions. Firstly, it 
may act as part of the Hippo pathway to control proliferation and organ size and secondly it 
may act in differentiated cells to maintain senesence. 
 
Interestingly, the quantitative PCR data from the NUAK1 null MEFs show there is a significant 
upregulation of mitochondrial genes (Figure 3.16). There is no inidication if this is a direct 
consequence of NUAK1 deletion or if the cell is simply producing more energy in response to 
proliferative cues created as a result of a different pathway. Further assessment of other 
pathways in NUAK1 positive and null cells would give a better indication of what pathways 
were being affected. A previous study had associated some of the downstream functions of 
NUAK1 to the evidence that inhibition of NUAK1 causes a drop in ATP levels in cells with 
deregulated Myc expression (Liu et al., 2012). Some data from my study does question this 
finding, as AMPK activity was found to be unchanged in NUAK1 null MEFs (Figure 3.17). 
However, the study by Liu and colleagues did suggest it was the deregulation of Myc 
expression that causes a reliance on NUAK1 activity, so this may indicate that under basal 
conditions, AMPK activity would remain unchanged when NUAK1 is deleted. 
 
Very few NUAK1 substrates have been identified in the literature and attempts to use mass 
spectrometry approaches to identify novel interactions has produced a huge amount of data. 
Crucially, several previously identified NUAK1 interacting partners have appeared in my mass 
spectrometry screens such as USP9X and MYPT1 (Figure 3.18). A previous study has indicated 
NUAK1 can bind to to the MYPT1-PP1β complex and regulate the phosphorylation of myosin 
light chain (Zagorska et al., 2010). The confirmation that NUAK1 can interact with MYPT1 and 
potentially regulate MLC phosphorylation reveals several possible downstream pathways. 
MLC phosphorylation has an integral role in the regulation of cell adhesion and polarity in 
non-muscle cells (Vicente-Manzanares et al., 2009). Complicating the issue, another report 
has also identified NUAK2, a close homologue of NUAK1, as being able to phosphorylate 
MYPT1 (Yamamoto et al., 2008). Resolving these interactions and any potential redundancy 
between the two closely related kinases would be important for understanding this function. 
 Chapter 3  - In vitro and cellular characterisation of NUAK1 
128 
 
Interestingly, the C. elegans orthologue of NUAK1 and NUAK2 (unc-82) has also been shown 
to be involved in myosin filament organisation (Hoppe et al., 2010). These potential functions 
are supported by evidence from the mass spectrometry screens, as the main gene ontology 
functions identified are aspects such as microtubule organisation and mitosis (Figure 3.18). 
Specifically, some of the other proteins that are identified in the screens include MLC, PP1 
and CDC16 which are all involved in cell cycle regulation. As part of the analysis of the mass 
spectrometry data, it was thought that due to the presence of many acidic peptides, 
particularly in the neuronal phosphoscreen, that NUAK1 may crosstalk with the CK2 pathway. 
The finding that a pan-CK2 substrate antibody detects no difference between NUAK1 
knockout and wild-type tissues would suggest that NUAK1 does not affect this pathway. 
However, these findings must be interpreted with caution as it is difficult to know exactly 
what this antibody recognises. One feature that this highlights is the difficulty of working with 
such large data sets as it can be unclear exactly what they reveal about the function of a 
protein of interest. 
 
In summary, the data presented in this chapter shows that NUAK1 has a basal level of activity 
and the control of its function is likely to regulated by several different mechanisms. It is also 
shown that NUAK1 is anti-proliferative, at least in growing cells, as its deletion leads to an 
increase in proliferation. Finally, various data are presented from mass-spectrometry screens 
which support previous evidence of NUAK1 interactions and provide a useful resource for 
further investigation of its function.  
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4  Generation and characterisation of global and liver-
specific NUAK1 knockout mice 
4.1 Introduction 
At the beginning of this project little was known about the in vivo role of NUAK1 as most 
previous studies had focussed on the homology with the AMPK α subunits and activation by 
LKB1 (Lizcano et al., 2004), or the role of NUAK1 in tumour progression (Kusakai et al., 2004b; 
Suzuki et al., 2004b). A study aiming to identify new genes involved in mouse brain 
development uncovered NUAK1 as a potential regulator of ventral body wall closure by 
generating mice with a global deletion of NUAK1 (Hirano et al., 2006). This study showed that 
mice lacking NUAK1 display embryonic lethality, due to an omphalocele phenotype, meaning 
that this approach would be of limited use for studying the in vivo role of the kinase. Also, this 
study did not make the connection that the kinase was NUAK1 displaying homology with the 
AMPK α subunits, despite the kinase having already been identified and named earlier as part 
of a project cataloguing the human kinome (Manning et al., 2002). The study identified NUAK1 
as having homology to SNF1, but did not relate the findings to other reports on AMPK-related 
kinases. No other groups have verified the global NUAK1 knockout phenotype and only one 
publication has demonstrated a conditional NUAK1 knockout phenotype (Inazuka et al., 
2012).  
 
During the course of this project, a study was published showing a phenotype in skeletal 
muscle-specific NUAK1 knockout mice (Inazuka et al., 2012). Despite deleting the kinase in a 
tissue where it is relatively highly expressed, no morphological or metabolic phenotype was 
observed under basal conditions (section 1.3.4 ). A phenotype was only observed when the 
mice were fed on a high-fat diet, indicating that other conditional knockout phenotypes may 
be subtle or only observed under challenged conditions.  
 
The use of knockout animal models have historically provided a huge amount of insight into 
the role of signalling molecules, especially kinases, as the regulatory systems in cells and 
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tissues can compensate and adapt to gene deletion in a more realistic manner. Knockout 
mouse models of AMPK, originally focussed on investigating metabolic processes, have also 
helped reveal its involvement in the control of non-metabolic processes such as cell growth 
and organization of the cytoskeleton (Viollet et al., 2009). Total gene deletion may not 
realistically recapitulate pathological states where signalling cascades are over activated or 
inhibited and therefore phenotypes may be more extreme, however they still provide a useful 
experimental tool to study the in vivo role of signalling cascades. 
 
In this chapter the phenotype of the global NUAK1 knockout mouse is confirmed using a 
different genetic model to the previously published study. Tissue expression data is also 
shown and the rationale for deleting NUAK1 in the liver is explained in the context of the LKB1 
liver-specific knockout mouse. Phenotyping data is presented for the liver-specific NUAK1 
knockout mouse and potential mechanisms are investigated. 
 
4.2 Results 
4.2.1 NUAK1 knockout strategy 
Embryonic stem cells carrying the CSD knockout first, promoter driven construct were 
obtained from the trans-NIH Knock-Out Mouse Project (KOMP). These cells were then used 
to re-derive mice on a C57Bl/6 background which were heterozygous for the construct. The 
construct was designed such that mice that are homozygous for the construct have global 
deletion of NUAK1. 
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Figure 4.1 The generation of NUAK1 global and conditional knockout mice (adapted from 
KOMP website) 
The construct carries recognition sites for FLP recombinase and loxP sites for production of a 
floxed construct which can then be conditionally deleted using the cre-lox recombination 
system. The neomycin insert is available as a selectable marker and is used to culture the 
embryonic stem cells. The LacZ is available as an expression marker and can be used to track 
the activation of the gene promoter in histological sections. The selectable markers in the 
construct prevent NUAK1 expression leading to global deletion of the gene in homozygotes. 
 
Initially mice were bred such that they were heterozygous for the KOMP construct. A 
genotyping strategy was developed to differentiate between wild-type mice, mice that were 
heterozygous for the construct and any potential homozygotes. When breeding two 
heterozygous mice to try and produce homozygotes (global NUAK deletion), in the first few 
litters no homozygous mice were identified despite the Mendelian frequency predicting one 
quarter of the mice should be homozygous. 
 
 
 
 
 
 
 
KOMP construct 
Homozygotes are 
NUAK1 null 
Floxed construct 
(post FLP 
recombinase) 
Deleted 
construct 
(NUAK1-/-) 
Wild-type 
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4.2.2 NUAK1 global knockout mice 
DNA was extracted from ear biopsies of mice at weaning age (3 – 4 weeks) and used in a PCR 
reaction to determine the presence of wild-type or recombined construct alleles. 
 
 
Figure 4.2 NUAK1 construct knockout genotyping 
A typical agarose gel of PCR genotyping of offspring from a heterozygous NUAK1 construct 
cross is shown. Primers were designed against part of exon 2 of NUAK1 and an intronic region, 
such that two different sized bands would be amplified in the wild-type and construct alleles. 
The mice with a single smaller band amplified are wild-type and the mice where two bands 
have been amplified are heterozygous for the KOMP construct.  
 
 
Note that there are no homozygous mice observed – which would be identified by a single 
larger band on the gel (Figure 4.2). This suggests that the embryos that are homozygous for 
the construct are not viable. To confirm if the previously identified embryonic lethality was 
recapitulated in this model, heterozygous mice carrying the NUAK construct were paired and 
pregnant mothers were sacrificed at embryonic day 12.5 and embryonic day 15.5 and the 
embryos harvested. Embryo genotypes were confirmed using the same method as above 
(data not shown). 
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Figure 4.3 NUAK1 global knockouts have an omphalocele phenotype 
Mouse embryos from litters deriving from crosses of parent mice that are heterozygous for 
the knockout construct. (A) Embryos from E12.5. The formation of an omphalocele phenotype 
is just starting to become visible in the NUAK1 knockout. (B) Embryos from E15.5. The 
omphalocele phenotype is very visible in the NUAK1 knockout embryo showing where the 
abdominal wall has failed to close, leaving key organs in a herniated sac outside the body. 
 
 
 
NUAK1 +/+  NUAK1 -/- 
NUAK1 +/+  NUAK1 -/- 
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Figure 4.4 NUAK1 global knockouts have defects in abdominal wall closure 
E15.5 wild-type and NUAK1 null embryos were harvested and fixed in 4% paraformaldehyde. 
Embryos were sectioned and stained with haematoxylin and eosin (H&E). Lateral sections 
from (A) wild-type and (B) NUAK1 null embryos clearly show the presence of the omphalocele 
phenotype with large abdominal deformities. Transverse sections from (C) wild-type and (D) 
NUAK1 null embryos also show the severity of the omphalocele phenotype because of the 
lack of ventral body wall closure. 
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The previous report of NUAK1 knockout used a targeted construct which was inserted into 
the coding region of exon 1 (Hirano et al., 2006). The KOMP method inserts a large selection 
cassette between exons 1 and 2 to prevent transcription. Provided both methods result in 
robust deletion of NUAK1, the resulting phenotype would be expected be the same. By 
studying wild-type and knockout embryos, it is clear that the same omphalocele phenotype 
is observed in the KOMP construct model, verifying the previous finding (Figure 4.3). The 
original global knockout study attributed the phenotype to a defect in the closure of 
abdominal bands in the midline leading to lack of closure of the ventral body wall (Hirano et 
al., 2006). Fixing and staining embryos made using the KOMP construct reveals similar defects 
in ventral body wall closure (Figure 4.4).  
 
4.2.3 Tissue specific NUAK1 knockout mice 
Given that the global NUAK1 knockout is embryonically lethal it is impossible to study the 
effect of NUAK1 deletion in adult tissues without creating a tissue-specific conditional 
knockout. Choosing a tissue in which to create a conditional knockout depends on a several 
factors: 
 Potential role of the protein in that tissue 
 Expression level 
 Availability and specificity of recombinase mouse lines for deletion 
 
Several tissue-specific knockout models have produced unexpected phenotypes or minimal 
phenotypes despite good in vitro evidence that the protein would cause a severe phenotype 
(Viollet et al., 2009). Therefore, there is no guaranteed method for selecting a tissue to target 
and a decision has to be made on the best available evidence.  
 
To assess the tissue distribution of NUAK1 and to assess subsequent generation of tissue-
specific knockouts, a specific antibody is required to recognise the endogenous protein to be 
able to interpret accurate results from any western blotting. Various commercial antibodies 
were tested and the specificity and sensitivity of the best available commercial antibody (Cell 
Signalling) is outlined in Figure 4.5. 
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Figure 4.5 Validation of a NUAK1 specific antibody 
(A) A serial dilution of wild-type recombinant NUAK1 was resolved on a 10% SDS-PAGE Tris-
Glycine gel and transferred to PVDF membrane for immunodetection. The membrane was 
incubated with anti-NUAK1 primary antibody (Cell Signalling) followed by fluorescently 
labelled secondary antibody for detection, as before. (B) Lysate from wild-type and NUAK1 
knockout MEFs was resolved on a 10% SDS-PAGE Tris-Glycine gel, transferred to PVDF 
membrane and incubated with anti-NUAK1 antibody followed by fluorescently labelled 
secondary antibody for detection, as before.  
 
 
The best available antibody clearly recognises recombinant NUAK1 protein and shows almost 
complete deletion of a band of the correct size when comparing a blot of wild-type and 
NUAK1 knockout MEF lysates (Figure 4.5). While the antibody may not be particularly 
sentitive, from these data it can be reasonably assumed that the antibody does specifically 
recognise NUAK1.   
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Figure 4.6 Tissue distribution of NUAK1 in adult mice 
(A) mRNA derived from different mouse tissues was converted to cDNA and used for 
quantitative PCR to determine the relative levels of NUAK1 and NUAK2 transcripts in the 
indicated tissues. (B) Equal amounts of different tissue lysates (20μg total lysate) were 
resolved on a 10% SDS-PAGE Tris-Glycine gel and transferred to PVDF membrane for 
immunodetection with anti-NUAK1 antibody, followed by fluorescently labelled secondary 
antibody for detection, as before.   
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Using the best available antibody there is still some non-specific interaction with other 
proteins on the blot but the most strongly detected band is of the correct size to correspond 
to NUAK1. NUAK1 is clearly most highly expressed in brain as shown by the blot and the qPCR 
data (Figure 4.6). Although no evidence has emerged for a specific neural role for NUAK1, this 
evidence would support making a conditional knockout in the brain. However, the availability 
of neural-specific cre recombinase mouse lines is limited. There are several cell-type specific 
cre lines but none that can delete a gene across a range of neural tissues (Gong et al., 2007). 
Without further data to narrow down the expression of NUAK1, it is difficult to accurately 
predict the phenotype of a conditional knockout based on a sub-set of neuronal cells. Of the 
other tissues analysed, liver was of particular interest because of previous data showing the 
importance of the upstream kinase, LKB1, in the regulation of bile acid transport and 
canalicular membrane integrity (Woods et al., 2011). Although the qPCR data indicates that 
there is very little NUAK1 mRNA in the liver (Figure 4.6A), the blot indicates that there may 
be a small amount of protein (Figure 4.6B), meaning that there may be a functional role for 
NUAK1 in the organ. The liver was chosen primarily because of an interest in LKB1 function 
based on previous data from our laboratory and interest in NUAK1 as a potential mediator of 
the observed phenotype.  
 
In order to produce conditional knockouts the mice that were heterozygous for the construct 
were crossed with mice expressing the FLP recombinase under the control of the human β 
actin promoter (Dymecki, 1996). This cross deletes the LacZ and neomycin cassettes, 
producing a construct with exon 2 of NUAK1 flanked by loxP sites (Figure 4.1), which can then 
be deleted by conditional expression of the cre recombinase. To produce liver-specific 
knockout mice, animals that were homozygous for the loxP flanked exon 2 constructs were 
crossed with mice carrying the cre recombinase under the control of the albumin promoter 
which specifically deletes NUAK1 in hepatocytes (Postic et al., 1999). 
 
Mice that carried the FLP recombinase gene were obtained from the Jackson Laboratory and 
DNA was extracted from mice at weaning age. Genotyping methods were optimised to 
confirm the presence of the FLP and cre recombinases and the homozygosity of the floxed 
NUAK1 construct (Figure 4.7). Regions were identified where a single band could be amplified 
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from both the wild-type allele and the floxed allele but with a size difference such that the 
two genotypes could be differentiated. Details of the oligonucleotide primers used for PCR 
genotyping are given in Appendix 1. 
 
Mice that carried the FLP recombinase gene were crossed with heterozygous mice carrying 
the KOMP NUAK1 construct to obtain mice that were heterozygous for the “floxed” NUAK1 
allele (Figure 4.1 and Figure 4.2). The confirmation of deletion of the selection cassette by the 
FLP recombinase and confirmation of the floxed allele was done by PCR genotyping (Figure 
4.7B). Primers were designed against exon 2 of NUAK1 and an exonic region outside the 5’ 
loxP site. This provided two different sized bands in the wild-type and floxed alleles. 
 
Mice carrying cre recombinase under the control of the albumin promoter (alb cre) were 
obtained from the Jackson Laboratory. Mice carrying the alb cre gene were crossed with 
homozygous floxed NUAK1 mice to obtain mice with NUAK1 specifically deleted in the liver. 
The presence of cre recombinase was confirmed by a PCR reaction across an exonic region of 
the cre which amplified a 100bp band. PCR primers against a ubiquitous housekeeping gene, 
interleukin-2 (IL2) was used as a positive control (Figure 4.7C). 
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Figure 4.7 Genotyping of conditional knockout mice 
(A) The presence of the FLP recombinase gene was confirmed by PCR genotyping. Primers 
were designed across an exonic region of the FLP gene which amplified a 750bp band. A 
typical agarose gel of offspring from a heterozygous FLP mice cross is shown. (B) A typical 
agarose gel of a heterozygous floxed NUAK1 cross is shown. Wild-type mice are characterised 
by a single smaller band (531bp), heterozygous mice are shown by two bands (531bp and 
658bp) and homozygous floxed mice are shown by a single larger band (658bp). (C) A typical 
agarose gel of a heterozygous alb cre crossed with a homozygous alb cre is shown. The 
presence or absence of the cre is shown by the 100bp band. 
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4.2.4 Young liver-specific NUAK1 knockout mice 
Once it had been confirmed by PCR genotyping that the correct transgenic construct was 
present (Figure 4.7), the knockout in the liver was confirmed by western blotting. 
 
 
 
Figure 4.8 Confirmation of liver-specific NUAK1 deletion 
Crude lysate from wild-type and NUAK1 knockout livers was resolved on a 10% SDS-PAGE Tris-
Glycine gel, transferred to PVDF membrane and incubated with anti-NUAK1 antibody (Cell 
Signalling). A small amount of NUAK1 protein is present in the knockout liver lysates, most 
likely because the albumin cre only deletes expression in hepatocytes and the lysates will 
contain protein from other liver tissues. 
 
Deletion of NUAK1 was confirmed in the liver (Figure 4.8) and because the hepatocyte-specific 
expression of the alb cre strain is well characterized (Postic et al., 1999) there is minimal 
chance of any off-target deletion of NUAK1, however no appropriate analyses were carried 
out to confirm this. 
 
Based on the data from the LKB1 liver-specific knockout mice (Woods et al., 2011), the initial 
objective was to establish if there was a metabolic phenotype. Mice were maintained under 
standard conditions and no obvious changes in eating, drinking or breeding behaviour was 
observed initially. To assess any potential gross morphological changes, a small cohort of mice 
were sacrificed and basic organ and body weight measurements were taken.  
 
 
 
 
 
 
 Chapter 4 - Generation and characterisation of global and liver-specific NUAK1 knockout mice 
142 
 
A        B 
 
 
C        D 
 
 
E 
 
Figure 4.9 Young liver-specific NUAK1 knockout mice appear physiologically normal under 
basal conditions 
(A) Body weights (B) Liver weights (normalised to body weight) (C) Spleen weights 
(normalised to body weight) and (D) Kidney weight (normalised to body weight). All 
measurements were taken from 10 – 12 week old liver-specific NUAK1 knockout mice and 
wild-type littermates. No significant difference (p>0.05) was detected for any of these 
parameters between wild-type and knockout animals using a one-way ANOVA and Bonferroni 
correction. (E) Heart weights (normalised to body weight) from 10 – 12 week old liver-specific 
NUAK1 knockout mice and wild-type littermates. A small but significant difference (p<0.05) is 
seen in the male mice but not the female mice. 
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Mice were harvested at a reasonable adult age (10 – 12 weeks) and no significant difference 
was seen in body weight or liver size. A small but significant difference was seen in male 
knockout heart size (Figure 4.9). 
 
The body weights of liver-specific NUAK1 knockout animals was unchanged, but there could 
be a difference in the ratio of fat to lean mass if there were underlying metabolic changes. 
There is a clear epidemiological link between incidence of liver dysfunction and obesity in 
human patients and either pathological state can exacerbate the other (Tolman and Dalpiaz, 
2007). To assess if there were more subtle changes in body morphology, wild-type and liver-
specific NUAK1 mice were analysed using an EchoMRI® machine. This machine uses NMR 
techniques to create contrast between soft tissues by taking advantage of the differences in 
relaxation times of the hydrogen proton spins in different environments. 
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Figure 4.10 Young liver-specific NUAK1 knockout mice have a normal body composition 
The body composition of 8 – 10 week old liver-specific NUAK1 knockout mice and their wild-
type littermates was assessed using an EchoMRI machine. Plots show mean ± S.E.M. of the 
indicated number of animals and statistical significance was analysed using the student’s t-
test to compare the different genotypes within each sex. (A) Whole body fat mass 
measurements. (B) Whole body lean mass. (C) The ratio between fat mass and lean mass. (D) 
Free water content (normalised to body weight). No significant difference (p>0.05) was 
detected for any of these parameters between wild-type and knockout animals. 
  
 
Even after more sensitive analysis, no changes were seen in the body composition of NUAK1 
liver-specific knockout mice, suggesting their overall body morphology is normal (Figure 4.10). 
 
Although no changes were observed in whole body morphology, there is a possibility that 
liver function could be affected in some way that does not manifest itself as a major whole 
body phenotype. To assess any potential changes in liver structure, wild-type and NUAK1 
knockout livers were fixed for histological staining. 
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          WT      KO 
Figure 4.11 Young liver-specific NUAK1 knockout mice have normal liver morphology 
The right lobe of livers from wild-type and liver-specific NUAK1 knockout mice were harvested 
and fixed in 10% formalin. The lobes were sectioned and stained with haematoxylin and eosin 
(H&E). The sections were imaged and any differences in duct structure, hypertrophy and 
hyperplasia were observed. Representative images for each genotype are shown and no 
obvious morphological differences were observed between wild-type and liver-specific 
NUAK1 knockout mice. 
 
 
Livers from at least 5 mice of each genotype were assessed with histological staining and no 
changes in duct structure or cell morphology were observed (Figure 4.11). Compared to LKB1 
liver-specific knockout mice, which have a very severe phenotype and die within 2 – 3 weeks 
of birth (Woods et al., 2011), mice lacking NUAK1 expression in the liver appear structurally 
normal. 
 
To assess if the liver was functioning correctly, various serum metabolites can be measured 
to ensure that metabolic processes in the liver are being performed correctly. In cases of liver 
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damage or dysfunction major changes are seen in some serum metabolites and several of the 
compounds tested are used as clinical diagnostics of liver disease. 
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Figure 4.12 Young liver-specific NUAK1 knockout mice show normal serum metabolite 
levels 
Serum was isolated from 10 – 12 week old male wild-type (n=4) and liver-specific NUAK1 
knockout (n=4) littermates. The serum was analysed for several indicative metabolites (A) 
Triglycerides (B) High density lipoprotein (HDL) (C) Low density lipoprotein (LDL) (D) Free fatty 
acids (E) Albumin (F) Alanine aminotransferase (G) Aspartate aminotransferase (H) Alkaline 
phosphatase (I) Cholesterol. Plots are all mean ± S.E.M. of samples from 4 mice. In almost all 
cases no significant difference (p>0.05) was observed between knockouts and wild-types 
when analysed using the student’s t-test. A modest but significant increase was observed in 
cholesterol levels (p<0.05) when analysed using a student’s t-test.  
 
Across the range of metabolites tested, NUAK1 knockout mice appeared to have normal liver 
function (Figure 4.12). A small but significant increase in cholesterol was detected but this 
could be attributed to variation of the assay or the small number of animals used for the test. 
The slight increase in cholesterol may be indicative of a small degree of liver dysfunction but 
without other indicators it is difficult to conclusively establish that NUAK1 liver-specific 
knockout mice have changes in liver metabolism.  
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In order to study the metabolic profile of these mice further primary hepatocytes were 
derived from 6 – 8 week old wild-type and liver-specific NUAK1 knockout mice. The 
hepatocytes were then analysed on the Seahorse Bioscience XF24 Extracellular Flux Analyzer 
with the assistance of Dr Alicia Garcia (Clinical Sciences Centre). The Seahorse Bioanalyser 
measures oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) and by 
using a series of chemicals can measure different mitochondrial parameters. Firstly the basal 
OCR is measured and by addition of oligomycin, a complex V inhibitor, it is possible to monitor 
the ATP-linked respiration capacity. Subsequently a mitochondrial uncoupler, carbonyl 
cyanide p-trifluoromethoxyphenylhydrazone (FCCP) is injected to measure the theoretical 
maximal OCR. Then antimycin A and rotenone are injected to eliminate all mitochondrial 
electron transfer and measure the non-mitochondrial portion of energy production. It is 
designed to detect metabolic changes in cell cultures in real time. If a gene deletion was to 
cause metabolic changes it would be likely to directly or indirectly affect mitochondrial 
function and this system is a simple way of measuring several fundamental mitochondrial 
parameters simultaneously. By adding these chemicals it can measure basal respiration, ATP 
turnover, proton leak, and spare respiratory capacity. If any of these have changed then it 
gives a clear indication that functional changes have occurred within the mitochondria. 
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Figure 4.13 NUAK1 knockout hepatocytes from young mice have a normal mitochondrial 
profile 
(A) The normalised oxygen consumption rate profile from the XF24 machine. Two biological 
replicates were used for each genotype. The different chemicals are injected at the indicated 
concentrations at the specified points. (B) The 4th point from each data set is taken and the 
normalised means ± S.E.M. of four repeats from two different animals are plotted. (C) The 
oxygen consumption rate from each chemical addition can be converted to calculate the 
percentage of oxygen consumption derived from each source shown. No significant 
difference (p>0.05) was detected between wild-type and NUAK1 knockout hepatocytes when 
the data was analysed using the student’s t-test. 
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Comparing NUAK1 knockout hepatocytes to their wild-type equivalents it is clear that there 
is no change in the four parameters measured by the system, indicating that the mitochondria 
in the liver are functionally normal (Figure 4.13).  
 
Another important metabolic function that is performed in the liver is gluconeogenesis – the 
generation of glucose from non-carbohydrate carbon sources such as pyruvate. As the mice 
are housed in a temperature controlled environment and are fed ad libitum on an ideal diet, 
it is possible that under physiologically healthy conditions, gluconeogenesis rarely occurs. 
Therefore to test if there are changes in the gluconeogenesis pathways, wild-type and NUAK1 
knockout hepatocytes were subjected to a hepatic glucose output assay which detects the 
rate of gluconeogenesis when the cells are only provided with pyruvate as a carbon source. 
This is measured by replacing the culture medium with basal DMEM containing lactate and 
pyruvate and measuring the concentration of glucose in the medium over a time course. The 
glucose concentration is measured using a colorimetric glucose oxidase assay. The protein 
concentration of the cells is used to normalise the values to produce a rate of glucose 
production per mg of protein. 
 
Figure 4.14 NUAK1 knockout hepatocytes from young mice have a normal hepatic glucose 
output 
Hepatic glucose output from wild-type and NUAK1 knockout hepatocytes is shown. 
Measurements were taken in triplicate from two mice of each genotype. No significant 
difference (p>0.05) was observed when the data was analysed using the student’s t-test. 
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The results of the hepatic glucose output assay show that loss of NUAK1 in the hepatocytes 
does not affect gluconeogenesis pathways and should not impair the functional role of the 
liver in maintaining blood glucose levels under conditions of stress (Figure 4.14). 
 
The study that assessed the phenotype of skeletal-muscle specific NUAK1 knockout mice 
identified a phenotype where NUAK1 deletion protected against high-fat diet induced glucose 
intolerance (Inazuka et al., 2012). Glucose intolerance is a phenotype normally associated 
with obesity and early diabetic pathology. The impaired glucose tolerance is caused by insulin 
insensitivity and indications that NUAK1 may phosphorylate and regulate insulin receptor 
substrate 1 (IRS1) may suggest that liver-specific NUAK1 knockout mice may have improved 
glucose tolerance (Inazuka et al., 2012). 
 
Glucose tolerance of liver-specific NUAK1 knockout mice and wild-type littermates was 
measured by administering an intraperitoneal bolus dose of glucose (1g/kg) to mice that had 
been fasted overnight. The blood glucose levels were then measured over a period of two 
hours. 
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Figure 4.15 Young liver-specific NUAK1 knockout mice have a normal glucose tolerance 
Blood glucose levels after intraperitoneal glucose administration is shown in separate plots 
for (A) Males and (B) Females. The plots show the mean ± S.E.M. for the indicated number of 
animals at each time point. The data at each time point were assessed using the student’s t-
test and no significant difference (p>0.05) was observed. 
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No variation in glucose tolerance was observed under basal conditions in the NUAK1 liver-
specific knockout mice (Figure 4.15). To some extent these data support the muscle-specific 
NUAK1 knockout study that only saw the reduced glucose intolerance phenotype under 
stressed conditions (Inazuka et al., 2012).  
 
Given that no major changes were observed in several key metabolic indicators, it was 
thought that there could be a more subtle phenotype in the liver-specific NUAK1 knockout. 
To assess this the mice were housed in a Columbus Instruments Comprehensive Lab Animal 
Monitoring System (CLAMS). This is an automated system that can measure calorimetry, 
activity, feeding, drinking and sleep detection. The variety of data can indicate if there is a 
minor change in the metabolic profile of the mice. The first 16 – 20 hours of data from the 
CLAMS system was disregarded as an acclimatisation period as the animals will often be 
stressed during the initial period in the apparatus. 
 
The respiratory exchange ratio (RER) is an indicator of the energy source being used to 
produce ATP in the cell. This is calculated as a ratio between the VO2 and the VCO2. The 
respiratory exchange ratio values are then plotted over a time course. 
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Figure 4.16 Young liver-specific NUAK1 knockout mice have a normal respiratory exchange 
ratio 
O2, CO2 and RER plots from the CLAMS system. For each of the time courses, the data has been 
analysed for statistical significance by integrating the area under the curve and plotting the 
mean ± S.E.M. of at least of four mice of each genotype. Data is shown for both males (A) 
VO2, (B) VCO2, (C) RER and females (D) VO2, (E) VCO2, (F) RER. All these data have then been 
analysed using the student’s t-test and no significance differences (p>0.05) were observed.  
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The CLAMS system did not detect any change in VO2, VCO2 or RER between wild-type and liver-
specific knockout animals, indicating that their metabolic profile and the energy source they 
are using is normal (Figure 4.16). The CLAMS system is also able to convert the RER 
measurements into heat production by deriving a calorific value (CV) based on the respiratory 
exchange ratio. This calorific value is then combined with the VO2 data to calculate heat 
according to the following equations:  
 
CV = 3.815 +1.232 x RER 
Heat = CV x VO2 
 
The constants for determining the calorific value have been determined from studies 
investigating oxidation of defined ratios of fat and carbohydrate (Columbus Instruments data 
sheet).  
 
Any variation in heat production would indicate that the animals are having to burn more 
calories to maintain homeostatic functions, suggesting possible metabolic dysfunction. 
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Figure 4.17 Young liver-specific NUAK1 knockout mice burn the same amount of calories as 
wild-type mice 
Heat production was calculated from RER and VO2 measurements. The time course data is 
shown alongside integrated area under the curve calculations for statistical comparison. The 
mean ± S.E.M. was plotted for at least four mice of each genotype. (A) Males and (B) Females. 
All these data were analysed using the student’s t-test and no significant differences (p>0.05) 
were observed. 
 
 
These data suggest that there is no variation in the metabolic function in NUAK1 liver-specific 
knockout mice (Figure 4.16 and Figure 4.17), however the systems controlling metabolism are 
diverse and multi-factorial and there could be confounding effects that are masking the 
observation of any phenotype. To ensure that liver-specific NUAK1 knockout mice have the 
same food consumption and behaviour profile as wild-type mice, their activity and food and 
water intake were measured. 
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The CLAMS system is able to monitor total food and water consumption and this has been 
normalised to the animal’s body weight to control for any increase due to greater size. The 
data is plotted as a time course from the start of when the animals enter the CLAMS system, 
hence why there may be some disturbances in the early readings. 
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D 
 
 
 
Figure 4.18 Young liver-specific NUAK1 knockout mice have normal food and water 
consumption 
Food and water intake plots from the CLAMS system. The data has been analysed for 
statistical significance by integrating the area under the curve and plotting the mean ± S.E.M. 
for each of four mice of each genotype. Data is shown for both males (A) Food (B) Water and 
females (C) Food (D) Water. All these data were analysed using the student’s t-test and no 
significant differences (p>0.05) were observed.  
 
 
There was no change in food or water consumption due to deletion of NUAK1 in the liver 
(Figure 4.18), so activity measurements were made to assess any potential behavioural 
differences. The CLAMS system has a mechanism for dual axis detection of animal motion 
using infrared photocells. These detect counts for each movement that the animal makes so 
it is possible to track their cumulative movement over the course of the time in the monitoring 
cages. 
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A 
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Figure 4.19 Young liver-specific NUAK1 knockout mice have unchanged activity and 
movement levels 
Movement plots from the CLAMS system. The cumulative movement in the x-axis and the z-
axis were counted for at least four animals of each sex and genotype. The mean ± S.E.M. was 
plotted for (A) Males and (B) Females. All these data were analysed using the student’s t-test 
and no significant differences (p>0.05) were observed. 
 
 
All these data suggest that there is no variation in food and water intake or activity levels that 
might affect the metabolic measurements of the animals (Figure 4.19). This would also 
suggest that there are no other feedback mechanisms that are affecting behaviour or eating 
patterns. 
 
 
 
 
NUAK1 
+/+
NUAK1 
-/-
0
50000
100000
150000
200000
T
o
ta
l 
a
c
ti
v
it
y
 c
o
u
n
ts
 (
x
-a
x
is
)
NUAK1 
+/+
NUAK1 
-/-
0
5000
10000
15000
20000
T
o
ta
l 
a
c
ti
v
it
y
 c
o
u
n
ts
 (
z
-a
x
is
)
NUAK1 
+/+
NUAK1 
-/-
0
50000
100000
150000
200000
250000
T
o
ta
l 
a
c
ti
v
it
y
 c
o
u
n
ts
 (
x
-a
x
is
)
NUAK1 
+/+
NUAK1 
-/-
0
10000
20000
30000
ns
T
o
ta
l 
a
c
ti
v
it
y
 c
o
u
n
ts
 (
z
-a
x
is
)
 Chapter 4 - Generation and characterisation of global and liver-specific NUAK1 knockout mice 
161 
 
4.2.5 CDE diet treated liver-specific NUAK1 knockout mice 
After extensive efforts to discover a phenotype in the liver-specific NUAK1 knockout mice 
under basal conditions it seemed that they were functionally normal. Following on from 
reports in the literature that NUAK1 is involved in mediating cell adhesion (Zagorska et al., 
2010) and evidence from culturing NUAK1 null MEFs, other studies have also suggested 
NUAK1 is involved in cell survival during deregulated MYC expression (Liu et al., 2012). Based 
on these data a decision was made to induce an artificial stress on the livers to observe any 
potential changes in cell proliferation in response to liver damage. After discussions with 
collaborators (Stuart Forbes et al., Edinburgh University) the best available diet was a choline-
deficient, ethionine supplemented (CDE) diet. Wild-type and liver-specific NUAK1 knockout 
mice were placed on this diet for a maximum of three weeks with food and water intake and 
changes in body weight monitored over this time to ensure there was no unnecessary pain, 
suffering or harm done to the animals. 
 
Although a large degree of liver damage was expected after treatment with the diet, serum 
metabolites were measured, as before, to assess if there were any variations in response to 
the diet between wild-type and liver-specific NUAK1 knockout animals. 
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Figure 4.20 Liver-specific NUAK1 knockout mice fed a CDE diet show no difference in serum 
metabolites 
Serum was isolated from 12 – 16 week old male wild-type (n=8) and liver-specific NUAK1 
knockout (n=9) littermates that had been fed the same CDE diet for 3 weeks. The serum was 
analysed for several indicative metabolites (A) Triglycerides (B) High density lipoprotein (HDL) 
(C) Low density lipoprotein (LDL) (D) Free fatty acids (E) Albumin (F) Alanine aminotransferase 
(G) Aspartate aminotransferase (H) Alkaline phosphatase (I) Cholesterol. Plots are all mean ± 
S.E.M. of samples from at least 8 mice. In almost all cases no significant differences (p>0.05) 
were observed between knockouts and wild-types when analysed using the student’s t-test. 
A modest but significant reduction was observed in triglyceride levels and a significant 
increase was observed in alanine aminotransferase (ALT) (p<0.05). 
 
Generally the response to the damage induced by the diet was the same between wild-type 
and liver-specific knockout animals (Figure 4.20). Clearly the livers have been damaged 
significantly, indicated by a substantial increase in various metabolites compared to 
untreated animals (Figure 4.12). After feeding on the CDE diet a significant increase in alanine 
aminotransferase (ALT) levels was observed in liver-specific NUAK1 knockout animals. 
However, this could be partly due to diurnal variation as small but not clinically significant 
diurnal variations in ALT levels have been observed in humans (Ruhl and Everhart, 2013). 
Blood samples were taken at the same time of day so this may not be the cause of the 
variation, but the levels of rest may vary as some mice become more inactive than others in 
response to the CDE diet (data not shown). 
 
The main reason for feeding with the CDE diet was to induce cell proliferation in liver stem 
cells to see if there is a difference in the response to liver damage. To assess this livers from 
treated animals were fixed and then processed by collaborators at Edinburgh University 
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(Stuart Forbes et al.). Liver sections were stained with pan-cytokeratin antibodies, a marker 
of liver progenitor cells (Boulter et al., 2012). 
A 
     
             WT      KO 
 
B 
 
Figure 4.21 Liver-specific NUAK1 knockout mice fed a CDE diet produce more cytokeratin 
positive liver progenitor cells 
The right lobe of livers from wild-type (n=4) and liver-specific NUAK1 knockout mice (n=5) 
were harvested and fixed in 10% (v/v) formalin. The lobes were sectioned and stained using 
a pan-cytokeratin (panCK) antibody. (A) The sections were imaged and the number of panCK 
positive cells were counted in each field of view. (B) At least 20 fields of view were counted 
for each of four different mice and the total average for each genotype was determined. A 
significant difference (p<0.001) was observed between the wild-type and NUAK1 liver-specific 
knockout mice when analysed using a student’s t-test. 
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A significant difference was observed in the ability of the liver-specific NUAK1 mice to respond 
to acute injury, suggesting that NUAK1 may play a role in the adaptation and response to 
damage in pathological conditions (Figure 4.21). This could help explain why muscle-specific 
NUAK1 knockout mice required a stress stimulus to produce a phenotype (Inazuka et al., 
2012).  However, although the NUAK1 null livers showed a greater proliferation of progenitor 
cells, there was no improvement in liver function compared to wild-type mice, indicated by 
serum metabolite measurements (Figure 4.20). This suggests that the damage to the livers is 
equivalent, however there may be a better response to the insult over a longer time period. 
 
 
4.2.6 Aged liver-specific NUAK1 knockout mice 
To assess if this variation in response to damage was only seen in acute injury or whether 
variation could be observed over a longer time period, a decision was made to age a cohort 
of mice to see if any morphological or functional changes were observed as a result of natural 
damage caused by ageing. Wild-type and liver-specific NUAK1 knockout mice were kept under 
identical conditions and fed the same chow diet. 
 
Similar metabolic phenotyping analyses were applied to the aged mice to assess if the 
deletion of NUAK1 in the liver had adversely affected or changed the gradual adaptation to 
the ageing process in the liver. 
 
The body composition of 50 – 52 week old liver-specific NUAK1 knockout mice and their wild-
type littermates was assessed using an EchoMRI instrument and livers were harvested to 
assess if there was a longer term variation in organ mass due to NUAK1 deletion.  
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Figure 4.22 Aged liver-specific NUAK1 knockout mice have slightly lower body weight and 
body fat percentage 
(A) Body weight of 50 – 52 week old liver-specific NUAK1 knockout males and females was 
slightly lower than their wild-type littermates, although not statistically significant. (B) Whole 
body fat mass measurements showed a modest but not significant reduction in both male 
and female knockout mice. (C) Whole body lean mass measurements showed no difference  
between liver-specific NUAK1 knockouts and wild-type littermates (D) The ratio between fat 
and lean mass showed a substantial but not significant (p>0.05) reduction in both males and 
females. (E) 30 -38 week old male liver-specific NUAK1 knockout mice have no change in liver 
weight (normalised to body weight) compared to their wild-type littermates. Plots show mean 
± S.E.M. of the indicated number of animals and statistical significance was analysed using the 
student’s t-test to compare the different genotypes within each sex. 
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Figure 4.23 Aged liver-specific NUAK1 knockout mice have slightly smaller epididymal fat 
pads 
The epididymal fat pads of 30 – 38 week old male liver-specific NUAK1 knockout mice and 
their wild-type littermates were harvested. (A) Epididymal fat pads of liver-specific NUAK1 
knockout males had slightly lower weights compared to their wild-type littermates, although 
not statistically significant (p>0.05). (B) Epididymal fat pad sized normalised to body weight 
still show a small but not significant reduction in size. Plots show mean ± S.E.M. of the 
indicated number of animals. 
 
When assessing the overall body morphology of the aged mice it was clear that there was a 
slight, but not significant reduction in body weight and fat mass in the liver-specific NUAK1 
knockout mice (Figure 4.22). Also, when the size of a specific fat pad was measured, a slight 
reduction was also observed in liver-specific NUAK1 knockout mice (Figure 4.23). Although 
the number of animals was small, there was a clear change in the fat mass to lean mass ratio 
(Figure 4.22). The mechanism for this was unclear but it suggested that there are phenotypic 
differences in response to ageing that were caused by NUAK1 deletion in the liver.  
 
To see if there was any indication that a specific pathway was being affected by loss of NUAK1, 
serum metabolites were measured as before. 
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I 
  
J 
    
Figure 4.24 Aged liver-specific NUAK1 knockout mice show unchanged serum metabolite 
levels 
Serum was isolated from 50 - 52 week old male wild-type (n=6) and liver-specific NUAK1 
knockout (n=5) littermates. The serum was analysed for several indicative metabolites (A) 
Triglycerides (B) High density lipoprotein (HDL) (C) Low density lipoprotein (LDL) (D) Free fatty 
acids (E) Albumin (F) Alanine aminotransferase (G) Aspartate aminotransferase (H) Alkaline 
phosphatase (I) Cholesterol and (J) Glucose. Plots are all mean ± S.E.M. of samples from at 
least 5 mice of each genotype. In all cases no significant differences (p>0.05) were observed 
between knockouts and wild-types when analysed using the student’s t-test. 
 
 
No differences were seen in the serum metabolite profile of aged wild-type mice compared 
to liver-specific NUAK1 knockout mice (Figure 4.24), providing no evidence to suggest why 
there is a slight reduction in body weight and fat mass as a result of NUAK1 deletion. Some 
metabolites showed clear differences across both genotypes compared to the younger mice, 
for example alanine aminotransferase (see Figure 4.12F and Figure 4.24F). This suggests that 
the absence of NUAK1 has not affected the adaptation to ageing in these pathways. 
 
Given that there was a modest decrease in body weight and slightly lower body fat percentage 
in the liver-specific NUAK1 knockouts yet the liver function appeared to be unchanged, it is 
possible that there was a significant whole body metabolic phenotype that was linked to age-
related differences in liver regeneration. To assess any whole body changes in metabolism 
the CLAMS system was used to measure a variety of important data that can indicate if there 
is a minor change in the metabolic profile of the mice.  
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Figure 4.25 Aged liver-specific NUAK1 knockout mice have an increased respiratory 
exchange ratio 
O2, CO2 and RER plots from the CLAMS system monitoring 50 - 52 week old mice. For each of 
the time courses, the data has been analysed for statistical significance by integrating the area 
under the curve and plotting the mean ± S.E.M. for each of at least five mice of each genotype. 
Data has been shown for both males (A) VO2, (B) VCO2, (C) RER and females (D) VO2, (E) VCO2, 
(F) RER. All these data have then been analysed using the student’s t-test and all showed a 
significant increase (p<0.05). 
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The RER and VO2 values were used to calculate heat production as an overall readout of the 
liver-specific NUAK1 knockout animals burning more calories.  
 
A 
 
B  
 
 
Figure 4.26 Aged liver-specific NUAK1 knockout mice burn more calories than wild-type 
mice 
Heat production was calculated from RER and VO2 measurements from 50 – 52 week old mice. 
The time course data is shown alongside integrated area under the curve calculations for 
statistical comparison. Readings are shown for (A) Males and (B) Females. The data has been 
analysed for statistical significance by integrating the area under the curve and plotting the 
mean ± S.E.M. for each of at least five mice of each genotype. A significant increase (p<0.01) 
was observed for the males and a small but insignificant increase was observed for the 
females. 
 
 
A significant increase was seen in respiratory exchange ratio in both male and female liver-
specific NUAK1 knockout mice (Figure 4.25), suggesting a change in their energy source that 
they are burning more carbohydrate and less fat. Whether this is due to changes in the 
availability of fat because deposition in fat stores is reduced is unclear. The increase in heat 
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production also suggests that the liver-specific NUAK1 knockout mice are burning more 
calories overall, irrespective of the food source (Figure 4.26). 
 
Food and water intake measurements were taken to establish if the knockout mice were 
eating more to provide the increase in carbohydrates being used for energy. The CLAMS 
system is able to monitor total food and water consumption and this has been normalised to 
the animal’s body weight to control for any increase due to greater size. The data is plotted 
as a time course from the start of when the animals enter the CLAMS system, hence why 
there may be some disturbances in the early readings. 
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Figure 4.27 Aged liver-specific NUAK1 knockout mice have moderately increased food and 
water consumption 
Food and water consumption plots from the CLAMS system monitoring 50 - 52 week old mice. 
Data has been shown for both aged males (A) Food (B) Water and aged females (C) Food (D) 
Water. The data has been analysed for statistical significance by integrating the area under 
the curve and plotting the mean ± S.E.M. for each of at least five mice of each genotype. A 
modest but not significant increase was observed in water consumption in the male mice. A 
significant increase (p<0.05) was observed in both food and water intake in the female mice.  
 
These data show that the aged liver-specific NUAK1 mice appear to eat and drink slightly more 
than their wild-type littermates (Figure 4.27), which could account for the increased 
utilisation of carbohydrates as an energy source but does not entirely fit with the reduced 
body weight and fat mass measurements (Figure 4.22 and Figure 4.23). The mice appear to 
be eating more but not gaining weight, so therefore they must somehow be expending the 
extra energy accounted for in the heat calculations, such that it cannot be laid down in fat 
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deposits. The activity levels of aged mice were measured to see if the knockout mice were 
being more active, which would help explain their reduced body weight and body fat 
percentage.  
 
 
A 
 
B 
 
 
Figure 4.28 Aged liver-specific NUAK1 knockout mice have unchanged activity and 
movement levels 
Movement measurements from the CLAMS system monitoring 50 - 52 week old mice. The 
cumulative movement in the x-axis and the z-axis were counted for at least five animals of 
each sex and genotype. The mean ± S.E.M. was plotted for (A) Males and (B) Females. All 
these data were analysed using the student’s t-test and no significant differences (p>0.05) 
were observed. 
 
 
 
 
Activity levels are unchanged in aged liver-specific NUAK1 knockout mice so burning the extra 
energy through movement cannot be the reason for their reduced body weight and fat 
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percentage (Figure 4.28). It is unclear if the reduced body weight and fat percentage confer 
any health advantage on the liver-specific NUAK1 knockout mice, as survival studies have not 
been conducted, but in human clinical studies of liver disease, increased body fat is an 
indicator of increased morbidity and mortality (Tolman and Dalpiaz, 2007). This may indicate 
that liver-specific NUAK1 knockout mice would be healthier in old age. 
 
Collectively these data show that there is a definite variation in the adaptation of mice to age 
related changes in liver function depending on the expression of NUAK1. The biochemical 
basis for this change is unclear but the increase in proliferation of liver stem cells in response 
to damage may be the underlying reason. It may be that NUAK1 deletion does not directly 
change liver function but, through a mechanism regulating proliferation, the absence of 
NUAK1 enhances the ability of the liver to regenerate and maintain healthy bodily function. 
 
 
 
 
 
 
 
 
 
 
 
 
4.3 Discussion 
To date observations from only one tissue-specific NUAK1 knockout mouse model have been 
published (Inazuka et al., 2012). Given that the general aim of the field of AMPK and related-
kinases is to understand the physiological function of these proteins in vivo and establish 
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potential mechanisms to activate or inhibit these pathways, it is important to understand the 
role of NUAK1 in different tissues of interest. The data gathered from different tissue-specific 
knockouts may indicate downstream targets that can be investigated in other experiments 
and can also provide evidence of physiological functions that may be of clinical interest. 
 
Initial results confirmed the omphalocele phenotype previously reported in NUAK1 global 
deletion (Figure 4.3) (Hirano et al., 2006). Although no new information was gathered from 
the knockout embryos, the same lack of closure of the ventral body wall was observed. Lack 
of closure of the ventral body wall is possibly due to lack of cell outgrowths during 
development and this observation would fit with previous data suggesting NUAK1 knockout 
MEFs have fewer outgrowths and are more adherent (Zagorska et al., 2010). One interesting 
observation is that the ROCKI and ROCKII double knockout mice show the same omphalocele 
phenotype (Thumkeo et al., 2005). Given that ROCK is known to be an important regulator of 
MLC phosphorylation (Figure 1.12) (Matsumura, 2005), this provides an interesting link that 
NUAK1 and ROCK pathways may converge on the same downstream activator that causes the 
closure of the ventral body wall and potentially other MLC linked functions. It would be 
interesting to assess if NUAK1 deletion has an impact on the expression or phosphorylation 
of known members of the ROCK pathway.  
 
Data of tissue distribution of NUAK1 shown in this thesis (Figure 4.6) partially agrees with a 
previous report that found NUAK1 expressed in heart, kidney, brain, liver, and skeletal muscle 
(Fisher et al., 2005). This indicates that the antibody used in my experiments is comparable 
to reagents used in previous studies. From previous reports, changes in NUAK1 expression 
were primarily involved in mediating cell proliferation phenotypes in cancer (Chang et al., 
2012; Chen et al., 2013a; Kusakai et al., 2004a; Lu et al., 2013). The only other indication of a 
potential phenotype from deleting NUAK1 was the liver-specific knockout of the upstream 
kinase LKB1, which causes serious metabolic defects (Shaw et al., 2005; Woods et al., 2011).  
 
Initial investigation of a phenotype in the liver-specific NUAK1 knockout mice found there was 
no obvious whole-body phenotype (Figure 4.9). The slight increase in male knockout mice 
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heart weight could be the consequence of the small number of animals used for the study or 
it could be representative of a secondary phenotype as a result of NUAK1 deletion in the liver. 
There are various examples of liver pathology that can have a secondary effect in the heart 
and several whole-body changes that can affect both tissues (Naschitz et al., 2000). However, 
without a further indication of a potential mechanism for this increase in heart size it is 
difficult to speculate how NUAK1 deletion would cause this. Also, in light of the subsequent 
observations of a minimal phenotype in young, healthy liver-specific NUAK1 knockout mice it 
is unlikely that there would be a significant secondary phenotype in the heart. Previous 
reports have shown in mouse models that inhibition of the Hippo pathway can produce 
grossly oversized organs (Dong et al., 2007). Evidence shown here would suggest that deletion 
of NUAK1 does not activate LATS1 or inhibit YAP/TAZ (Figure 1.10) sufficiently to produce a 
reduction in organ size by modulating the Hippo pathway (Figure 4.10). This is consistent with 
other indications that the Hippo pathway can define an upper limit for organ size but 
upregulation of the pathway to inhibit YAP/TAZ would not produce smaller organs (Pan, 
2010). 
 
Body composition analysis indicated there were no variations in fat mass or lean mass, 
indicating that there was unlikely to be a basal metabolic phenotype (Figure 4.10). This may 
suggest that NUAK1 has no relevant function in mature, differentiated tissues. However, as 
in vitro data and published reports link NUAK1 to regulation of myosin phosphorylation 
(Zagorska et al., 2010) or senescence regulation (Humbert et al., 2010), these effects may not 
produce a major phenotype in a young, healthy liver.  
 
The LKB1 liver-specific knockout phenotype is caused by changes in hepatocyte polarity and 
it was thought that there may be a partial recapitulation of this in NUAK1 deleted livers (Fu 
et al., 2011; Woods et al., 2011). It is possible that a partial phenotype could be compensated 
for by other mechanisms in the liver and this would mask any obvious whole-body 
phenotypes. However, after histological analysis of NUAK1 deleted livers, there were no 
detectable structural changes compared to wild-type mice (Figure 4.11). No differences were 
observed in hypertrophy or hyperplasia, indicating that NUAK1 deletion in hepatocytes does 
not have the same effect of increasing proliferation that was seen in NUAK1 deleted MEFs 
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(Figure 3.15). This could be due to a number of factors, including possible activation of the 
Hippo pathway by other mechanisms, which would limit organ size. 
 
After several attempts to establish the presence of a phenotype in the NUAK1 null livers, 
serum metabolites were analysed for any changes in indicators of liver function. By measuring 
these metabolites it is possible to get a more sensitive readout of liver function that may not 
be manifested as a whole-body phenotype. After analysis of several clinically indicative serum 
metabolites it is clear that NUAK1 liver-specific knockout mice are functionally normal and 
healthy (Figure 4.12). 
 
All these data indicate that normal liver function was maintained after the deletion of NUAK1, 
however these observations could mask an underlying change in liver metabolism that is only 
manifested under conditions of stress. The mice are maintained in tightly controlled 
environmental conditions and fed on a nutrient rich diet, meaning that they are unlikely to 
undergo any major metabolic stress during their development. Also, minor metabolic insults 
may be resolved by redundant pathways such that differences would be masked. By isolating 
hepatocytes from NUAK1 null livers it is possible to manipulate their metabolic function and 
determine if there are underlying changes. However, even when the hepatocytes are 
subjected to a series of mitochondrial stresses, the NUAK1 null cells show no difference in 
comparison to wild-type cells (Figure 4.13 and Figure 4.14). Hepatic glucose output was 
significantly increased in LKB1 knockout hepatocytes (Woods et al., 2011), but this was not 
observed in NUAK deleted livers, suggesting NUAK1 is not an essential downstream target 
regulating this mechanism. 
 
Although liver function appeared to be maintained in young liver-specific NUAK1 knockout 
mice, there was potential for a peripheral metabolic phenotype if processes such as insulin 
signalling were affected. However, no difference was seen in glucose tolerance tests 
comparing wild-type and liver-specific NUAK1 knockout mice (Figure 4.15). By all overt 
phenotyping parameters, there appeared to be no functional difference as a result of deleting 
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NUAK1 in the liver, but to confirm this the CLAMS system was used to measure various 
metabolic and behavioural parameters to ensure no subtle phenotype was overlooked. 
 
After extensive attempts to phenotype a large number of animals of both sexes, none of the 
data showed any significant difference across any of the parameters (Figure 4.16 - Figure 
4.19). Collectively the CLAMS data shows that deletion of NUAK1 in the liver does not affect 
the animal’s metabolism, eating behaviour or activity levels. Although this is frustrating that 
there was no manifest phenotype in the young mice, it highlights some of the difficulties of 
phenotyping animal models with targeted gene deletions. From these data it is highly unlikely 
that NUAK1 is involved in mediating any of the effects of LKB1 deletion in the liver, adding 
further credence to the hypothesis that NUAK1 may not be entirely dependent on LKB1 
phosphorylation to be active. It also demonstrates how genes that may have a highly 
significant developmental function, in this case aiding closure of the ventral body wall and 
maintaining embryo viability, may only have mild or subtle effects in adult tissues. 
 
These data are also comparable to the previous study reporting the effects of NUAK1 deletion 
in muscle where no basal phenotype was observed (Inazuka et al., 2012). This study did see a 
significant phenotype when placing the animals on a high fat diet, indicating that the deletion 
of NUAK1 in adult tissues may only have an effect under stressed conditions. The muscle-
specific NUAK1 phenotype in that report was attributed to reduced phosphorylation of IRS1, 
potentially by NUAK1. However, current data in the literature and in vitro findings in my study 
(Figure 3.18) do not suggest that NUAK1 has any involvement with phosphorylating 
components of the insulin signalling pathway. Data from this study and others, including the 
muscle-specific NUAK1 deletion, suggest that NUAK1 primarily targets cytoskeletal 
components. The current model for how changes in the phosphorylation of cytoskeletal 
proteins may affect disparate mechanisms such as glucose metabolism is poorly understood. 
However, it is highly possible that NUAK1 elicits its effects by modulation of cytoskeletal 
components which then cause secondary phenotypes in other pathways. This may also 
explain why minimal phenotypes are seen under basal conditions, as cytoskeletal 
organisation has many redundant mechanisms and minor changes in one component may be 
compensated for, which may not be possible in pathways such as insulin signalling. 
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Based on the need for a stress treatment to elicit a phenotype in NUAK1 muscle-specific 
knockout mice, a similar experiment was conducted in liver knockout mice. The CDE diet was 
used to induce liver damage. Ethionine addition to rodent diets has been used for decades as 
a way to induce wide spread damage in many digestive and metabolic tissues (Koch Weser 
and Popper, 1952). Ethionine acts as a methionine antagonist so interferes with protein 
transcription and recent studies have modified a choline deficient diet to produce more 
targeted liver damage, without such severe fat accumulation or necrosis (Akhurst et al., 2001). 
During the course of the CDE diet feeding, body weights were monitored and showed that 
the pathology was no more severe in liver-specific NUAK1 mice than wild-type mice (data not 
shown). Given that there may have been a difference in the NUAK1 null livers ability to 
respond to the induced damage, metabolite measurements were made as before and no 
difference was seen, suggesting the change in liver function caused by the diet is similar 
(Figure 4.20). On harvesting tissues, the apparent level of fat accumulation and weight of the 
livers were also equivalent across both groups (data not shown). 
 
After CDE diet feeding data suggested there was no significant difference in the change in 
liver function, but as several studies have previously shown, liver damage diets can be used 
to induce proliferation of hepatic progenitor cells (oval cells in mice). These cells have been 
shown to be important in liver regeneration and possibly in the early progression of 
hepatocellular carcinoma (Boulter et al., 2012; Lee et al., 2006). After analysis of treated livers 
it was clear that NUAK1 null livers had a much greater proliferation of oval cells (Figure 4.21). 
The exact mechanisms involved in producing a proliferation response in oval cells is unclear 
but some research suggests there are cell-cell interactions and cell-matrix interactions within 
stereotypical niches that produce extra cellular signals, prompting an increase in proliferation 
(Lorenzini et al., 2010). Whether NUAK1 is part of a network involved in receiving these signals 
or if it influences the proliferation through a different intrinsic network is unclear. It is possible 
that NUAK1 exerts this effect through the Hippo pathway as the progenitor cells are more 
similar to cells during development than senescent adult cells. 
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Interestingly, this increased proliferation may have two effects. Firstly, if controlled by normal 
mechanisms it could improve the repair of normal tissues, however there are some 
indications that increased progenitor cell proliferation can lead to uncontrolled growth and 
cancer (Lee et al., 2006). If this greater proliferation does contribute to an increased risk of 
cancer in a NUAK1 deleted model, this also contradicts previous reports of higher NUAK1 
expression being associated with cancer progression (Bell et al., 2013; Chen et al., 2013a; Cui 
et al., 2013; Kusakai et al., 2004a). 
 
After observing a different response in NUAK1 null livers to an acute damage insult, there was 
potential for a differential response to chronic damage as part of the normal ageing process. 
Although the aged mice only became available for analysis towards the end of this project, 
various phenotype measurements indicate that the deletion of NUAK1 does affect the 
response to ageing.  
 
Firstly, body composition showed that aged NUAK1 null mice were slightly leaner and had a 
lower overall body fat percentage (Figure 4.22). Although this analysis was not significant, it 
showed a clear trend and with greater numbers would be likely to show significance. 
Interestingly, the overall body fat percentage was lower and also the size of an individual fat 
pad was lower (Figure 4.23), suggesting that the effect may be systemic rather than targeted 
to an individual tissue or organ. Importantly, liver function was maintained in aged mice after 
NUAK1 deletion (Figure 4.24), suggesting that the changes in body morphology are not due 
to dysfunction of the liver. 
 
On assessing the indirect calorimetry measurements from the CLAMS system, the most 
striking difference was an increase in the respiratory exchange ratio, consistent across both 
male and female mice (Figure 4.25). The respiratory exchange ratio is a measure of the energy 
source, with a lower value indicating a higher fat diet and a higher value indicating more 
carbohydrates are being burned. As all the mice were being fed on identical chow diets, 
changes in the RER must be due to metabolic differences. Interestingly, a similar study of a 
transgenic rat model, using identical indirect calorimetry measurements saw an increase in 
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respiratory exchange ratio (Harasym et al., 2013). This transgenic model was the BHE/cdb rat 
which has a global loss-of-function mutation in the ATP synthase α-subunit. This study 
appears to have many other parallels with the observations in aged NUAK1 liver-specific 
knockout mice. Firstly the rats are leaner and lighter, showing a similar body morphology to 
the NUAK1 liver knockout mice (Figure 4.22). Crucially there is also no change in circulating 
lipid levels, suggesting lipid metabolism is unchanged (Figure 4.24) (Harasym et al., 2013). 
Lastly, both my study and the BHE/cdb rat study observed an increase in food consumption 
during the CLAMS analysis (Figure 4.27).  
 
Initially, the hypothesis for the phenotype observed in the BHE/cdb rat was that decreased 
ATP levels would raise the AMP:ATP and ADP:ATP ratios and activate AMPK. Increased AMPK 
activity would then activate catabolic pathways such as glucose uptake, through GLUT4 
signalling, and lipid oxidation, while inhibiting gluconeogenesis (Harasym et al., 2013). 
However, no increase in AMPK phosphorylation or activation of downstream targets was 
observed. One explanation that was proposed by Harasym and colleagues was that due to the 
lack of function of ATP synthase, the cell fails to produce sufficient ATP and to compensate 
for this the animal increases metabolic flux of carbohydrates, which would account for the 
increased RER and heat production. Presumably the increased water consumption observed 
in my study (Figure 4.27) parallels the increase in food consumption to ensure the mice 
receive adequate hydration. 
 
Several other interesting facets of the biochemical analysis from the BHE/cdb rat study also 
parallel some findings in relation to NUAK1. Firstly, they observed an increase in expression 
of mitochondrial proteins such as Cox4, similar to the observed increase in my study of Cox6b 
expression in NUAK1 null MEFs (Figure 3.16). Also, they saw a downregulation of Akt signalling 
in liver and soleus muscle, which would be consistent with Akt acting as an upstream kinase 
of NUAK1 (Suzuki et al., 2004b). However, some in vitro data from my study questions this 
finding (Figure 3.7), so this would require more work to establish if this is a real interaction. 
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Another encouraging finding that may provide a functional link between the phenotype seen 
in the BHE/cdb rat and the liver-specific NUAK1 knockout mouse is the fact that several ATP 
synthase subunits were seen to be differentially phosphorylated in the MEF SILAC experiment 
(Appendix 2.1). It is possible that NUAK1 could influence the activity of the ATP synthase 
complex, either directly or indirectly to produce a similar phenotype to the loss-of-function 
mutation seen in the BHE/cdb rats. A marginal reduction in ATP synthesis would then produce 
longer term functional changes which could influence whole-body morphology, as seen in the 
rat model. More work is required to establish if this interaction is real and if NUAK1 can 
regulate ATP synthase in this way. Also, de-convoluting the primary and secondary 
phenotypes of this effect would be challenging and require much more in vitro confirmation 
of potential interactions.  
 
Interestingly in the BHE/cdb rat study they also saw improved glucose tolerance so it would 
be useful to perform glucose tolerance tests in the aged NUAK1 liver-specific knockout mice 
to test if this improved in line with the other phenotypic similarities seen between the two 
models. Similarly, the BHE/cdb rat study also saw an upregulation of pyruvate 
dehydrogenase, so conducting a pyruvate tolerance test would be interesting to establish if 
this phenotype was similar after NUAK1 deletion. Encouragingly, the ATP-synthase mutated 
rat study found relatively small changes in muscle insulin signalling, suggesting that the liver 
is a more important organ than skeletal muscle in modulating the changes in glucose 
homeostasis (Harasym et al., 2013). 
 
In conclusion, the exact mechanisms regulating the embryonic omphalocele phenotype are 
unclear but as discussed in section 3.3  there are potentially two divergent mechanisms that 
NUAK1 could be regulating. Firstly, NUAK1 could be pro-proliferative under developmental 
conditions by downregulating LATS1 and activating YAP/TAZ as part of the Hippo pathway 
(Figure 1.10), causing an increase in cell growth and closure of the ventral body wall, 
potentially explaining the omphalocele phenotype in NUAK1 deleted embryos. However, in 
differentiated mature tissues, it could be anti-proliferative by downregulating LATS1 and 
maintaining senescence, thereby reducing the turnover and replacement of cells such as 
hepatocytes (Humbert et al., 2010). This anti-proliferative effect may also contribute to the 
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phenotypes observed in liver-specific NUAK1 knockout mice during the normal ageing 
process, such as reduced fat accumulation. Similarly, during injury or damage, when the stem 
cells are already up regulated and the organ partially returns to a “developmental” state, the 
pro-proliferative mechanism could influence an increased response, leading to better repair 
of damaged tissue but also more possible risk of cancer. 
 
The results from this liver-specific knockout model show that proteins can still have an 
important physiological function despite there being only a very low level of expression in the 
tissue of interest (Figure 4.6). This highlights the difficulty of choosing tissues for targeted 
gene deletion studies and indicates that crucial steps of signalling pathways may be regulated 
by relatively lowly expressed proteins. Overall the data presented in this chapter provide 
some interesting insights into the in vivo role of NUAK1 and to date represents only the 
second study of NUAK1 in a tissue-specific knockout model. Although the mice appeared not 
to have a basal phenotype, there was a significant difference in the response of NUAK1 null 
livers to damage and ageing. These results may provide useful indications of the processes 
which NUAK1 is involved in and similarities to other transgenic animal models may provide 
new avenues for research. 
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5  Generation and characterisation of heart-specific 
NUAK1 knockout mice 
5.1 Introduction 
During the course of this project data was published showing the first reported effect of a 
NUAK1 tissue-specific knockout (Inazuka et al., 2012). On a high fat diet, skeletal muscle-
specific NUAK1 knockout mice had a lower fasting blood glucose level, improved glucose 
tolerance, higher insulin sensitivity and a higher concentration of muscle glycogen than wild-
type mice. This publication and preliminary data from the liver-specific knockout model led 
to an interest in the possible effect of deleting NUAK1 in cardiac muscle. Given the absence 
of a significant phenotype in young liver-specific NUAK1 knockout mice a decision was made 
midway through my project to create another tissue-specific knockout which may produce a 
significant phenotype. Western blot and quantitative PCR data previously shown confirms 
that there is significant expression of NUAK1 in heart tissue (Figure 4.6).  
 
To produce heart-specific NUAK1 knockout mice, animals carrying the “floxed” NUAK1 
construct (Figure 4.1) were crossed with mice carrying cre recombinase under the control of 
the α-myosin heavy chain (αMHC) (a gift of Prof. Michael Schneider, National Heart and Lung 
Institute).  
 
There were communications from the Schneider group and published data to suggest that 
some αMHC cre mouse lines develop a mild cardiac hypertrophy phenotype in mice that are 
homozygous for the cre alone after 8 – 10 weeks of age (Buerger et al., 2006). This report 
indicates that the phenotype was not observed in transgenic lines with lower expression of 
cre recombinase, suggesting a dose-dependent or threshold of cre expression necessary for 
the phenotype. For this reason I decided to use mice younger than 10 weeks and both cre-
positive and cre-negative controls were used to eliminate any possible effects of the cre-
expression alone. 
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In this chapter the phenotyping data is presented for the heart-specific NUAK1 knockout 
mouse and a stress treatment is used to assess the effect of the absence of NUAK1 on damage 
response in a different tissue than the liver. 
 
5.2 Results 
5.2.1 Heart-specific NUAK1 knockout mice 
DNA was extracted from an ear biopsy taken from mice at weaning age. To establish the 
homozygosity of the NUAK1 floxed construct, primers were designed against exon 2 of NUAK1 
and an exonic region outside the 5’ loxP site. Mice carrying cre recombinase under the control 
of the α-myosin heavy chain promoter (αMHC) were crossed with homozygous floxed NUAK1 
mice to obtain mice with NUAK1 specifically deleted in the heart. 
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Figure 5.1 Breeding and genotyping of heart-specific NUAK1 knockout 
(A) Mice that were homozygous for the floxed NUAK1 construct (Figure 4.1) were confirmed 
by PCR genotyping. Wild-type mice are characterised by a single smaller band (531bp), 
heterozygous mice are shown by two bands (531bp and 658bp) and homozygous floxed mice 
are shown by a single larger band (658bp). (B) The presence of αMHC cre recombinase was 
confirmed by a PCR reaction across an exonic region of the cre which amplified a 300bp band. 
 
The αMHC cre genotyping method amplifies a band from an exonic region of the recombinase 
gene meaning there is no amplification in wild-type animals and no way to distinguish mice 
that are heterozygous or homozygous for the cre. As the level of cre expression may affect 
the phenotype, efforts were made to ensure only heterozygous cre mice were used for 
breeding, however it was impossible to confirm this by PCR genotyping. 
 
Once the recombination event had been confirmed by PCR genotyping (Figure 5.1), the 
deletion of the gene was confirmed by western blotting and quantitative PCR.  
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Figure 5.2 Confirmation of NUAK1 deletion in heart tissue by western blot and quantitative 
PCR analyses 
(A) Total tissue lysate from heart-specific NUAK1 knockout and wild-type mice was resolved 
on a 10% SDS-PAGE Tris-Glycine gel and transferred to PVDF membrane for 
immunodetection. The membrane was incubated with anti-NUAK1 and anti-AMPK phospho 
T172 antibodies. (B) mRNA purified from whole hearts from wild-type and heart-specific 
NUAK1 knockout mice was converted to cDNA and used to determine the expression of 
NUAK1. The values are shown as a fold change against the wild-type value. qPCR values are 
normalised to GAPDH. 
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Deletion of the gene was confirmed by western blot and qPCR (Figure 5.2). A small amount of 
residual protein can be observed in the knockout animals as the αMHC-cre only deletes the 
specified gene in the cardiac myocytes but the total lysate will contain protein from 
endothelial tissue, cardiac fibroblasts and other cells still expressing NUAK1. The lack of 
phospho-T172 staining on the band corresponding to NUAK1 may indicate that there is little 
activity or is more likely to be a sensitivity issue when being compared alongside AMPK. The 
phospho-T172 staining of pAMPKα1 in Figure 5.2A acts as a positive control for the antibody 
and indicates that the activity of AMPK is unchanged in the NUAK1 knockout hearts. Also, the 
cardiac myocyte-specific expression of the αMHC cre strain is well characterized (Gulick and 
Robbins, 2009) so there is minimal chance of any off-target deletion of NUAK1, however no 
appropriate analyses were carried out to confirm this.  
 
Given that the correct recombination events had been confirmed by PCR genotyping, it was 
possible to start assessing if there was a basal phenotype as a result of the loss of NUAK1. 
Initially basic body and organ weight measurements were taken to assess any potential gross 
morphological changes. 
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A           B 
 
C          D 
 
 
Figure 5.3 Heart-specific NUAK1 knockout mice have no gross morphological changes under 
basal conditions 
Body measurements and organ weights were taken from 7 – 8 week old heart-specific NUAK1 
knockout mice, αMHC cre positive and negative control animals. Data is shown for (A) Body 
weight, (B) Heart weight normalised to body weight, (C) Heart weight normalised to tibia 
length and (D) Lung weight normalised to body weight. In all measurements no significant 
difference (p>0.05) was observed between cre negative controls, cre positive controls and 
knockouts when analysed using a one-way ANOVA and Bonferroni correction. Plots are all 
mean ± S.E.M. of measurements from at least 6 mice of each genotype. 
 
Clearly there is no change in body weight or heart size under basal conditions as a result of 
NUAK1 deletion (Figure 5.3). Studies have also shown there can be an increase in lung weight 
in models of chronic heart failure (Kingsbury et al., 2003) so lung weight was measured (and 
normalised to body weight) to ensure there were no secondary morphological changes as a 
result of the NUAK1 knockout. No change in lung weight was observed in heart-specific 
NUAK1 knockout animals. 
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5.2.2 Echocardiography of heart-specific NUAK1 knockout mice 
Many parameters can be measured to assess heart function but factors such as blood 
pressure and heart rate are difficult to measure over a time course without use of telemetry 
equipment which requires challenging and risky surgery to implant into the mice. Individual 
time points can be taken without the need for telemetry but the measurements are generally 
taken under anaesthetic which affects the heart rate and blood pressure substantially. Also it 
is more likely that deletion of NUAK1 would affect the structure and morphology of the heart 
rather than the heart rate because data from my study and previous reports suggest that 
NUAK1 may elicit its effect by regulating pathways involved in cell proliferation.  
 
In order to further investigate any possible phenotype resulting from the knockout of NUAK1 
in cardiac muscle, echocardiography was conducted by a trained, genotype-blinded operator. 
Echocardiography is a useful tool for measuring various parameters of heart size, muscle 
thickness and cardiac output. The parameters measured provide the most efficient way of 
detecting any changes in heart structure. It is possible to detect subtle changes in heart 
function and, where possible, link these changes to morphological variations.  
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A         B 
 
C         D 
 
E         F 
 
Figure 5.4 Heart-specific NUAK1 knockout mice have no change in left ventricle size, 
posterior wall thickness and volume 
Echocardiography data from 10 – 12 week old heart-specific NUAK1 knockout mice and wild-
type littermates. Plots are shown of left ventricle diameter during (A) systole and (B) diastole. 
Left ventricular posterior wall thickness during (C) systole and (D) diastole. Left ventricular 
volume during (E) systole and (F) diastole. The significance indicated on the charts represents 
(* = p<0.05) when analysed using a one-way ANOVA and Bonferroni correction. Plots are all 
mean ± S.E.M. of repeat measurements from at least 6 mice of each genotype. 
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Initial measurements of left ventricle wall thickness and volume showed no difference 
between wild-type and heart-specific NUAK1 knockout mice. The only parameter that showed 
any difference was left ventricle posterior wall thickness (Figure 5.4). Heart specific NUAK1 
knockout mice have slightly thicker left ventricle posterior wall compared to cre negative 
controls. However there is no difference between cre positive and knockout animals, 
suggesting this variation is largely an effect of the cre expression. 
 
A         B 
  
Figure 5.5 Heart-specific NUAK1 knockout mice have increased left ventricular anterior wall 
thickness during diastole 
Echocardiography data from 10 – 12 week old heart-specific NUAK1 knockout mice and wild-
type littermates. Plots are shown of left ventricular anterior wall thickness during (A) systole 
and (B) diastole. The significance indicated on the charts represents (* = p<0.05, ** = p<0.01) 
when analysed using a one-way ANOVA and Bonferroni correction. Plots are all mean ± S.E.M. 
of repeat measurements from at least 6 mice of each genotype. 
 
 
Other measurements also show parameters where a difference is seen between knockout 
animals and cre negative or cre positive mice, suggesting the variation is due to deletion of 
NUAK1 (Figure 5.5). A significant increase in thickness of the left ventricular anterior wall was 
measured in knockout animals but only during diastole. Changes in diastolic function may not 
manifest any phenotype under basal conditions provided the systolic function is maintained. 
It is likely that systolic function is maintained as the mice appear to have no adverse global 
phenotype. However, more severe differences in cardiac function may be observed with the 
influence of an insult aimed at stressing the heart. 
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Figure 5.6 αMHC cre mice have a cardiac phenotype independent of NUAK1 knockout 
Echocardiography data from 10 – 12 week old heart-specific NUAK1 knockout mice and wild-
type littermates. Plots are shown of (A) ejection fraction and (B) fractional shortening.  The 
significance indicated on the charts represents (** = p<0.01, *** = p<0.001) when analysed 
using a one-way ANOVA and Bonferroni correction. Plots are all mean ± S.E.M. of repeat 
measurements from at least 6 mice of each genotype. 
 
 
Reports of cardiac dysfunction from the group that provided the αMHC cre mice were 
confirmed when it was discovered that there were some parameters that varied in cre 
positive mice, irrespective of whether NUAK1 was deleted. The ejection fraction, which 
represents the fraction of blood pumped out of the left ventricle during each cardiac cycle, 
was reduced, indicating that the expression of the cre reduces cardiac function. Fractional 
shortening, which is a measure of the proportion of the diastolic dimensions that are lost 
during systole, was also reduced in heart-specific NUAK1 knockout mice. A more significant 
difference (p<0.001 rather than p<0.01) was observed between the cre negative controls and 
the knockouts compared to the cre-positive controls however no significant difference 
(p>0.05) was observed between the cre positive controls, and the heart-specific NUAK1 
knockouts, suggesting the phenotype was due to the presence of the αMHC cre (Figure 5.6). 
Although all these parameters indicate how the structure of the heart is affected, one of the 
best overall readouts of cardiac function is the total cardiac output, which takes into account 
left ventricle size and ejection fraction. 
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Figure 5.7 Heart-specific NUAK1 knockout mice have decreased cardiac output under basal 
conditions 
Cardiac output data from 10 – 12 week old heart-specific NUAK1 knockout mice and wild-type 
littermates. A significant difference (p<0.001) was observed in cardiac output in heart-specific 
NUAK1 knockouts when compared to both cre-positive and cre-negative controls. The plot is 
mean ± S.E.M. of repeat measurements from at least 6 mice of each genotype and analysed 
using a one-way ANOVA and Bonferroni correction. 
 
A small but significant difference (p<0.05) was also observed in comparing the cardiac output 
between cre-positive and cre-negative controls suggesting that the reduction in cardiac 
output may not be entirely due to the loss of NUAK1 and that the αMHC cre may have a partial 
phenotype (Figure 5.7). 
 
Collectively, these data suggest that a certain degree of systolic cardiac function is being lost 
as a result of cre expression and this is exacerbated by the additional deletion of NUAK1. The 
mechanism behind this may be difficult to establish as the phenotype of the cre positive mice 
may confound any mechanism observed in the NUAK1 deleted hearts.  
 
Cre - Cre + NUAK1
-/-
0
5
10
15
20
*
***
***
C
a
rd
ia
c
 o
u
tp
u
t 
(m
l/
h
r)
WT WT
Chapter 5 - Generation and characterisation of heart-specific NUAK1 knockout mice 
197 
 
5.2.3 Angiotensin II treatment of heart-specific NUAK1 knockout mice 
The phenotype of heart-specific NUAK1 knockout under basal conditions is very mild and the 
mice seem otherwise phenotypically normal. Many other global and conditional mouse 
knockout models do not show significant phenotypes without the influence of a stressor 
(Ayadi et al., 2012). Using a treatment to promote a stress response also creates a more 
physiologically relevant result as it simulates chronic or acute stresses present in 
cardiovascular pathologies. Also, given the previous data from the liver-specific NUAK1 
knockout model where a difference was only seen in response to damage or aging (Figure 
4.21 and Figure 4.26), it is possible that the same will be true in the heart-specific knockout 
model. A common compound used to promote a stress response in cardiac models is 
angiotensin II. This is a peptide which causes hypertension via a mechanism of 
vasoconstriction and sympathetic nervous system stimulation (see section 1.7 ). Mice were 
dosed with angiotensin II at a rate of 1.2mg/kg/day using a subcutaneous mini pump.  Mice 
were dosed for a maximum of two weeks whilst food and water intake and changes in body 
weight were monitored over this time to ensure there was no unnecessary pain, suffering or 
harm done to the animals. Following this treatment, body and organ weight measurements 
were taken to assess any potential gross morphological changes. 
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Figure 5.8 Heart-specific NUAK1 knockout does not affect body weight or lung weight after 
treatment with angiotensin II 
8 - 10 week old heart-specific NUAK1 knockout male mice, αMHC cre positive and negative 
control animals were dosed with 1.2mg/kg/day angiotensin II for 14 days and measurements 
were taken. Data is shown for (A) Body weight and (B) Lung weight normalised to body 
weight. In all measurements no significant difference (p>0.05) was observed between cre 
negative controls, cre positive controls and knockouts when analysed using a one-way ANOVA 
and Bonferroni correction. Plots are all mean ± S.E.M. of measurements from at least 5 mice 
of each genotype. 
 
Clearly there is no change in body weight or lung weight after treatment with angiotensin II 
when comparing wild-type and heart-specific NUAK1 knockout mice (Figure 5.8). Treatment 
with angiotensin II raises systemic blood pressure, causing pulmonary hypertension and the 
lack of change in lung weight suggests there is no genotype dependent variation in the effects 
of pulmonary hypertension on the lungs of the treated mice. The signalling effects of 
angiotensin II are wide-ranging and effect a number of different pathways (Nguyen Dinh Cat 
and Touyz, 2011). The most significant effect is raising blood pressure, which causes a range 
of adaptations in an attempt to maintain normal blood flow.  
 
The AT1R receptor is a G protein-coupled receptor that acts as the main signal transducer for 
angiotensin II. Acute increases in angiotensin II levels leads to positive feedback and increased 
AT1R expression, but chronic increases in angiotensin II create a negative feedback loop which 
downregulates its own receptor (Lassegue et al., 1995). Crucially, many other molecules such 
as LDL, insulin and nitric oxide can also affect angiotensin II signalling either directly by 
modulating AT1R receptor expression or indirectly by regulating vascular tone in the case of 
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nitric oxide (Mehta and Griendling, 2007). This makes the interpretation of any variation in 
the effects of angiotensin II difficult to understand. 
 
Hearts were harvested from angiotensin II treated mice to analyse how they adapted to the 
increased blood pressure and to see if the absence of NUAK1 changes the ability of the heart 
to adjust to the stress. 
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Figure 5.9 Heart-specific NUAK1 knockout mice have a greater increase in heart size and 
weight after treatment with angiotensin II 
8 - 10 week old heart-specific NUAK1 knockout male mice, αMHC cre positive and negative 
control animals were dosed with 1.2mg/kg/day angiotensin II for 14 days and measurements 
were taken. (A) NUAK1 null hearts shown alongside wild-type cre negative hearts after 
angiotensin II treatment. (B) Heart weight normalised to body weight. (C) Heart weight 
normalised to tibia length. Separate plots also show the heart weight normalised to (D) body 
weight and (E) tibia length against the untreated measurements to highlight the proportional 
size change after treatment with angiotensin II. The significance indicated on the charts 
represents (* = p<0.05) when analysed using a one-way ANOVA and Bonferroni correction. 
Plots are all mean ± S.E.M. of repeat measurements from at least 5 mice of each genotype. 
 
The data shows that heart-specific NUAK1 mice show a greater increase in heart size after 
treatment with angiotensin II compared to both other groups (Figure 5.9). Although the 
increase in weight between hearts from NUAK1 deleted mice versus control cre positive mice 
is not statistically significant, there is clearly a trend and it is likely that with greater numbers 
the results would become statistically significant. These data also support the previous 
indication that there can be a partial phenotype as a result of the αMHC cre expression 
(Buerger et al., 2006). The lack of NUAK1 expression appears to exacerbate the effect of 
angiotensin II treatment, leading to a stronger response against the increased blood pressure 
resulting in a greater increase in heart mass. 
 
To assess if the increase in heart mass was due to hypertrophy or hyperplasia, hearts from 
angiotensin II treated mice were harvested and fixed for histological staining. 
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WT         KO 
Figure 5.10 Heart-specific NUAK1 knockout mice show no structural differences to wild-type 
mice after treatment with angiotensin II 
Hearts from 8 - 10 week old heart-specific NUAK1 knockout and wild-type mice that have 
been dosed with 1.2mg/kg/day angiotensin II for 14 days were harvested and fixed in 10% 
(v/v) formalin. Hearts were sectioned and stained with haematoxylin and eosin (H&E). 
Representative images are shown for both genotypes. General morphology, cell size and 
muscle banding were assessed and no change was seen between wild-type and NUAK1 
knockout hearts.  
 
The H&E stained hearts showed no obvious difference in cell size or cell number, suggesting 
that other adaptations in the muscle tissue must have produced the overall change in heart 
mass. Striated gaps appear in the heart muscle in both wild-type cre negative and heart-
specific NUAK1 knockout mice as an indication of where the muscle has stretched to 
accommodate the higher blood pressure (Figure 5.10). While it is hard to quantify, there 
appear to be larger striations in wild-type cre negative hearts compared to NUAK1 null hearts.  
The greater increase in heart mass in NUAK1 deleted hearts may be due to effects on the 
remodelling process, changing the degree of fibrosis and collagen accumulation in response 
to stretching and damaging the muscle fibres. To analyse if there is a difference in the degree 
of fibrosis or glycogen accumulation in the heart muscle after angiotensin II treatment, 
sections of fixed hearts were stained with Sirius red stain and periodic acid schiff stain. 
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Figure 5.11 Heart-specific NUAK1 knockout mice show no difference in glycogen 
accumulation or fibrosis after treatment with angiotensin II 
Hearts from 8 - 10 week old heart-specific NUAK1 knockout and wild-type mice that have 
been dosed with 1.2mg/kg/day angiotensin II for 14 days were harvested and fixed in 10% 
(v/v) formalin. Hearts were and sectioned and stained with the indicated stain. Periodic acid 
staining (PAS) was used to highlight glycogen accumulation in (A) wild-type and (B) knockout 
hearts. Sirius red staining was used to assess collagen fibrosis in (C) wild-type and (D) 
knockout hearts. Representative images are shown for both genotypes and no obvious was 
difference was noted for either stain. 
PAS 
staining 
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5.2.4 Echocardiography of angiotensin II treated heart-specific NUAK1 
knockout mice 
The degree of glycogen accumulation and quantity of collagen fibres appears to be similar for 
both wild-type cre negative and heart-specific NUAK1 knockout mice (Figure 5.11), indicating 
that the difference in the change in mass is not caused by variations in fibrosis or significant 
changes in cardiac metabolism. Glycogen was not measured biochemically and this would 
provide a better indication of overall accumulation within the tissue but histological analysis 
indicates very little change.  
 
In previous studies using angiotensin II treatment to induce cardiac hypertrophy, various 
changes in cardiac structure were observed but in some transgenic models and C57Bl/6 
controls, these had little effect on cardiac function, suggesting there was compensatory 
hypertrophy (Harding et al., 2011). Other studies have shown angiotensin II treatment causes 
no change or marginally decreased left ventricular systolic function with no signs of heart 
failure (Haudek et al., 2010; Xu et al., 2008; Zhang et al., 2010).  
 
To establish if the greater increase in heart mass has an effect on cardiac function, 
echocardiography was performed, as before. The echocardiography also measures various 
parameters of heart structure to try and establish how the loss of NUAK1 leads to a greater 
increase in heart size. 
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Figure 5.12 Heart-specific NUAK1 knockout mice have more dilated left ventricles and 
increased left ventricular volume after treatment with angiotensin II 
Echocardiography data from 8 - 10 week old heart-specific NUAK1 knockout mice, cre positive 
and cre negative controls that have been dosed with 1.2mg/kg/day angiotensin II for 14 days. 
Data is shown for left ventricle diameter during (A) systole and (B) diastole. Plots are also 
shown for left ventricle volume during (C) systole and (D) diastole. The significance indicated 
on the charts represents (** = p<0.01, *** = p<0.001) when analysed using a one-way ANOVA 
and Bonferroni correction. Plots are all mean ± S.E.M. of measurements from at least 5 mice 
of each genotype. 
 
Crucially an effect was seen in both left ventricle diameter and volume during both systole 
and diastole, indicating a consistent phenotype in the NUAK1 null hearts (Figure 5.12). In all 
cases the difference is slightly smaller between the cre positive controls and the knockouts 
compared to the cre negative mice suggesting there is a partial effect of the cre, but a more 
significant effect of the NUAK1 deletion.  
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A           B 
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Figure 5.13 Heart-specific NUAK1 knockout mice have narrower posterior walls after 
treatment with angiotensin II 
Echocardiography data from 8 - 10 week old heart-specific NUAK1 knockout mice, cre positive 
and cre negative controls that have been dosed with 1.2mg/kg/day angiotensin II for 14 days. 
Data is shown for left ventricle anterior wall thickness during (A) systole and (B) diastole. Plots 
are also shown for left ventricle posterior wall thickness during (C) systole and (D) diastole. 
The significance indicated on the charts represents (** = p<0.01, *** = p<0.001) when 
analysed using a one-way ANOVA and Bonferroni correction. Plots are all mean ± S.E.M. of 
measurements from at least 5 mice of each genotype. 
 
Although a change was seen in left ventricle diameter and volume, only a small change was 
seen in one of the wall thickness measurements (Figure 5.13). This indicates that the muscle 
walls have stretched but have maintained their thickness. Similarly the ventricle walls have 
not increased in thickness so the left ventricle therefore has a larger volume but no thicker 
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muscle to contract and pump blood, suggesting there would be a loss of systolic cardiac 
function. 
 
A           B 
 
C           D 
 
Figure 5.14 Heart-specific NUAK1 knockout mice have lower ejection fraction and fractional 
shortening after treatment with angiotensin II 
Echocardiography data from 8 - 10 week old heart-specific NUAK1 knockout mice, cre positive 
and cre negative controls that have been dosed with 1.2mg/kg/day angiotensin II for 14 days. 
Data is shown for (A) ejection fraction and (B) fractional shortening. Data is shown compared 
to untreated mice for contrast. This is shown for (C) ejection fraction (D) fractional shortening 
The significance indicated on the charts represents (** = p<0.01, *** = p<0.001) when 
analysed using a one-way ANOVA and Bonferroni correction. Plots are all mean ± S.E.M. of 
measurements from at least 5 mice of each genotype. 
 
The ejection fraction and fractional shortening measurements, which are both strong 
indicators of systolic function, show that only the heart-specific NUAK1 knockout mice 
showed a significant decrease after angiotensin II treatment (Figure 5.14). Cre positive control 
mice also showed a decrease in both measurements compared to cre negative controls after 
angiotensin II treatment but this difference exists in basal conditions (Figure 5.6). This shows 
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that in wild-type mice, irrespective of cre expression, there is no change in ejection fraction 
or fractional shortening in response to angiotensin II treatment. Therefore the extra reduction 
seen in the knockout hearts would suggest this phenotype is due to NUAK1 deletion. 
A           B 
 
Figure 5.15 Cardiac output in NUAK1 knockout hearts is unchanged compared to wild-types 
after angiotensin II treatment 
Cardiac output data from 8 - 10 week old heart-specific NUAK1 knockout mice, cre positive 
and cre negative controls that have been dosed with 1.2mg/kg/day angiotensin II for 14 days. 
(A) Data only from angiotensin II treated mice. (B) Data from treated mice compared to 
untreated mice of each genotype. The significance indicated on the charts represents (** = 
p<0.01, *** = p<0.001) when analysed using a one-way ANOVA and Bonferroni correction. 
Plot is mean ± S.E.M. of measurements from at least 5 mice of each genotype. 
 
The cardiac output of NUAK1 mice shows no significant difference to either group of control 
mice after angiotensin II treatment, eliminating the difference seen under basal conditions 
(Figure 5.7). Both sets of control mice show significant reductions in cardiac output after 
angiotensin II treatment, possibly contradicting earlier reports that systolic function is 
maintained in control mice after treatment (Harding et al., 2011; Haudek et al., 2010). 
Collectively these data suggest that although heart-specific NUAK1 knockout mice have a 
basal cardiac phenotype, they are able to maintain cardiac output better than wild-type 
animals after angiotensin II treatment. However, the reduction in ejection fraction and 
fractional shortening (Figure 5.14) suggest that there may still be a loss of systolic function 
after cardiac insult. 
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5.3 Discussion 
In light of the published study into the role of NUAK1 in skeletal muscle (Inazuka et al., 2012) 
and other data indicating that NUAK1 is highly expressed in heart (Figure 4.6) (Fisher et al., 
2005), heart-specific NUAK1 knockout mice were created and characterised. 
 
When confirming the deletion of NUAK1 had taken place correctly, there was a surprising 
finding that the AMPK phospho-T172 antibody which is known to cross-react with T211 on 
NUAK1 (Figure 3.5) did not detect any phosphorylation of NUAK1 in the heart (Figure 5.2). 
This could be due to the kinase not being phosphorylated but is more likely to be a sensitivity 
issue of the antibody as it is being compared on the same blot to its correct antigen, 
phosphorylated AMPKα. Despite this lack of cross-reaction with the pT172 antibody, the 
quantitative PCR data and NUAK1 blot showed a robust reduction in expression, confirming 
that NUAK1 had been deleted correctly. 
 
Initial phenotyping of the mice showed no difference in heart size and no secondary 
pathologies affecting the cardiovascular system (Figure 5.3). Consistent with this, there were 
no observed behavioural or activity changes with the mice. Initial echocardiography results 
showed no significant difference across most of the parameters measured, however a small 
difference was seen in left ventricle posterior wall thickness during diastole (Figure 5.4). This 
difference was very small and only seen when compared to cre negative wild-type, suggesting 
it may be an effect of the αMHC cre expression. A small difference was also noticed in left 
ventricle anterior wall thickness during diastole (Figure 5.5), indicating the variation in 
thickness of the posterior wall may be a real change. However, this could also be partly due 
to normal variation within the small sample size. Increasing the number of animals tested 
would be likely to reduce the variation and decrease the significance of these results. 
 
The measurement of systolic function highlighted the previous issues that had been noted 
about the αMHC cre mice having a cardiac hypertrophy phenotype. Changes were seen in 
systolic function (ejection fraction and fractional shortening) irrespective of NUAK1 deletion 
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(Figure 5.6). Although this issue potentially masked the discovery of a phenotype as a result 
of NUAK1 deletion, it also showed that NUAK1 had no additional effect on reducing systolic 
function relative to the cre positive mice.  
 
This discovery would suggest that NUAK1 null heart tissue can maintain systolic function to a 
comparable level as cre positive mice, meaning that any changes in diastolic function may not 
be detected as healthy circulation should be maintained. Again, in a similar manner to the 
muscle-specific NUAK1 knockout mice a stress treatment was chosen to test the response of 
the heart tissue to damage.  
 
After an acute systemic increase in blood pressure caused by angiotensin II treatment, the 
heart responds by pumping harder to maintain circulation (Tsukamoto et al., 2013). Any 
variation in heart size or structure in response to this increase, corresponding to genotype, 
would indicate a difference in the ability of the cardiac myocytes to respond to damage, 
potentially meaning they would respond differently to pathological stresses.  
 
Initial measurement of body weight and lung weight after angiotensin II treatment detected 
no change between NUAK1 null hearts and wild-type equivalents (Figure 5.8). This suggested 
that there was no difference in secondary cardiovascular effects and that there was no change 
in systemic effects of eating and activity behaviour that might influence body weight. 
However, significant changes were noted in heart size when normalised to either body weight 
or tibia length (Figure 5.9). This suggests that the cardiac muscle has responded differently 
either by increasing cell size, proliferation or by stretching and increasing fibrosis. Again, 
NUAK1 could be influencing cell proliferation by mechanisms discussed previously, such as 
the hippo pathway, however no evidence was detected for hyperplasia in H&E stained 
sections of treated hearts (Figure 5.10). In addition to this, no significant structural changes 
were noticed in the histological analysis, providing few clues as to the mechanism for the 
increased heart mass. It is possible that the striations seen in histological analysis, caused by 
stretching of the heart muscle, are slightly wider in wild-type hearts compared to NUAK1 null 
hearts (Figure 5.10). This may be mediated by a cell adhesion phenotype, correlating with 
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other anecdotal data from my studies and a previous report that suggests deletion of NUAK1 
causes an increase in cell adhesion (Zagorska et al., 2010). 
 
Echocardiography of the angiotensin II treated mice showed a dilated left ventricular 
cardiomyopathy phenotype in both wild-type and NUAK1 deleted hearts, but with a larger 
dilation in the absence of NUAK1 (Figure 5.12). Alongside this, very little change was detected 
in left ventricular wall thickness, suggesting that the absence of NUAK1 does not increase and 
may protect against the thinning of the muscle wall as the ventricle dilates (Figure 5.13).  
 
In relation to the resulting cardiac function from these changes in left ventricle size, 
echocardiography showed that there was a significant decrease in ejection fraction and 
fractional shortening in NUAK1 null hearts, compared to either cre negative or cre positive 
wild-types. Interestingly, the knockout mice were the only animals that showed a significant 
decrease in both these parameters after angiotensin II treatment compared to untreated 
animals of the same genotype (Figure 5.14C and D). This suggests that the proportion of blood 
in the left ventricle that is pumped during each heart cycle decreases as a result of NUAK1 
loss, indicating a partial loss of systolic function and contractility. However, the cardiac output 
of NUAK1 knockout mice does not decrease relative to the untreated animals whereas both 
cre positive and cre negative controls show marked decrease to levels similar to NUAK1 null 
mice (Figure 5.15). This raises the interesting prospect that the loss of NUAK1 causes a basal 
reduction in cardiac output, possibly as a result of developmental differences, but then 
protects against any further reduction as a result of stress treatment or pathology. 
 
Some indications in the literature suggest there may be a possible mechanism for this 
phenotype. An unbiased human genome wide study to establish gene loci involved in 
determining muscle strength identified NUAK1 as a potential mediator of this phenotype 
(Windelinckx et al., 2011). This study identified polymorphisms in the gene but did not 
indicate if the mutations would cause gain or loss-of-function. It is possible that the identified 
mutations cause a reduction in NUAK1 activity, leading to a loss of muscle strength. This may 
explain the basal reduction in cardiac output as the left ventricle walls would be less able to 
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contract. Interestingly, the muscle strength study also identified PPP1CC (the γ isoform of 
protein phosphatase 1 catalytic subunit) as another candidate gene, suggesting that there 
may be links to the previously discussed involvement of NUAK1 in protein phosphatase 
targeting and organisation of the cytoskeleton through MLC phosphorylation. 
The lack of change in cardiac output of heart-specific NUAK1 knockout mice after angiotensin 
II treatment suggests that their hearts may be capable of contracting better under stress, 
which would contradict the initial loss of function under basal conditions. However, one very 
interesting feature that is seen in all of the NUAK1 tissue-specific knockout data presented 
here and in a previous study (Inazuka et al., 2012), is that they all require a stress treatment 
to elicit a phenotype. This could indicate an interesting facet of NUAK1 function in that it may 
have a developmental role, which can be compensated for in deleted tissues, especially when 
animals are maintained in highly controlled environments, but a separate role in response to 
ageing or damage. It would be interesting to age a cohort of heart-specific NUAK1 knockout 
mice and assess if there is a comparable phenotype to the liver-specific knockout mice. 
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6  Summary and Future Work 
This thesis has provided various data that contribute to the study of NUAK1 and the field of 
AMPK-related kinases. There is a variety of evidence for possible in vivo roles and indications 
of mechanisms from in vitro studies that may provide a mechanistic basis for the observed 
changes. Some of the data shown here supports and strengthens the existing evidence in the 
literature of a role for NUAK1 in myosin phosphorylation and cell proliferation, however some 
conflicting evidence still exists which will require more work to resolve.  
 
6.1 In vitro observations 
Data presented in my thesis shows that NUAK1 has a basal level of activity, both in vitro in a 
bacterial expression system and in cells. This contradicts previous reports but various issues 
and possible reasons for these differences have been highlighted. The role of 14-3-3s in 
regulating NUAK1 activity was further explored and data linking it to possible control of 
phosphorylation by LKB1 was presented. The evidence that NUAK1 has a basal level of 
activity, without the need for activation by LKB1, is compelling, but has not been replicated 
by other investigators. However there is a range of evidence in the literature to suggest that 
there could be basal activity and other regulatory mechanisms in the AMPK-related kinase 
family. The differences in these observations may be due to regulatory mechanisms that are 
not yet understood, which confound the activity measurements under different experimental 
conditions. The subcellular localisation of NUAK1 was investigated but no significant evidence 
to determine a specific role for the kinase was found. Various data exploring previous reports 
into the activation of NUAK1 and its similarities to the other related kinases were presented 
and indications towards novel pathways were provided by mass spectrometry screens.  
 
The data presented here partly supports the previous mechanism which linked NUAK1 to 
controlling MLC phosphorylation (Zagorska et al., 2010). However certain differences were 
observed, specifically that 14-3-3 bound directly to NUAK1, an interaction which may affect 
its activity or localisation, thereby having a different effect on MLC phosphorylation. The 
observed phenotype of increased cell adhesion fits with this previous model, suggesting that 
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any differences in the mechanism are likely to be due to differences in experimental 
techniques or conditions but these may yet be key to understanding the overall physiological 
role of NUAK1. 
 
Further in vitro work will be required to establish the role of binding partners, such as 14-3-3 
and the function of the C-terminal part of the protein where autophosphorylation is likely to 
play a role in regulating NUAK1. Analysis of some of the potential pathways highlighted here 
such as the regulation of ATP synthase and myosin phosphorylation require further work in 
vitro and in cell based systems to validate. Further mutation and truncation of the protein 
could reveal insights into the regions important for regulation. As a further project it would 
be very useful to crystallise and establish the structure of NUAK1 and of the kinase bound to 
14-3-3ε. This would provide insight into the activation and regulation of the protein and this 
understanding could be applied to other AMPK-related kinases to determine if there are any 
similarities. Little evidence was provided in my study for the role of the ubiquitination in 
NUAK1 regulation and aspects of this mechanism are still uncertain. Further understanding 
of the function of NUAK1 binding USP9X and validation of where and how ubiquitin marks are 
attached to NUAK1 could add another dimension to the localisation and control of the kinase.  
 
The increased growth rate observed in MEFs derived from the NUAK1 global knockout 
embryos agrees with previous work from our laboratory (Humbert et al., 2010) but conflicts 
with various reports of NUAK1 overexpression being associated with increased cell growth 
(Chen et al., 2013a; Cui et al., 2013). The experimental approach of these studies differs 
significantly from this thesis as they are based on retrospectively screening for changes in 
cancer models. This approach may lead to different results as several pathways could be 
affected and the observed phenotype may not solely be due to changes in NUAK1 activity. 
Also, it is not clear that the increased growth rate observed in NUAK1 null MEFs in this report 
would correlate with increased growth rate in every in vivo environment. However increased 
proliferation of oval cells in NUAK1 null livers may suggest that this phenotype does apply to 
certain in vivo situations. Interestingly, a study showing increased NUAK1 expression 
associated with non-small cell lung cancer invasion and metastasis also observed increased 
cell adhesion following NUAK1 knockdown. Determining how the proliferation of NUAK1 null 
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cells relates to their adhesion phenotype will be crucial to understanding the in vivo 
significance of this kinase, particularly in relation to cancer. It is possible that NUAK1 
knockdown or deletion consistently increases cell adhesion due to changes in myosin 
phosphorylation, but only increases cell proliferation under certain in vivo conditions or under 
favourable experimental cell culture conditions. 
 
6.2 In vivo observations 
This thesis presents data from two tissue-specific knockout mouse models of NUAK1, adding 
to the one previous report that has shown any physiological role for the kinase in adult tissues 
(Inazuka et al., 2012). As part of my studies the phenotype of global NUAK1 deletion in mice 
was confirmed and MEFs were produced as a useful in vitro tool. 
 
Both the in vivo models presented in this thesis support the finding in the previous study that 
the observed phenotype is mild or insignificant under basal conditions. This could be due to 
redundancy within the AMPK-related kinase family or other effectors that feed into the 
pathways that NUAK1 controls. In order to fully understand the effect of changes in NUAK1 
expression on pathological conditions, it will be key to understand why the loss of NUAK1 
signalling does not produce a basal phenotype and what the various compensatory 
mechanisms might be.  
 
Thorough phenotyping of young-liver specific NUAK1 knockout mice indicated that the loss 
of NUAK1 in the liver did not create an overt phenotype under basal conditions. After a stress 
treatment diet, a greater proliferation of oval cells in NUAK1 null livers provides some 
evidence of a possible phenotype and links some of my in vitro findings to possible in vivo 
mechanisms. Although the aged mice only became available later during my studies, 
substantial efforts to phenotype NUAK1 liver-specific knockout mice under aged conditions 
suggested that there was a difference in the response to ageing due to NUAK1 deletion. This 
interesting phenotype shows some similarities to another animal model and inferences from 
in vitro data in my report may indicate possible mechanisms for this effect. The role of NUAK1 
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in potentially reducing age-related liver degeneration and metabolic problems suggest that it 
may be a useful clinical target. However, further understanding of the pathways involved will 
be necessary to ensure inhibitors or activators are targeting the correct processes. 
 
Data from the heart-specific NUAK1 knockout mice again showed that there was a minimal 
phenotype under basal conditions, although this was partially confounded by the phenotype 
of the αMHC cre mice. Structural differences in the heart in response to angiotensin II 
treatment were observed as a result of NUAK1 deletion but little evidence was uncovered to 
explain the mechanisms underlying this variation.  Taken together, both sets of in vivo data 
may indicate that NUAK1 has a minimal role in adult tissues but could have a more significant 
role during development or under conditions of proliferation in response to stress. Both stress 
treatments used in my studies were severe and acute treatments but it would be interesting 
to establish what response would be seen after mild or chronic stresses were applied to 
NUAK1 transgenic animal models. Mild and chronic stresses would represent a better 
recapitulation of pathological states and may reduce confounding or off-target influences 
from large responses to severe stress. 
 
Results from my animal models indicate more work that could reveal mechanistic insight into 
the function of NUAK1 as well as provide better evidence for its physiological role. It would 
be interesting to assess any potential role of the kinase in development by harvesting tissues 
from animals at earlier time points and measuring any functional changes in tissues of 
interest. Similarly, useful data would be gained from ageing tissue-specific mouse models and 
conducting Kaplan-Meier analysis to establish if there was any change in mortality as a result 
of NUAK1 deletion in a particular tissue. Data from the liver-specific NUAK1 knockout mice 
would suggest that there may be an improvement in age related degeneration, indicating that 
the mice may live longer, however this has not been shown conclusively. Also, stress 
treatments could be applied at different time points to establish the interplay between a 
potential role in development and a role in response to pathological insult. 
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Studies have identified human mutations in NUAK1 that could be linked to specific 
phenotypes (Windelinckx et al., 2011) and further evidence from animal models would 
provide a better indication of human pathologies to assess for changes in NUAK1. Also, human 
mutations identified in previous studies could be tested in vitro and in cell conditions to 
understand if they caused a gain or loss-of-function.  
 
6.3 Future directions 
One key aspect of NUAK1 regulation, and something that is common across the AMPK and 
related-kinase field, is the lack of understanding around the protein phosphatases that are 
responsible for dephosphorylating the kinases in vivo. This aspect is of particular interest with 
regard to NUAK1 as it is known to be able to interact with components of the protein 
phosphatase system (such as MYPT1), raising the possibility that it may influence its own 
phosphorylation in a negative feedback loop by activating and targeting protein phosphatase 
complexes. There is potential for studying this mechanism in other model organisms such as 
C. elegans where preliminary evidence already shows that the NUAK1 orthologue can 
regulate myosin organisation (Hoppe et al., 2010). Clearly cytoskeletal organisation is 
complex and multifactorial process and NUAK1 may contribute to a small part of this but 
identifying the precise interactions will be important for modulating the pathways.  
 
Given that the aged liver-specific NUAK1 knockout mice show a significant metabolic 
phenotype, it would be of interest to interrogate this system biochemically to establish what 
changes have occurred and what pathways are influenced. These data may also provide 
insight into possible pathologies that could be linked to human variation in NUAK1 expression 
or activity. 
 
A non-specific inhibitor of NUAK1, BX795, has been identified and it would be interesting to 
treat cells and animal models with this compound to see if reduction in NUAK1 activity would 
recapitulate the phenotype or function seen in NUAK1 deleted models (Clark et al., 2009). 
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Evidence from these studies would also provide a better insight for potential pharmacological 
treatment if NUAK1 is identified as a pathological mediator. 
 
This thesis does not precisely clarify the role of NUAK1 in cell proliferation but various data 
from my studies suggest reasons for differences observed in previous studies and possible 
mechanisms that may be regulated by NUAK1. There is substantial interest in the literature 
surrounding the role of NUAK1 in cancer and future studies may be able to build on the data 
shown here to clarify this. Useful data could be provided by establishing NUAK1 transgenic 
mouse models on cancer-prone backgrounds with deregulated Myc expression to study the 
in vivo significance of previous reports into NUAK1 function (Liu et al., 2012). Similarly, other 
cancer inducing models such as diet treatments could be used to establish the role of NUAK1 
as part of in vivo pathological systems. 
 
Although this study sheds new insight into some aspects of NUAK1 function, it clearly shows 
that there is likely to be some redundancy within these mechanisms. Further investigation of 
other proteins in the AMPK-related kinase family would improve the knowledge of signalling 
pathways downstream of LKB1 and would provide more evidence for potential drug 
treatments of these pathways. Also, given the evidence that NUAK1 does not necessarily 
require LKB1 for activity, this questions similar findings reported for other AMPK-related 
kinases (Lizcano et al., 2004). As the knowledge of these interlinking pathways is improved, 
the ability to attenuate and control them pharmacologically will also increase. Expanding the 
existing knowledge of inhibitors such as BX795 and identifying specific interactions for 
downstream pathways will be key to understanding the role and regulation of NUAK1 for 
potential therapeutic treatments. 
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Appendices 
Appendix 1 – Table of oligonucleotides used in this study 
The following oligonucleotides were used in this study for the purpose of mutagenesis of the 
NUAK1 construct in the pRSFDuet-1 vector, genotyping mice or conducting quantitative PCR 
experiments.  
Purpose Direction Sequence 5’ – 3’ 
NUAK1 D196A 
mutagenesis 
Forward TGCAATATTAAGATTGCTGCCTTTGGGCTTTCCAACCTG 
Reverse CAGGTTGGAAAGCCCAAAGGCAGCAATCTTAATATTGCA 
FLP genotyping 
Forward GGTCCAACTGCAGCCCAAGCTTCC 
Reverse GTGGATCGATCCTACCCCTTGCG 
NUAK1 KOMP 
construct 
Forward GTTGCTATAAAATCCATCCGTAAGGACAAA 
Reverse GAAACCTGTCTTTCTCGACTACTGGCTTTCAGTAA 
NUAK1 conditional 
construct 
Forward TACGCGCTTTGTAATGGGATGCTCCTGTAATAGGATGTCT 
Reverse GCTCGTCCTTAATTTTGTCCTTACGGATGGATTTTATAGCAAC 
αMHC cre genotyping 
Forward ATGACAGACAGATCCCTCCTATCTCC 
Reverse CTCATCACTCGTTGCATCGAC 
Alb cre genotyping 
Forward GCGGTCTGGCAGTAAAAACTATC 
Reverse GTGAAACAGCATTGCTGTCACTT 
AMPKα1 qPCR 
Forward Qiagen QuantiTect primer pair Prkaa1 (sequence unknown) QT00286923 
Reverse Qiagen QuantiTect primer pair Prkaa1 (sequence unknown) QT00286923 
AMPKα2 qPCR 
Forward Qiagen QuantiTect primer pair Prkaa2 (sequence unknown) QT00140518 
Reverse Qiagen QuantiTect primer pair Prkaa2 (sequence unknown) QT00262206 
AMPKβ1 qPCR 
Forward Qiagen QuantiTect primer pair Prkab1 (sequence unknown) QT00262206 
Reverse Qiagen QuantiTect primer pair Prkab1 (sequence unknown) QT00140518 
AMPKγ1 qPCR 
Forward Qiagen QuantiTect primer pair Phkg1 (sequence unknown) QT00103054 
Reverse Qiagen QuantiTect primer pair Phkg1 (sequence unknown) QT00103054 
Cox6b qPCR 
Forward Qiagen QuantiTect primer pair Cox6b (sequence unknown) QT00096012 
Reverse Qiagen QuantiTect primer pair Cox6b (sequence unknown) QT00096012 
Ndufs4 qPCR 
Forward Qiagen QuantiTect primer pair Ndufs4 (sequence unknown) QT00148799 
Reverse Qiagen QuantiTect primer pair Ndufs4 (sequence unknown) QT00148799 
NUAK1 qPCR 
Forward GTTGCTATAAAATCCATCCGTAAGGACAAA 
Reverse ACTGATGATATGAGGATGGTTGAGGGATGA 
NUAK2 qPCR 
Forward Origene NUAK2 primer pair (sequence unknown) MP209041 
Reverse Origene NUAK2 primer pair (sequence unknown) MP209041 
GAPDH qPCR 
Forward AGGTCGGTGTGAACGGATTTG 
Reverse TGTAGACCATGTAGTTGAGGTCA 
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Appendix 2 – Raw data from mass spectrometry screens 
The data from the NUAK1 mass spectrometry screens is presented in the form it was 
produced after searching the MASCOT database.  In each case the highest ranking proteins 
have been screened by the method listed. 
 
Appendix 2.1 – Raw data from MEF SILAC experiment (see Section 2.2.21.1 ) 
The highest ranking proteins have been ordered by the quantitative ratio of peptides detected 
in the “heavy” compared to the “light” lysates. This ratio is labelled as “H/L Ratio” and 2 was 
used as a threshold of sufficient increase.  
H/L 
Ratio 
Protein 
H/L 
Ratio 
Protein 
118.46 ATP synthase subunit d, mitochondrial 5.6796 Methylthioribose-1-phosphate isomerase 
87.948 Cystatin-B 5.6322 182 kDa tankyrase-1-binding protein 
44.817 Calpactin I light chain 5.6043 
Inhibitor of nuclear factor kappa-B kinase-
interacting protein 
43.743 GTPase-interacting protein 2 5.5946 Actin regulatory protein CAP-G 
42.235 Cyclin-dependent kinase inhibitor 2A, isoform 3 5.5643 C-type mannose receptor 2 
37.467 ATP synthase subunit f, mitochondrial 5.4832 Inosine triphosphate pyrophosphatase 
35.81 Acetoacetyl-CoA thiolase 5.301 COP9 homolog 
34.675 CD44 antigen 5.1779 Fascin 
32.961 Cellular retinol-binding protein 5.1304 
Latent-transforming growth factor beta-
binding protein 1 
32.944 3-ketoacyl-CoA thiolase A, peroxisomal 5.1247 Antioxidant enzyme B166 
32.861 
Cytochrome b5 outer mitochondrial membrane 
isoform 
5.0896 Post-proline cleaving enzyme 
31.89 Peptidyl-tRNA hydrolase 2, mitochondrial 4.9573 Carboxy terminus of Hsp70-interacting protein 
31.062 Beta-2-microglobulin 4.9112 Actin cross-linking family 7 
27.853 6.8 kDa mitochondrial proteolipid 4.8662 Band 4.1-like protein 2 
27.644 Collagen alpha-1(VI) chain 4.7941 Cathepsin Z 
27.35 Neuron cytoplasmic protein 9.5 4.787 Asparagine synthetase [glutamine-hydrolyzing] 
27.023 Putative uncharacterized protein 4.7718 Formyltetrahydrofolate synthetase 
26.814 Cellular retinoic acid-binding protein 1 4.7712 ICD-M 
26.071 3,2-trans-enoyl-CoA isomerase, mitochondrial 4.7639 Placental thrombin inhibitor 
24.96 UPF0368 protein Cxorf26 homolog 4.5879 Pitrilysin metalloproteinase 1 
24.162 Acetyl-Coenzyme A acetyltransferase 3 4.52 Putative uncharacterized protein 
23.456 Aspartyl aminopeptidase 4.5077 47 kDa heat shock protein 
23.441 6-phosphogluconolactonase 4.5015 Galactokinase 2 
22.176 Putative uncharacterized protein 4.4616 Cytosol aminopeptidase 
21.808 BPY2-interacting protein 1 4.4166 Tubulin--tyrosine ligase-like protein 12 
21.745 Glutathione S-transferase P 1 4.4125 Tpm1 protein 
20.69 O-phosphoserine phosphohydrolase 4.4114 Protein G7a 
20.112 D4 4.3878 WASH complex subunit FAM21 
19.974 
UDP-N-acetylhexosamine pyrophosphorylase-
like protein 1 
4.3617 Diaphorase-1 
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H/L 
Ratio 
Protein 
H/L 
Ratio 
Protein 
19.784 Glutathione S-transferase GT8.7 4.3482 Pyrroline-5-carboxylate reductase 3 
19.438 26S protease subunit S5 basic 4.3127 
Transmembrane emp24 domain-containing 
protein 5 
19.414 ATP synthase subunit b, mitochondrial 4.2903 Thrombospondin 1 
18.551 ATP synthase subunit e, mitochondrial 4.2876 Aconitate hydratase, mitochondrial 
18.441 E2-induced gene 5 protein homolog 4.2674 UDP-glucose 6-dehydrogenase 
18.326 5-methylthioadenosine phosphorylase 4.259 Dynamin-1 
18.079 Inosine phosphorylase 4.2321 Tumor protein D52-like 2 
17.733 La autoantigen homolog 4.2245 Adenosine 5-phosphotransferase 
17.614 Cytochrome b5 4.2162 Complex I-75kD 
17.467 Endogenous carboxypeptidase inhibitor 4.1213 Alpha-2 type I collagen 
17.367 Glutathione S-transferase Mu 2 4.078 Palladin 
17.313 Zyxin 4.0265 CDC47 homolog 
17.285 Carboxypeptidase C 3.992 35-alpha calcimedin 
17.198 ATP synthase subunit g, mitochondrial 3.9452 Beta-catenin 
17.108 D-dopachrome decarboxylase 3.9107 HLA-B-associated transcript 3 
16.809 Sepiapterin reductase 3.871 Calponin H2, smooth muscle 
16.721 Putative uncharacterized protein 3.8262 E3 ubiquitin-protein ligase UBR3 
16.493 Epidermal-type fatty acid-binding protein 3.7362 EH domain-containing protein 1 
16.473 AHD-M1 3.6032 
Lamina-associated polypeptide 2, isoforms 
alpha/zeta 
16.345 Aldehyde dehydrogenase family 1 member L2 3.6003 
Tyrosine-protein phosphatase non-receptor 
type 23 
16.322 Galactokinase 3.5441 Macropain chain Z 
16.288 Cytochrome c oxidase polypeptide VIc 3.5367 Aspartate beta-hydroxylase 
16.014 60S ribosomal protein L29 3.5231 Dihydropteridine reductase 
16.014 
Ubiquitin-activating enzyme E1 domain-
containing protein 1 
3.4956 Dedicator of cytokinesis protein 7 
15.967 Atlastin-3 3.4845 Epiplakin 
15.915 Prosaposin 3.4821 UDP--Glc:glycoprotein glucosyltransferase 
15.211 Low molecular mass protein 19 3.4803 Delta-aminolevulinic acid dehydratase 
15.169 Anastellin 3.4389 Alcohol dehydrogenase [NADP+] 
14.985 DDAHII 3.4321 GDI-1 
14.969 ES1 protein homolog, mitochondrial 3.431 ABP-280-like protein 
14.908 
Long-chain specific acyl-CoA dehydrogenase, 
mitochondrial 
3.429 Hydroxysteroid (17-beta) dehydrogenase 10 
14.698 Aldehyde reductase 3.3969 ADP-ribosylation factor-like protein 10C 
14.582 Fibulin-2 3.3754 Anaphase-promoting complex subunit 1 
14.504 Complex I-20kD 3.3683 80K-H protein 
14.329 Sphingosine-1-phosphate aldolase 3.3592 Copine III 
14.258 
Sterol-4-alpha-carboxylate 3-dehydrogenase, 
decarboxylating 
3.3278 Heterogeneous nuclear ribonucleoprotein A3 
13.886 
Beta-type platelet-derived growth factor 
receptor 
3.3039 AFG3-like protein 2 
13.837 Ferritin L subunit 1 3.2605 Transportin-3 
13.663 Cargo selection protein TIP47 3.2246 Putative uncharacterized protein 
13.385 63 kDa membrane protein 3.2031 Aldehyde dehydrogenase family 18 member A1 
13.259 E3 ubiquitin-protein ligase NEDD4 3.1754 Lon protease homolog, mitochondrial 
13.209 Alpha-mannosidase 2 3.1378 Myosin, heavy polypeptide 10, non-muscle 
13.019 Ubiquitin carboxyl-terminal hydrolase 3.1375 Methionine--tRNA ligase 
12.883 Adenine nucleotide translocator 1 3.1359 Adenylate cyclase-inhibiting G alpha protein 
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H/L 
Ratio 
Protein 
H/L 
Ratio 
Protein 
12.661 Annexin A4 3.1277 Laminin B1 chain 
12.503 17-beta-hydroxysteroid dehydrogenase 12 3.0812 Pyrroline-5-carboxylate reductase 2 
12.463 65 kDa FK506-binding protein 3.0417 ERT2 
12.457 Dihydropyrimidinase-related protein 3 3.0159 
C-Jun-amino-terminal kinase-interacting 
protein 4 
12.377 Glutathione S-transferase 5.7 2.9745 Inositol monophosphatase 1 
12.343 Cathepsin B 2.9621 Lysyl hydroxylase 3 
12.312 Xanthine dehydrogenase 2.9457 
ER-Golgi intermediate compartment 53 kDa 
protein 
12.106 52 kDa FK506-binding protein 2.9432 Cadherin-associated Src substrate 
12.105 Myb-binding protein 1A 2.9366 Protein transport protein Sec31A 
11.79 Perlecan (Heparan sulfate proteoglycan 2) 2.9118 Thimet oligopeptidase 
11.732 Actin-depolymerizing factor 2.8566 Protein Gamm1 
11.338 Amine oxidase [flavin-containing] A 2.8548 Cathepsin D 
11.28 Ferritin heavy chain 2.8484 COP9 signalosome complex subunit 7a 
11.24 Thy-1 antigen 2.8297 300 kDa mannose 6-phosphate receptor 
11.123 4.1B;Band 4.1-like protein 3 2.8229 Endoplasmic reticulum resident protein 44 
10.985 Kinectin 2.8167 Ras-related protein Rab-2A 
10.941 Gelsolin 2.7983 
Succinyl-CoA ligase [GDP-forming] subunit 
alpha, mitochondrial 
10.868 Bone marrow stromal antigen 2 2.797 SDP3 protein 
10.765 Interferon-gamma-inducible protein Mg11 2.7461 Hsc70-interacting protein 
10.59 CYPLI 2.7424 Diadenosine tetraphosphate synthetase 
10.514 Gem-associated protein 5 2.7331 Ribosome receptor protein 
10.506 Glutaminyl-tRNA synthetase 2.7152 Aflatoxin B1 aldehyde reductase member 2 
10.446 AGE 2.6943 155 kDa nucleoporin 
10.32 Dennd4c protein 2.6869 3-oxoacid-CoA transferase 1 
10.292 19 kDa FK506-binding protein 2.6776 Annexin A7 
10.288 Cyclin-dependent kinase 4 inhibitor A 2.6641 17 kDa myosin light chain 
10.211 Adenine phosphoribosyltransferase 2.6613 33 kDa VAMP-associated protein 
10.208 Cholesterol-regulated 39 kDa protein 2.6253 Chromosome-associated protein E 
10.192 Protein-tyrosine kinase 7 2.6106 Asparagine--tRNA ligase 
10.101 
2-amino-3-ketobutyrate coenzyme A ligase, 
mitochondrial 
2.6076 ADP-ribosylation factor-like protein 1 
9.8024 14 kDa lectin 2.5982 Sorcin 
9.7776 
Androgen-regulated short-chain 
dehydrogenase/reductase 1 
2.5842 Tubulin beta-6 chain 
9.5464 Acid maltase 2.5758 Formylglycinamide ribotide amidotransferase 
9.5436 Fragilis 2.56 Phosphate carrier protein, mitochondrial 
9.5412 Sorting nexin-1 2.5521 Complex III subunit 8 
9.5241 Glucosamine-6-sulfatase 2.548 PAF acetylhydrolase 30 kDa subunit 
9.4823 35 kDa lectin 2.5365 12 kDa FK506-binding protein 
9.4811 
Loss of heterozygosity 11 chromosomal region 2 
gene A protein homolog 
2.5347 Aspartate--tRNA ligase 
9.339 Calumenin 2.533 Chloride intracellular channel protein 4 
9.32 Ribonuclease inhibitor 2.5308 21 kDa polypeptide 
9.2627 Imidazoline receptor 1 2.5304 Alpha-actinin cytoskeletal isoform 
8.9735 A-kinase anchor protein 12 2.5057 CDC10 protein homolog 
8.9681 Translin 2.5004 
Neural precursor cell expressed 
developmentally down-regulated protein 5 
8.8691 Adenylosuccinase 2.4946 TES1/TES2 
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H/L 
Ratio 
Protein 
H/L 
Ratio 
Protein 
8.6744 
Arf-GAP with Rho-GAP domain, ANK repeat and 
PH domain-containing protein 1 
2.4776 
Calcium-binding mitochondrial carrier protein 
Aralar1 
8.5512 Cytochrome c oxidase polypeptide IV 2.4749 PAF acetylhydrolase 29 kDa subunit 
8.4815 Interferon-stimulated protein 15 2.44 Putative uncharacterized protein Myo9a 
8.4497 Endometrial progesterone-induced protein 2.4375 Tripeptidyl aminopeptidase 
8.4083 Ankyrin-2 2.4358 Fibrous sheath component 2 
8.3811 NSFL1 cofactor p47 2.4232 Septin-9 
8.3505 Tubulin beta-2B chain 2.4097 67 kDa calelectrin 
8.3209 HCNPpp 2.4096 Rho GTPase-activating protein 1 
8.2784 Dihydropyrimidinase-related protein 2 2.4011 High density lipoprotein-binding protein 
8.2337 p23 2.3805 
5-aminoimidazole-4-carboxamide 
ribonucleotide formyltransferase 
8.2304 Complex I-B14.5b 2.3711 A kinase (PRKA) anchor protein 2 
8.2144 Inverted formin-2 2.3695 DnaJ homolog subfamily C member 2 
8.1087 Putative uncharacterized protein Col6a3 2.3485 Citrate synthase, mitochondrial 
8.0475 BAT2 domain-containing protein 1 2.34 Elongation factor 1-alpha 1 
8.0437 Glutathione S-transferase omega-1 2.3276 Septin-11 
7.9589 Microsomal signal peptidase 25 kDa subunit 2.3245 Isocitrate dehydrogenase 3 (NAD+) beta 
7.9245 Ubiquitin conjugation factor E4 B 2.2946 15S Mg(2+)-ATPase p97 subunit 
7.9011 
Pyridoxal-dependent decarboxylase domain-
containing protein 1 
2.2821 11S regulator complex subunit alpha 
7.7396 Myosin regulatory light chain 12B 2.2774 
cAMP-dependent protein kinase catalytic 
subunit alpha 
7.7071 Cavin-1 2.2748 Cytosolic NADP-isocitrate dehydrogenase 
7.6894 Apoptosis regulator BAX 2.2475 SEC23-interacting protein 
7.5652 
Proline synthase co-transcribed bacterial 
homolog protein 
2.2326 Ras-related protein Rab-18 
7.5018 Alpha-tropomyosin 2.2252 Anchorin CII 
7.4569 ADH-C2 2.1884 11S regulator complex subunit beta 
7.3865 Alpha-2-macroglobulin receptor 2.163 ACC-alpha 
7.2854 
Procollagen-proline,2-oxoglutarate-4-
dioxygenase subunit alpha-1 
2.141 Spectrin alpha 2 
7.2348 [Acyl-carrier-protein] S-acetyltransferase 2.1387 
LIM and senescent cell antigen-like domains 1, 
isoform CRA_c 
7.2067 
Phosphoenolpyruvate carboxykinase [GTP], 
mitochondrial 
2.128 Coronin-1B 
7.1812 
Glucocorticoid-attenuated response gene 16 
protein 
2.1224 Archain 
7.1387 Annexin A1 2.1085 ERT1 
6.9973 High mobility group protein 2 2.0955 
Rab3 GTPase-activating protein 150 kDa 
subunit 
6.9588 
Synaptic vesicle membrane protein VAT-1 
homolog 
2.0832 Reticulon-3 
6.9217 2,3-epoxysqualene--lanosterol cyclase 2.0818 Endopeptidase Clp 
6.8851 Protein FAM129A 2.0808 Cytoplasmic FMR1-interacting protein 1 
6.7669 Complex I-MLRQ 2.0578 Elongin 15 kDa subunit 
6.7154 Eukaryotic translation initiation factor 2A 2.0542 GTP-binding protein MMR1 
6.587 Dipeptidyl peptidase 9 2.0433 ATP synthase subunit O, mitochondrial 
6.5257 Alpha-1 type I collagen 2.0424 Isopentenyl pyrophosphate isomerase 1 
6.4314 Acetoacetyl-CoA synthetase 2.0364 
Minichromosome maintenance deficient 5, cell 
division cycle 46 (S. cerevisiae) 
6.4029 MCG140951 2.0353 Major vault protein 
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H/L 
Ratio 
Protein 
H/L 
Ratio 
Protein 
6.2763 Esterase 10 2.0311 Complex III subunit 1 
6.2219 Cytochrome c oxidase polypeptide II 2.0243 Epithelial protein lost in neoplasm 
6.1564 Ubiquitin-conjugating enzyme E2 variant 1 2.0229 Ras suppressor protein 1 
6.1439 Thrombospondin-2 2.019 Deubiquitinating enzyme 5 
6.0721 Alpha-N-acetylglucosaminidase 2.017 MEK-binding partner 1 
6.0714 ADP-ribosylation factor 4 2.013 Protein LSM12 homolog 
5.9181 Cellular myosin heavy chain, type A 2.0115 GTP-binding protein SAR1a 
5.9124 Erythrocyte band 7 integral membrane protein 2.0112 Dynein cytoplasmic 1 intermediate chain 2 
5.9021 14-3-3 protein eta 2.0052 Neurite outgrowth inhibitor 
5.8577 Parathymosin   
 
Appendix 2.2 – Raw data from NUAK1 neuronal phosphoscreen (see Section 2.2.21.2  
The highest ranking proteins have been ordered by the quantitative ratio of phosphopeptides 
detected in the 1μg experiment compared to the 5μg experiment. This ratio is labelled as 
“Phospho Ratio” and 2 was used as a threshold of sufficient increase.  
Phospho 
Ratio 
Protein 
Phospho 
Ratio 
Protein 
10.4492 
Voltage-dependent N-type calcium channel 
subunit alpha-1B 
2.4492 Neuromodulin 
7.5605 NUAK family SNF1-like kinase 1 2.4489 
Heterogeneous nuclear ribonucleoproteins 
C1/C2 
7.5566 U4/U6 small nuclear ribonucleoprotein Prp3 2.4386 Rho GTPase-activating protein 33 
7.2565 Myotubularin-related protein 7 2.4382 Protein RUFY3 
7.1870 NUAK family SNF1-like kinase 1 2.4311 Calnexin 
7.1460 Transcription factor 20 2.4281 CTP synthase 1 
7.1373 Rho GTPase-activating protein 10 2.4277 Microtubule-associated protein tau 
7.1373 T-complex protein 1 subunit gamma 2.4231 Microtubule-associated protein 1B 
6.5426 Syntaxin-binding protein 1 2.4220 Heat shock protein HSP 90-beta 
6.0902 Transcriptional activator protein Pur-beta 2.4187 Myristoylated alanine-rich C-kinase substrate 
5.9394 
Heterogeneous nuclear ribonucleoproteins 
C1/C2 
2.4119 Ankyrin-2 
5.7815 Cadherin-12 2.4103 Transmembrane protein 55B 
5.5190 Protein PRRC2A 2.4007 
Protein-methionine sulfoxide oxidase 
MICAL3 
5.3145 Disks large-associated protein 4 2.3977 60S ribosomal protein L14 
5.3092 
Amyloid beta A4 precursor protein-binding 
family A member 2 
2.3952 Coronin-1A 
5.2943 Serine/arginine repetitive matrix protein 1 2.3883 Cyclin-dependent kinase 16 
5.2035 Coatomer subunit gamma-1 2.3858 BTB/POZ domain-containing protein KCTD4 
5.1072 
Serine/threonine-protein phosphatase 6 
regulatory subunit 2 
2.3851 Drebrin 
5.0852 Heat shock protein HSP 90-beta 2.3815 Dystrophin 
5.0482 Heat shock protein HSP 90-alpha 2.3803 Phosphatidylinositol 4-kinase beta 
4.9492 
Peripheral-type benzodiazepine receptor-
associated protein 1 
2.3728 Microtubule-associated protein 2 
4.8865 THUMP domain-containing protein 1 2.3609 Ankyrin-2 
4.8786 PC4 and SFRS1-interacting protein 2.3547 Myristoylated alanine-rich C-kinase substrate 
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Phospho 
Ratio 
Protein 
Phospho 
Ratio 
Protein 
4.7987 B-cell CLL/lymphoma 9 protein 2.3456 Ubiquitin carboxyl-terminal hydrolase 10 
4.7039 Protein IWS1 homolog 2.3454 LIM domain-containing protein 2 
4.6766 Heat shock protein HSP 90-alpha 2.3429 Gamma-tubulin complex component 3 
4.6766 WASH complex subunit 7 2.3391 Heat shock protein HSP 90-beta 
4.5338 Vacuolar protein sorting-associated protein 4B 2.3376 
Pyridoxal-dependent decarboxylase domain-
containing protein 1 
4.5053 Translocation protein SEC62 2.3367 NCK-interacting protein with SH3 domain 
4.4163 Dematin 2.3335 Protein phosphatase 1 regulatory subunit 1A 
4.3980 Band 4.1-like protein 1 2.3259 CTTNBP2 N-terminal-like protein 
4.3544 
Dual specificity mitogen-activated protein 
kinase kinase 2 
2.3254 Protein TANC2 
4.2874 Heat shock protein HSP 90-alpha 2.3234 Catenin beta-1 
4.2830 Microtubule-associated protein 1B 2.3188 SLIT-ROBO Rho GTPase-activating protein 2 
4.0329 tRNA pseudouridine(38/39) synthase 2.3061 Neuronal membrane glycoprotein M6-a 
3.9165 Heat shock protein HSP 90-alpha 2.3033 Adenomatous polyposis coli protein 
3.9029 Myristoylated alanine-rich C-kinase substrate 2.2899 
Calmodulin-regulated spectrin-associated 
protein 1 
3.8958 Dihydropyrimidinase-related protein 2 2.2879 Catenin alpha-2 
3.8682 T-complex protein 1 subunit gamma 2.2868 Reticulon-4 
3.6936 Myristoylated alanine-rich C-kinase substrate 2.2829 
Connector enhancer of kinase suppressor of 
ras 2 
3.6863 Pinin 2.2801 Microtubule-associated protein 2 
3.6714 MARCKS-related protein 2.2646 CREB-regulated transcription coactivator 1 
3.6055 Obscurin 2.2597 
Cyclic AMP-dependent transcription factor 
ATF-2 
3.5733 
Cutaneous T-cell lymphoma-associated 
antigen 5 homolog 
2.2484 Serine/arginine repetitive matrix protein 2 
3.5690 Dematin 2.2450 Soluble lamin-associated protein of 75 kDa 
3.5665 Interleukin enhancer-binding factor 3 2.2389 Heat shock protein HSP 90-beta 
3.5562 Traf2 and NCK-interacting protein kinase 2.2385 Myristoylated alanine-rich C-kinase substrate 
3.5428 Microtubule-associated protein tau 2.2384 Protein phosphatase 1H 
3.4887 
Small glutamine-rich tetratricopeptide repeat-
containing protein alpha 
2.2378 Hepatoma-derived growth factor 
3.4582 Myosin-9 2.2362 Serine/threonine-protein kinase PAK 1 
3.4504 Myosin-9 2.2344 Ran-binding protein 3 
3.4358 MARCKS-related protein 2.2221 
Connector enhancer of kinase suppressor of 
ras 2 
3.4028 Ras-related protein Rab-31 2.2184 Monocarboxylate transporter 1 
3.3524 Heat shock protein HSP 90-beta 2.2129 
Zinc finger Ran-binding domain-containing 
protein 2 
3.3350 MARCKS-related protein 2.2122 Ataxin-2-like protein 
3.3169 Splicing factor 45 2.2091 Kinesin light chain 1 
3.3103 Unconventional myosin-Va 2.2074 MARCKS-related protein 
3.2969 Inositol 1,4,5-trisphosphate receptor type 1 2.2073 Nestin 
3.2832 Actin-binding LIM protein 1 2.2056 
G protein-regulated inducer of neurite 
outgrowth 1 
3.2812 Serine/arginine repetitive matrix protein 4 2.2047 Microtubule-associated protein 2 
3.2573 Microtubule-associated protein 2 2.2044 Coiled-coil domain-containing protein 85A 
3.2108 Numb-like protein 2.1995 CREB-regulated transcription coactivator 1 
3.1912 Heat shock protein HSP 90-alpha 2.1983 Microtubule-actin cross-linking factor 1 
3.1458 Microtubule-associated protein 2 2.1927 Heat shock protein HSP 90-beta 
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Phospho 
Ratio 
Protein 
Phospho 
Ratio 
Protein 
3.1133 Ankyrin-2 2.1895 Syntaxin-1A 
3.1115 Microtubule-associated protein tau 2.1885 Phosphoglucomutase-1 
3.0983 Band 4.1-like protein 1 2.1848 Dihydropyrimidinase-related protein 3 
3.0926 Ankyrin-2 2.1790 RNA-binding protein 39 
3.0805 Zinc finger CCCH domain-containing protein 18 2.1790 
Hepatoma-derived growth factor-related 
protein 2 
3.0736 Heat shock protein HSP 90-alpha 2.1737 Spectrin beta chain, non-erythrocytic 1 
3.0388 Sphingosine kinase 2 2.1718 Calnexin 
3.0171 Protein phosphatase 1 regulatory subunit 12A 2.1629 Gamma-adducin 
3.0148 E3 ubiquitin-protein ligase HECW2 2.1616 Uncharacterized protein KIAA0930 homolog 
2.9793 HIV Tat-specific factor 1 homolog 2.1597 CLK4-associating serine/arginine rich protein 
2.9447 SLIT-ROBO Rho GTPase-activating protein 2 2.1594 Calnexin 
2.9247 S-phase kinase-associated protein 1 2.1579 Neural cell adhesion molecule 1 
2.9144 
Arginine-glutamic acid dipeptide repeats 
protein 
2.1575 Protein piccolo 
2.9044 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(O) subunit gamma-3 
2.1551 
Nuclear ubiquitous casein and cyclin-
dependent kinase substrate 1 
2.8968 Probable phospholipid-transporting ATPase IA 2.1507 
Calmodulin-regulated spectrin-associated 
protein 2 
2.8855 
Hydroxymethylglutaryl-CoA synthase, 
cytoplasmic 
2.1493 SUZ domain-containing protein 1 
2.8603 Microtubule-associated protein tau 2.1492 
cAMP-specific 3',5'-cyclic phosphodiesterase 
4D 
2.8547 RNA polymerase-associated protein LEO1 2.1434 Interleukin enhancer-binding factor 3 
2.8490 Ubiquitin-conjugating enzyme E2 E3 2.1394 Target of Myb protein 1 
2.8312 Synapsin-2 2.1378 Reticulon-4 
2.7790 
Apoptotic chromatin condensation inducer in 
the nucleus 
2.1350 Serine/arginine repetitive matrix protein 2 
2.7631 Transmembrane protein 55B 2.1345 Serine/arginine repetitive matrix protein 2 
2.7619 Coilin 2.1343 
Centrosome and spindle pole associated 
protein 1 
2.7591 T-box brain protein 1 2.1301 La-related protein 1 
2.7527 Sickle tail protein 2.1271 
Epidermal growth factor receptor substrate 
15-like 1 
2.7527 
Serine/threonine-protein kinase PRP4 
homolog 
2.1234 Heat shock protein HSP 90-alpha 
2.7456 Protein phosphatase 1 regulatory subunit 7 2.1221 Microtubule-associated protein 1B 
2.7303 Microtubule-associated protein 1B 2.1221 Pinin 
2.7268 Probable E3 ubiquitin-protein ligase MYCBP2 2.1181 Ral GTPase-activating protein subunit beta 
2.7210 Ankyrin-2 2.1163 Band 4.1-like protein 1 
2.7157 Serine/arginine repetitive matrix protein 2 2.1159 
Eukaryotic translation initiation factor 4 
gamma 1 
2.6917 
Activating transcription factor 7-interacting 
protein 1 
2.1131 
Activating transcription factor 7-interacting 
protein 2 
2.6863 MARCKS-related protein 2.1124 Brain acid soluble protein 1 
2.6837 Stathmin 2.1099 
N-alpha-acetyltransferase 25, NatB auxiliary 
subunit 
2.6794 Dihydropyrimidinase-related protein 5 2.1096 Coiled-coil domain-containing protein 85A 
2.6678 Serine/arginine repetitive matrix protein 2 2.1090 Uncharacterized protein KIAA1211 
2.6650 Hepatoma-derived growth factor 2.1018 Protein SOGA1 
2.6611 Unconventional myosin-Va 2.1018 Treacle protein 
2.6599 Neuralized-like protein 4 2.0987 Shootin-1 
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Phospho 
Ratio 
Protein 
Phospho 
Ratio 
Protein 
2.6584 Ras-related protein Rab-31 2.0977 A-kinase anchor protein 5 
2.6465 
26S proteasome non-ATPase regulatory 
subunit 1 
2.0949 
Vacuolar protein sorting-associated protein 
26B 
2.6395 Neural cell adhesion molecule 1 2.0896 Serine/arginine repetitive matrix protein 2 
2.6221 Inactive phospholipase C-like protein 2 2.0840 
Interferon regulatory factor 2-binding 
protein-like 
2.6154 Protein IWS1 homolog 2.0835 Brain acid soluble protein 1 
2.6142 
Nuclear ubiquitous casein and cyclin-
dependent kinase substrate 1 
2.0833 Ras-related protein R-Ras2 
2.6062 Brain acid soluble protein 1 2.0625 Myotubularin-related protein 3 
2.5896 Myristoylated alanine-rich C-kinase substrate 2.0613 Elongation factor 1-delta 
2.5876 Band 4.1-like protein 4A 2.0596 
Phosphoribosyl pyrophosphate synthase-
associated protein 2 
2.5867 Synergin gamma 2.0594 Microtubule-associated protein 4 
2.5858 Adenomatous polyposis coli protein 2.0558 Serine/threonine-protein kinase LMTK3 
2.5717 182 kDa tankyrase-1-binding protein 2.0552 Tumor suppressor p53-binding protein 1 
2.5704 
cAMP-dependent protein kinase catalytic 
subunit beta 
2.0518 E3 ubiquitin-protein ligase HECW1 
2.5682 Elongation factor 1-delta 2.0484 G-protein-signaling modulator 1 
2.5635 Microtubule-associated protein 2 2.0467 Protein LSM12 homolog 
2.5275 TBC1 domain family member 24 2.0429 Serine/arginine repetitive matrix protein 1 
2.5236 Heat shock protein HSP 90-beta 2.0421 Putative RNA-binding protein 15B 
2.5235 Dedicator of cytokinesis protein 7 2.0365 Glutamate receptor-interacting protein 1 
2.5201 
Mitogen-activated protein kinase kinase 
kinase kinase 4 
2.0350 Reticulon-4 
2.5200 Protein TANC2 2.0344 Ankyrin-2 
2.5121 
Calcium/calmodulin-dependent protein kinase 
kinase 2 
2.0307 Reticulon-4 
2.4950 Reticulon-4 2.0302 Microtubule-associated protein 1B 
2.4912 Beta-adducin 2.0187 
Abnormal spindle-like microcephaly-
associated protein homolog 
2.4878 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(O) subunit gamma-2 
2.0179 Alstrom syndrome protein 1 homolog 
2.4816 Pre-mRNA-splicing factor CWC22 homolog 2.0162 
G protein-regulated inducer of neurite 
outgrowth 1 
2.4815 Heat shock protein HSP 90-beta 2.0147 Protein kinase C epsilon type 
2.4805 Rho guanine nucleotide exchange factor 12 2.0124 Sodium/calcium exchanger 1 
2.4796 
Regulating synaptic membrane exocytosis 
protein 2 
2.0099 Serine/arginine repetitive matrix protein 2 
2.4718 Heat shock protein HSP 90-beta 2.0083 Transcription intermediary factor 1-alpha 
2.4496 MARCKS-related protein 2.0065 Dedicator of cytokinesis protein 7 
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Appendix 2.3 – Raw data from NUAK1 SILAC IP (see Section 2.2.21.3 ) 
The highest ranking proteins have been ordered by the number of unique peptide hits that 
varied between the “heavy” immunoprecipitate and the “light” immunoprecipitate.  
Rank Protein Rank Protein 
1 
AMPK-related protein kinase 5;NUAK family 
SNF 
69 
Activator interaction domain-containing 
protein 2 
2 
Myosin phosphatase-targeting subunit 
1;Protein phosphatase 1 regulatory subunit  
70 ER lumen protein retaining receptor 2 
3 14-3-3 protein epsilon 71 4F2 cell-surface antigen heavy chain 
4 14-3-3 protein eta 72 Calcium-binding protein ERC-55 
5 ATP synthase subunit alpha, mitochondrial 73 CTCL tumor antigen se20-10 
6 Damage-specific DNA-binding protein 1 74 Solute carrier family 35 member E1 
7 Putative uncharacterized protein CWC22 75 One-twenty two protein 1 
8 14-3-3 protein gamma 76 
Medium tumor antigen-associated 61 kDa 
protein 
9 14-3-3 protein zeta/delta 77 DDB1- and CUL4-associated factor 1 
10 Deubiquitinating enzyme 7 78 Histone H1.3 
11 Coatomer subunit gamma-2 79 Ribonucleases P/MRP protein subunit POP1 
12 
DNA-directed RNA polymerase II 140 kDa 
polypeptide 
80 Ser/Arg-related nuclear matrix protein 
13 Heterogeneous nuclear ribonucleoprotein K 81 Fas ligand-associated factor 1 
14 SAPS domain family member 3 82 EEF1A protein 
15 Protein phosphatase 1 regulatory subunit 22 83 DNA polymerase delta subunit 3 
16 Importin-9 84 FAST kinase domain-containing protein 5 
17 Emerin 85 
Cleavage and polyadenylation specificity  
factor 100 kDa subunit 
18 DnaJ homolog subfamily A member 1 86 NF-X1-type zinc finger protein NFXL1 
19 F-box and WD repeats protein beta-TrCP2 87 NMDA receptor-regulated protein 2 
20 CUL4- and DDB1-associated WDR protein 2 88 Chorea-acanthocytosis protein 
21 Putative uncharacterized protein HCFC1 89 
cDNA FLJ77771, highly similar to Homo sapiens  
replication initiator 1, mRNA 
22 
Adapter-related protein complex 3 subunit 
beta-1 
90 Zinc finger protein 3 
23 Protein clk-2 homolog 91 CT-ZFP48 
24 Importin subunit beta-1 92 Protein FAM83H 
25 Deubiquitinating enzyme FAF-X 93 Importin subunit beta-3 
26 Breakpoint cluster region protein 2 94 
cDNA FLJ11352 fis, clone HEMBA1000020,  
highly similar to Tubulin beta-2C chain 
27 
Serine/threonine-protein phosphatase  
PP1-beta catalytic subunit 
95 
cDNA FLJ56823, highly similar to Protein-
glutamine  
gamma-glutamyltransferase E (EC 2.3.2.13) 
28 
Proteasome (Prosome, macropain) 26S 
subunit, non-ATPase, 6, isoform CRA_b 
96 Delta transcription factor 
29 Deubiquitinating enzyme 11 97 ATP-dependent metalloprotease FtsH1 
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Rank Protein Rank Protein 
30 300 kDa nuclear matrix antigen 98 ATP-dependent RNA helicase DDX18 
31 
Protein phosphatase 1 myosin-binding subunit 
of 85 kDa 
99 
Glutaminyl-peptide cyclotransferase-like 
protein 
32 O-GlcNAc transferase subunit p110 100 60S ribosomal protein L37a 
33 
140 kDa nuclear and cell adhesion-related 
phosphoprotein 
101 
cDNA FLJ16129 fis, clone BRACE2039823, 
highly similar to CDP-diacylglycerol--inositol3-
phosphatidyltransferase (EC 2.7.8.11) 
34 TRM1-like protein 102 PAI1 RNA-binding protein 1 
35 Swd2 103 
Mitochondrial 20 kDa outer membrane 
protein 
36 hSGT2 104 
cDNA FLJ56334, highly similar to SEC13-related 
protein 
37 60S ribosomal protein L17 105 Binder of OVCA1-1 
38 Fanconi anemia group I protein 106 Histone H3.3 
39 Protein phosphatase 1C catalytic subunit 107 60S ribosomal protein L30 
40 BMP2-induced 3-kb gene protein 108 28S ribosomal protein S23 
41 GCUNC-45 109 28 kDa heat shock protein 
42 APOBEC1-binding protein 2 110 Cell division cycle 5-like protein 
43 Protein SCO1 homolog, mitochondrial 111 Zinc finger protein 598 
44 Adenine nucleotide translocator 1 112 ElaC homolog protein 2 
45 RING finger protein 219 113 Conventional kinesin heavy chain 
46 
Dolichyl-diphosphooligosaccharide--protein  
glycosyltransferase 48 kDa subunit 
114 Testis-expressed sequence 10 protein 
47 6-phosphofructokinase, liver type 115 3D3/LYRIC 
48 Long-chain fatty acid transport protein 4 116 Nucleolar protein 1 
49 
cDNA FLJ58665, highly similar to 
Serine/threonine-protein phosphatase 2A 55 
kDa regulatory subunit B alpha isoform 
117 Putative uncharacterized protein 
DKFZp686M24262 
50 Cullin-associated and neddylation-dissociated 
protein 1 
118 HBV pre-S2 trans-regulated protein 2 
51 AIR carboxylase 119 Flavoprotein subunit of complex II 
52 Pre-mRNA-splicing factor SRP75 120 DNA-directed RNA polymerase, mitochondrial 
53 80 kDa nuclear cap-binding protein 121 
Heterogeneous nuclear ribonucleoprotein U-
like protein 2 
54 RNA-binding motif protein 34 122 DEAH box protein 36 
55 Cytoplasmic dynein 1 intermediate chain 2 123 UPF0488 protein C8orf33 
56 MAP7 domain-containing protein 2 124 
cDNA FLJ76962, highly similar to Homo sapiens 
nucleolar protein 5A (56kDa with KKE/D 
repeat) (NOL5A), mRNA 
57 aarF domain-containing protein kinase 3 125 
Bromodomain and WD repeat-containing 
protein 2 
58 14-3-3 protein beta/alpha 126 Coiled-coil domain-containing protein 8 
59 Met-induced mitochondrial protein 127 Novel nuclear protein 1 
60 HCLS1-associated protein X-1 128 BCL-6 corepressor-like protein 1 
61 H/ACA ribonucleoprotein complex non-core 
subunit NAF1 
129 28S ribosomal protein S31, mitochondrial 
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Rank Protein Rank Protein 
62 NAP-1-related protein 130 Zinc finger CCHC domain-containing protein 10 
63 cAMP-dependent protein kinase catalytic 
subunit alpha 
131 Conserved ERA-like GTPase 
64 Ran-binding protein 10 132 60 kDa chaperonin 
65 Condensin-2 complex subunit D3 133 Histone H1.2 
66 E3RSIkappaB 134 Histone H1 
67 Macropain chain Z 135 Histone H1.4 
68 ARM protein lost in epithelial cancers on 
chromosome X 3 
  
 
 
Appendix 3 – Original identification of NUAK1 and 14-3-3ε binding 
FLAG tagged NUAK1 was transfected into HEK293T cells and immunoprecipitated with M2-
FLAG resin and eluted with FLAG peptide. The eluted protein was further purified by size 
exclusion on the SMART system, resolved on a 10% SDS-PAGE Tris-Glycine gel and silver 
stained.  
 
An equivalent gel was transferred to Immobilon FL PVDF membrane for immunoblotting with 
anti-pan-14-3-3 antibody and is shown superimposed over the same fractions below the gel. 
The indicated bands were dissected from the gel and analysed by mass spectrometry. 
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The protein that co-purified with NUAK1 was identified specifically as 14-3-3ε. One peptide 
for another isoform of 14-3-3 was detected but it was confidently identified as the primarily 
the epsilon isoform. 
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